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Preface 
 
This study is focussed on the structural investigation of large molecular assemblies such as 
the 26S proteasome and the translocation machinery of the outer mitochondrial membrane. It 
is divided in two chapters and in both parts the structural and further functional analysis is 
based on X-ray crystallography.  
 
 
Chapter 1: Structural investigation of Rpn13, the multifunctional adaptor 
protein of the 26S proteasome 
 
The results in chapter 1 reveal that the multifunctional adaptor protein Rpn13 acts as a novel 
ubiquitin receptor of the 26S proteasome and deliver structural and biophysical details of its 
interaction with ubiquitin and with other proteasomal subunits. The crystal structure of the 
ubiquitin binding domain of Rpn13 reveals the molecular architecture of a Pleckstrin 
Homology (PH) domain and the NMR structure of the complex with ubiquitin shows a novel 
ubiquitin-binding mode. Additional NMR studies and domain mapping by truncation analysis 
provide further insights in the domain architecture of Rpn13 and the interaction with its 
partners Rpn2 and Uch37. 
 
 
Chapter 2: Crystallographic studies of the TOM core complex 
 
Chapter 2 presents the purification and crystallization of the mitochondrial protein 
translocase, the TOM core complex, from Neurospora crassa. Preliminary crystallographic 
data lead to the determination of space group and cell dimensions. This chapter also describes 
various experiments to improve the diffraction quality of the crystals and the co-
crystallization of TOM core complex with specific monoclonal antibody fragments. 
Furthermore, expression and refolding of the main component Tom40 is raised as an 
alternative approach in structural investigation of the TOM complex.  
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1 Structural investigation of Rpn13, the 
multifunctional adaptor protein of the 26S 
proteasome 
 
1.1  Abstract 
 
Proteasomes typically recognize substrate proteins by their covalently attached ubiquitin 
chains. The components that perform this role have remained elusive, with Rpn10/S5a being 
the only established proteasomal ubiquitin receptor. This study provides structural and 
biophysical details of the multifunctional, proteasomal adaptor protein Rpn13 and presents the 
crystal structure of its ubiquitin binding domain, which forms a Pleckstrin Homology (PH) 
domain fold and thus was named the Pru domain (Pleckstrin–like receptor for ubiquitin). The 
NMR structure of Rpn13 Pru:ubiquitin complex reveals a novel ubiquitin-binding mode in 
which loops rather than secondary structural elements are used to capture ubiquitin. This is 
supported by mutational analysis of the interacting amino acid residues of Rpn13. Moreover, 
NMR studies exhibit that ubiquitin and the proteasomal subunit Rpn2/S1/PSMD1 bind 
simultaneously through surfaces at opposite sides of the Pru domain. Rpn13 enhances the 
deubiquitinating activity of its binding partner Uch37, and thus jointly promotes the 
recognition and processing of ubiquitin chains. As a step towards the mechanism of 
Rpn13:Uch37 interaction, this study describes the heterologous bicistronic coexpression of 
the human co-complex. Domain mapping localized the binding module at the C–terminal 
ends of both proteins. A model structure of Rpn13 complexed to diubiquitin is provided, 
which affords insights into how the role of Rpn13 as an ubiquitin receptor is coupled to 
substrate deubiquitination by Uch37. Rpn13 represents a multifunctional adaptor protein 
involved in recognition and targeting of ubiquitinylated substrate proteins to the proteasome 
and in recruitment and activation of Uch371. 
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1.2  Introduction 
 
1.2.1  Protein degradation 
 
Protein degradation plays a key role in regulation of various biological processes such as 
metabolism, cell cycle progression, antigen presentation and apoptosis2,3. Degradation is 
linked to the large class of enzymes called proteases and peptidases, which naturally occur in 
all organisms and constitute 1–5% of the gene content. Systematically, proteases belong to the 
group of C–N–hydrolases and are capable of catalyzing the cleavage of peptide bonds. They 
can either break specific peptide bonds (limited proteolysis), depending on the amino acid 
sequence of a protein, or break down a complete peptide to amino acids (unlimited 
proteolysis). Depending on the type of attack on the protein, proteases are divided into two 
categories, namely exo– and endopeptidases. Exopeptidases detach the terminal amino acids 
from N– or C–terminus of the polypeptide chain (e.g. aminopeptidases, carboxypeptidases), 
whereas endopeptidases attack internal peptide bonds (e.g. pepsin and trypsin). The two 
groups are further subdivided according to the character of their catalytic active site and 
reaction mechanism. 
Proteases are currently classified into six groups: 
 
1. Serine proteases    Ser and His residue in the active centre 
2. Threonine proteases   Thr residue in the active centre 
3. Cysteine proteases   Cys residue in the active centre 
4. Aspartic acid proteases   Asp residue in the active centre 
5. Metalloproteases    Metal ion in the active centre 
6. Glutamic acid proteases   Glu residue in the active centre 
 
The mechanism used to cleave a peptide bond involves a catalytic amino acid residue (serine, 
threonine and cysteine proteases) or a water molecule (as for aspartic acid, metallo– and 
glutamic acid proteases) which has to be converted to a nucleophile, so that it is able to attack 
the peptide carbonyl group. For example, the mechanistic class of serine proteases was 
originally distinguished by the presence of the Asp-His-Ser “charge relay” system or 
“catalytic triad”4. The catalytic triad spans the active site cleft, with serine on one side and 
aspartic acid and histidine on the other (Figure 1.1). The backbone NHs of glycine and serine 
built a pocket of positive charge, the oxyanion hole, which activates the carbonyl of the 
scissile peptide bond and stabilizes the negatively charged oxyanion of the tetrahedral 
intermediate (Figure 1.1).  
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Figure 1.1: (a) Schematic view of the catalytic mechanism of serine proteases. The peptide 
and the catalytic residues are depicted in red and blue, respectively5. 
 
Proteinases are involved in a multitude of physiological reactions from simple digestion of 
food proteins to highly–regulated cascades2,3. Proteolysis can be a destructive change, 
abolishing a protein's function or digesting to its principal components; it can be an activation 
of a function, or a signal in a signaling pathway. Acid proteases secreted into the stomach 
(such as pepsin) and serine proteases present in the duodenum (trypsin and chymotrypsin) 
enable digestion of proteins ingested by food. Blood serum contains proteinases (thrombin, 
plasmin, etc.) playing an important role in blood–clotting, as well as lysis of the clots, and in 
maintenance of the immune system. Degradation by proteases determines the lifetime of 
proteins which accomplish important physiological roles like hormones, antibodies, enzymes 
or transcription factors, thereby providing a fast regulatory relay system in the cell. The 
process is highly selective: some proteins are degraded within minutes, while others are 
practically stable. 
Protein hydrolysis represents an irreversible process and therefore substrate selection for 
degradation has to be strictly controlled. This is achieved by different mechanisms such as 
high substrate specificity (e.g. signal peptidases), inhibitory regulation (e.g. α1-antitrypsin and 
elastase), activation by limited proteolysis of zymogens (e.g. blood clotting system), co-
localization (e.g. in membranes), binding to cofactors (e.g. metalloproteases) and the 
confinement to specialized compartments (e.g. proteasome)6. 
The vast majority of cellular proteins is degraded by the cytosolic ubiquitin (Ub)–proteasome 
pathway. In this pathway, substrate proteins which are destined for degradation are marked by 
covalent attachment of ubiquitin in a process termed ubiquitination or ubiquitinylation.   
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1.2.2  Ubiquitination 
 
Proteins targeted for proteasomal degradation are tagged by the small protein ubiquitin which 
consists of 76 amino acids and which is highly conserved among eukaryotic species. 
Ubiquitin molecules are then further added on to previously-conjugated ubiquitin molecules 
to form a polyubiquitin chain mediating the recognition and degradation of substrate proteins 
by the 26S proteasome2. If the chain is longer than 3 ubiquitin molecules, the tagged protein is 
rapidly degraded into small peptides. Ubiquitin moieties are cleaved off the protein by 
deubiquitinating enzymes and are recycled for further use. The process of ubiquitination 
involves the ubiquitin–activating enzyme E1, ubiquitin–conjugating enzyme E2, and ubiquitin 
ligase E3 and consists of a several steps (Figure 1.2). 
 
 
Figure 1.2: Proteins are targeted for degradation by the proteasome by covalent modification 
of a lysine residue that requires the coordinated reactions of three enzymes. In the first step, 
an ubiquitin–activating enzyme (known as E1) hydrolyzes ATP and adenylates an ubiquitin 
molecule. This is then transferred to E1's active–site cysteine residue in concert with the 
adenylation of a second ubiquitin. This adenylated ubiquitin is then transferred to a cysteine 
of a second enzyme, the ubiquitin–conjugating enzyme (E2). Lastly, a member of a highly–
diverse class of enzymes known as ubiquitin ligases (E3) recognizes the specific protein to be 
ubiquitinated and catalyzes the transfer of ubiquitin from E2 to this target protein.  
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It starts with the activation of ubiquitin in a two-step reaction by an E1 ubiquitin-activating 
enzyme. This initial process requires ATP as an energy source and involves production of an 
ubiquitin-adenylate intermediate. The second step transfers ubiquitin to the E1 active site 
cysteine residue upon release of AMP which results in a thioester linkage between the C-
terminal carboxyl group of ubiquitin and the E1 cysteine sulfhydryl group. Afterwards, the 
ubiquitin is transferred from E1 to the active site cysteine of a ubiquitin-conjugating enzyme 
E2 via a trans(thio)esterification reaction. The final step of the ubiquitylation cascade is 
mediated by one of the hundreds of E3 ubiquitin-protein ligases. The E3, which may be a 
multi–protein complex, is generally responsible for targeting ubiquitination to specific 
substrate proteins and therefore acts as the substrate recognition module of the system 
(Figure 1.2). E3 ligases are capable of interaction with both E2 and substrate. The number of 
expressed E1, E2, and E3 proteins depends on the organism and cell type, but there are many 
different E3 enzymes present in eukaryotes, indicating that there is a huge number of targets 
for the 26S proteasome.  
 
 
1.2.3  26S proteasome 
 
The 26S proteasome is a huge macromolecular machine of approximately 2.5 MDa and 
represents a compartmentalized, ATP–dependent protease composed of more than 30 subunits 
that recognizes and degrades polyubiquitinated substrates. It is responsible for most of the 
nonlysosomal protein degradation in both the nucleus and cytosol. Its function is critical to a 
wide variety of cellular processes such as protein quality control, antigen processing, signal 
transduction, cell–cycle control, cell differentiation and apoptosis7,8. In higher eukaryotes, the 
subcellular location of the proteasome is mainly cytoplasmic and nuclear. In yeast cells, 
however, the nuclear envelope–endoplasmatic reticulum network and the nuclear periphery 
seem to be predominant sites of 26S proteasome action (ERAD = Endoplasmic Reticulum 
Associated Protein Degradation)9. Inhibition of this enzyme allowed identification of 
numerous protein substrates and revealed the importance of the proteasome–ubiquitin 
pathway. Consequently, a functionally impaired ubiquitin–proteasome system has been 
implicated in several human diseases10. The 26S proteasome contains a proteolytically active 
20S core particle (CP) capped at one or both ends by 19S regulatory particles (RP)8, which 
are responsible for substrate recognition, unfolding and translocation (Figure 1.3). 
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Figure 1.3: Schematic representation of the 26S 
proteasome consisting of 20S core and the 19S 
regulatory particle. Substrate proteins are marked 
with polyubiquitin, unfolded and translocated into 
the core. 
 
 
 
Core particles are ubiquitous among all three kingdoms of life. However, in contrast to 
eukaryotes, archaea contain a much more simply organized core particle, whereas eubacteria 
possess a proteasome–like protease termed HslV3. Despite all the differences, a common 
feature of the CPs and proteasome–related systems is the generation of peptide fragments 
with an average length distribution of about 2–29 amino acids residues. As a rule, these 
peptides have to be further degraded by other proteases to single amino acids, which can be 
utilized for de novo synthesis3. It is currently believed that proteasome degradation products 
in eukaryotes are further digested by prolyl oligopeptidase, thimet oligopeptidase and 
tripeptidyl peptidase II3,11,12.  
 
 
1.2.3.1 20S proteasome 
 
The most stable subcomplex of the 26S proteasome is the proteolytic 20S core particle (CP). 
It is a large threonine protease with a molecular mass of about 700 kDa. All CPs consist of 
four stacked heptameric ring structures following a cylindrical architecture (Figure 1.4)13-15. 
The heptameric rings themselves are composed of two different types of subunits, termed α 
and β. As anticipated from sequence comparison, the noncatalytic α subunit and the catalytic 
β subunit show similar folding, a four–layer structure in which two sheets of β strands are 
sandwiched between two layers of α helices14,16. The two outer rings of the barrel shaped core 
are built of seven α subunits, which serve as docking domains for the regulatory particles and 
form an exterior gate blocking unregulated access to the interior cavity17,18. As evident from 
the crystal structure of yeast CP, the N–termini of the α subunits protrude into the gate region 
of the cylinder in the absence of activating complexes, thus occluding substrate entry 
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(Figure 1.4c)14. Docking of an activator complex to the outer rim of the CP cylinder induces 
opening of the gate by a structural rearrangement of these N–termini18,19. The β subunits form 
the inner two heptameric rings, which contain the proteolytically active centres of the 
proteasome that face into the hollow interior of the CP. The interior chamber of the 20S 
proteasome is at most 53 Å wide, though the entrance can be as narrow as 13 Å, suggesting 
that substrate proteins must be at least partially unfolded to enter20. 
 
a)
 
Figure 1.4: (a) Schematic diagram of the proteasome 20S core particle viewed from one side. 
The α subunits that make up the outer two rings are shown in green, and the β subunits that 
constitute the inner two rings are shown in blue. (b) Structure of yeast 20S proteasome viewed 
from the side. All subunits are depicted in different colours. (c) Top view of yeast 20S 
proteasome showing the α subunits. The N–termini block the substrate entry. 
 
The number and the diversity of α and β subunits depend on the organism. The number of 
distinct and specialized subunits increases from prokaryotes to eukaryotes. In archaea such as 
Thermoplasma acidophilum, all α and β subunits are identical, whereas proteasomes from 
eukaryotic organisms such as yeast contain seven distinct but related types of each subunit. 
All 14 different eukaryotic proteasomal subunits contain characteristic insertion segments and 
termini, which represent well–defined contact sites between related subunits and lead to their 
unique locations at special positions within the particle. In eukaryotes, only the β1, β2, and β5 
subunits are proteolytically active and follow a common peptide bond cleavage mechanism. 
The architecture and the polarity of the substrate binding channel is unique for each of the 
sites, thereby generating a caspase-like cleavage site for β1, a trypsin-like cleavage site for β2 
and a chymotryptic-like activity for β514,21,22. Proteasomal active subunits belong to the 
family of Ntn–hydrolases, which use their N–terminal residue Thr1 as the catalytic 
nucleophile. All Ntn–hydrolases require a processing step that results in the exposure of the 
N–terminal amino group acting as a nucleophile. Therefore, 20S proteasomes have to follow a 
defined maturation pathway based on intrasubunit autolysis leading to the functionally active 
 b) c) 
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Ntn–protease complex3. In eukaryotes, the 20S core particle can be capped by regulatory 
complexes such as 11S (PA28) and 19S (PA700), which regulate substrate access and 
stimulate peptide hydrolysis. The 19S regulatory complex forms the most prominent and 
important regulator providing the link for proteasome–mediated proteolysis with the ubiquitin 
pathway of protein degradation2,8,23,24. 
 
 
1.2.3.2 19S regulatory subunit 
 
The ATP–independent 20S proteasome is fairly well characterized, and its maturation, 
catalytic mechanism, broad specificity, regulation and interactions have been described in 
detail. So far, there is less available data on the ATP–dependent 19S regulatory particle (RP), 
which functions as a gate opener in addition to its important roles in recognition of 
ubiquitinylated substrate, deconjugation of Ub chains, and unfolding of substrates prior to 
their translocation into the CP8,25. The regulatory particle, consisting of at least 19 subunits 
(Figure 1.5), can occupy one or both ends of the cylindrical core particle. Although a large 
number of subunits has been studied genetically, the functions of many subunits are still 
unknown8. Based on biochemical characteristics, the RP can be further subdivided in two 
assemblies, the “base” and the “lid”, which are located proximal and distal to the CP, 
respectively (Figure 1.5)26. The base is involved in unfolding of substrate proteins and their 
subsequent translocation into the central proteolytic chamber of the CP, whereas the lid-
complex is expected to function as the recognition scaffold for the marked polyubiquitinated 
substrates. The 19S subunits are designated by the mammalian “S” (subunit)27 or yeast “Rp” 
(regulatory particle)28 nomenclatures. 
The base complex contains six related, essential ATPases (Rpt1/S7, Rpt2/S4, Rpt3/S6, 
Rpt4/S10b, Rpt5/S6`, Rpt6/S8), which are responsible for the ATP requirement of proteasome 
activity, the two largest subunits Rpn1/S2 and Rpn2/S1 and the recently identified subunit 
Rpn13/Adrm129-32. ATPase complexes that regulate protein degradation in eukaryotes, 
bacteria and archaea are all members of the AAA+ (ATPases associated with various cellular 
activities) ATPase superfamily33. Specific interactions between the 19S Rpts (for regulatory 
particle triple–A protein) supported by cross–linking studies34 and the analogy to their 
bacterial counterparts suggest formation of a six–membered ring, which presumably 
associates directly with the α subunits of the core particle6,35. 
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Figure 1.5: Schematic representation of the yeast 26S proteasome. The CP is shown in blue, 
with active sites indicated in black. Docking of the RP (shown in red, orange, and yellow) 
allows opening of the gate and creates an open channel into the central cavity. The regulatory 
subunit is composed of two entities: the base (red) and the lid (orange), connected by Rpn10 
(yellow). Grouping of subunits is based on structural motifs or homology. Lid: PCI motifs 
(Rpn3, Rpn5, Rpn6, Rpn7, and Rpn9), Jab/MPN motifs (Rpn8 and Rpn11), with the remaining 
subunits ungrouped. Base: AAA proteins (all Rpts), UBL receptors bearing LRR–like repeats 
(Rpn1 and Rpn2), and Rpn13 remains ungrouped. Rpn10 lies outside of the traditional 
lid/base definition 
 
Since structural studies indicate that the gate region of the 20S core is blocked by the N–
termini of the α subunits, substrate entry into the proteolytic chamber is permitted14,18. It has 
been proposed that the ATPases open a channel to the interior of the core and are additionally 
responsible for substrate unfolding, which is required for efficient degradation by the 
proteasome36. The proteasomal ATPases possess a chaperone–like activity and are able to 
change the tertiary structure of a bound protein under ATP hydrolysis, eventually resulting in 
unfolding37,38. The two large subunit of the base, Rpn1 and Rpn2 (regulatory particle non–
ATPase), are related in sequence and show similarity to the leucine–rich repeat (LRR) 
domain, a common site for protein–protein interaction9,39. They are proposed to form α–
solenoid structures that contact the ATPases from the side opposite to the CP40. Functional 
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studies provide evidence that both subunits are able to bind to the UBL (ubiquitin–like) 
domains of Rad23 and Dsk2 through their LRR–like domain and mediate recognition of these 
proteins by proteasome41,42. The yeast Rad23 and Dsk2 belong to a family of proteins that 
contain a UBL and an ubiquitin–chain binding UBA (ubiquitin–associated) domain. Given 
that these UBL–UBA proteins can bind both ubiquitin and the proteasome, they might serve 
as adaptors that deliver ubiquitinylated cargo to proteasomes43-45.  
Besides unfolding of substrate proteins, a second major function of the RP is to provide 
binding sites for substrates conjugated to ubiquitin chains. So far, two components of the RP 
have been implicated in binding of ubiquitin conjugates, Rpn10/S5a46,47and Rpt548. Rpn10, 
which lies outside of the traditional lid/base definition, connects the base and the lid and 
recognizes ubiquitin–marked proteins via its UIM (ubiquitin–interacting motif) element. The 
base alone is competent to activate the peptide and casein–hydrolyzing activity of the 
proteasome CP to levels almost equivalent to those of wild–type proteasomes. However, 
degradation of ubiquitin–protein conjugates requires the intact RP. 
The lid as the second subassembly of the RP is composed of nine subunits (Rpn3/S3, Rpn5, 
Rpn6/S9, Rpn7/S10a, Rpn8/S12, Rpn9/S11, Rpn11/S13, Rpn12/S14 and Rpn15/Sem1/Dss1, 
Figure 1.5) and although seven of them are essential for viability in yeast, indicating a critical 
function during proteasomal substrate degradation, there is little structural and functional 
information available on their mechanistic roles. The lid subunits share sequence motifs (the 
PINT/PCI and the MPN motif) with components of the COP9/signalosome and the eukaryotic 
initiation factor 3 (eIF3) complexes, suggesting that these functionally diverse particles have a 
common evolutionary ancestry . The PINT/PCI domain is up to 200 residues in length and 
is predicted to form an α–helical structure . These domains have been found at the C–
termini of Rpn3, Rpn5, Rpn6, Rpn7, and Rpn9. The MPN domain, located in the N–termini 
of Rpn8 and Rpn11, spans approximately 140 residues and is predicted to assume α/β 
structure . Remarkably, all of the proteasome subunits that possess these motifs are found in 
the lid of the RP. Rpn12 and Rpn15 are the two components of the lid, which lack these 
structural motifs. Rpn11 functions as a metallo–isopeptidase that cleaves polyubiquitin chains 
from substrates en bloc . It belongs to the family of deubiquitinating enzymes (DUBs), 
which are suggested to assist in the removal of the polyubiquitin moiety from protein 
substrates prior to their translocation into the catalytic chamber. The smallest, non–essential 
proteasomal subunit, Rpn15, was initially identified as a suppressor of the growth arrest 
induced by overexpression of the UBL–UBA protein Dsk2 . Purified proteasomes lacking 
Rpn15 exhibit stability defects and its human ortholog, Dss1, has been implicated in split–
hand/split–foot disease . All of the known RP components are tightly associated with the 
particle, with the two exceptions of Rpn4/Son1/Ufd5 and Rpn14/PAAF1  and all are 
49-51
52,53
52
54,55
31
31,56
57,58
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conserved in eukaryotes. The Rpt subunits are 66–67% identical between yeast and human, 
whereas the non–ATPase subunits show lower amount of sequence identity, typically in the 
range of 33–47% . 39
In addition to the proteins that form the proteasome holocomplex, there is increasing variety 
of associating proteins, which not only influence the overall stability of the complex, but 
assist in different steps of proteasomal degradation. The increasing number of these 
associated proteins suggests that proteasomes are larger and more diverse in composition than 
previously assumed. 
 
 
1.2.4  Proteasome–associated proteins 
 
Proteasomal function is not only affected by its intrinsic components, but also by a wide 
variety of associating proteins. A group of ubiquitin–binding proteins assists in delivery of 
substrates to the proteasome, whereas proteasome–associated ubiquitin ligases and 
deubiquitinating enzymes may alter dynamics of ubiquitin chains already associated with the 
proteasome. The recognition of polyubiquitinated substrates by the 26S proteasome is 
essential for protein degradation in the cell, but the underlying mechanisms are not fully 
understood. Subunit Rpn10 clearly contributes to the capacity of the proteasome to bind 
ubiquitinated substrates32,46,47 through binding to ubiquitin chains via its UIM element. 
However, deletion of the RPN10 gene only produces mild cellular defects59, suggesting 
alternative recognition pathways or existence of other ubiquitin receptors. Two such 
alternatives may be substrate recognition by Rpt548 and the UBL–UBA shuttle system. UBL–
UBA proteins, such as Rad23, Dsk2 and Ddi1 in S. cerevisiae, which are ubiquitin receptors 
involved in proteasomal targeting, generally have an amino–terminal region that contains one 
UBL domain that is recognized by the proteasome41,43,47,60-62, and one or more UBA domains, 
which bind to ubiquitin63. Presumably, these proteins transport ubiquitinated substrates to the 
proteasome and in some cases initially recognize the ubiquitin conjugates while they are still 
bound to the E3 ligase that catalyzed their synthesis64-66. The proteasomal receptors for the 
UBL–UBA proteins are the base subunits Rpn1 and Rpn241,42,67.  
The existence of deubiquitinating activity within the proteasome had been anticipated well 
before its discovery, based on a likely requirement to recycle ubiquitin. At least three 
deubiquitinating enzymes are thought to contribute to deubiquitination by the proteasome: 
Rpn11, Ubp6 and Uch3754,55,68-70. Rpn11 couples the deubiquitination and degradation of 
proteasome substrates and point mutations in its metal–coordinating site impair substrate 
degradation54,55. The second proteasomal deubiquitinating enzyme, the cysteine protease 
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Ubp6, associates with the base and contains an N–terminal UBL domain which is necessary 
for the interaction with Rpn168,71. Association with the proteasome markedly stimulates 
Ubp6’s catalytic activity68, indicating an intimate functional relationship between Ubp6 and 
the proteasome. Moreover, Ubp6 seems to prevent translocation of ubiquitin into the core 
particle of the proteasome, and is therefore crucial for the maintenance of normal ubiquitin 
levels within the cell68,72,73. The third deubiquitinating enzyme (DUB) within the regulatory 
particle of proteasome and the only ubiquitin carboxy–terminal hydrolase (UCH)–family 
protease that is associated with mammalian proteasomes, is Uch37. In contrast to Rpn11, 
Uch37 disassembles polyubiquitin specifically from the distal end of the chain, a property that 
may be used to clear poorly ubiquitinated or unproductively bound substrates from the 
proteasome54,55. Therefore, Uch37 was proposed to function as an “editing” protease74,75. The 
base subunit Rpn13 recruits Uch37 to the proteasome and is able to stimulate its enzymatic 
activity76-78. Uch37 appears to be an abundant component of proteasomes from mammalian 
cells, Drosophila, and fission yeast, but is absent from budding yeast75,76,79,80. 
A third class of proteasome-associated proteins are the ubiquitin ligases (also called E3 
ubiquitin ligases) which covalently attach ubiquitin to a lysine residue on a target protein. The 
ubiquitin ligase is typically involved in polyubiquitination, which marks proteins for 
degradation by the proteasome. It operates in conjunction with an E1 ubiquitin–activating 
enzyme and an E2 ubiquitin–conjugating enzyme (see Section 1.2.2). Traditionally, the 
ubiquitination of substrates and their delivery to the proteasome have been viewed as 
independent steps in proteasomal protein degradation. The direct association of a variety of 
E2 ubiquitin–conjugating enzymes and E3 ubiquitin ligases with proteasomes suggests that, 
for some substrates, these two steps may be coupled. The most abundant of the ubiquitin 
ligases is the HECT domain–containing E3 ubiquitin ligase Hul5 (KIAA10 in mammals), 
which binds proteasomes through its N–terminus81. A second HECT E3 ubiquitin ligase is 
Ufd4, which also mediates proteasome binding through an N–terminal domain. Ufd4 binds to 
26S proteasomes apparently via the base subunits Rpt4 and Rpt682,83. In addition to Hul5 and 
Ufd4, a large number of other ligases from distinct families as well as E2 enzymes are 
associated with the proteasome. Recently, it has been shown that at least four E2 enzymes, 
Ubc1, Ubc2, Ubc4 and Ubc5, are able to interact with the proteasome in a non–competitive 
manner84. 
 
 
 
 
 
13 
Introduction  Chapter 1 
1.2.5  The novel base component Rpn13 
 
Several recent studies reported the identification of novel, non–essential subunits of the 19S 
regulatory particle, among them the yeast subunit Daq1/Rpn1331,71,85. Rpn13 from S. 
cerevisiae is an acidic 17.9 kDa protein that was identified by mass spectrometry in affinity–
purified proteasomes and deletion of RPN13 results in stabilization of the N–end–rule model 
substrate UbV76–Val–e∆Κ–βGal71. Significantly, yeast Rpn13 was found to be present in 
highly purified proteasomes in apparently stoichiometric amounts and identified as an 
additional subunit of the base subcomplex33. Database search analysis suggested that 
Adrm1/Arm1 is a mammalian ortholog of the yeast Rpn13 and indeed, several publications in 
2006 could support this assumption76-78,86. Adhesion regulating molecule 1 (Adrm1) was 
originally described as an interferon–γ–inducible, heavily glycosylated membrane protein of 
molecular mass 110 kDa87 with a proposed role in regulation of cell adhesion, but recent 
studies identified Adrm1 as a 42 kDa non–glycosylated base subunit of the 19S regulatory 
particle78-80,88. Like other proteasome subunits, human Rpn13 is localized in both the cytosol 
and the nucleus and cosediments with proteasomes upon glycerol–density centrifugation79. 
Cellular localization by differential centrifugation could also show that a small quantity of the 
protein is associated with cell membranes, also similar to subcellular localisation of the 26S 
proteasome86,88,89. The N–terminal region of Rpn13 binds to the base subunit 
Rpn2/S176,78,90,91, whereas a C–terminal region interacts with the base–associated 
deubiquitinating proteins, Uch37/UCHL578-80. Uch37 catalyzes deubiquitination from the 
distal end of Ub chains and is proposed to function as an editing isopeptidase that rescues 
poorly ubiquitinated substrates from being degraded74. The functional relationship of Rpn13 
with Uch37 extends beyond simply tethering it to the proteasome as Uch37 exhibits very little 
catalytic activity in its absence. As well as providing the determinant for recruitment to the 
proteasomes, the unique C–terminal tail of Uch37 serves as an inhibitory domain that keeps 
the uncomplexed enzyme inactive. Following association of the C–terminal domain of 
Rpn13/Adrm1 with the C–terminal tail of Uch37, autoinhibition is relieved, leading to 
increased activity76. 
However, yeast Rpn13, which contains 156 amino acids, is much shorter than the 407–
amino–acid human homologue. The N–terminal one–third of the human protein is 41% 
similar to yeast Rpn13, whereas the C–terminal two–thirds of human Rpn13, which are absent 
in budding yeast, has substantial similarity to its homologues from other eukaryotes, including 
the fission yeast S. pombe. Interestingly, Uch37 orthologues have been identified in S. pombe 
(Uch2) and metazoan species, but not in budding yeast, suggesting that the C–terminal 
domain evolved to recruit Uch37 to the proteasome78,80. 
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Deletion of yeast Rpn13 leads to the stabilization of some model substrates of the ubiquitin–
proteasome pathway71. In frogs, the homolog of Rpn13, Xoom, is required for embryonic 
development92, which presumably reflects a critical role for protein degradation. Knockdown 
of human Rpn13 (hRpn13) by small interfering RNA (siRNA) in HEK293T cells reduces 
overall degradation of short–lived proteins and causes accumulation of the rapidly degraded 
model substrate Ub–R–GFP. Similar decreases in proteolysis are observed upon 
overexpression of the C–terminal half of hRpn1379. Furthermore, the knockdown markedly 
reduces total cellular Uch37, the amount of proteasome–bound Uch37 and decreases 
deubiquitinating activities of 26S proteasomes76,78. Since the amount of Uch37 mRNA is 
unaltered in knockdown cells, the reduction of cellular Uch37 levels is probably a 
posttranscriptional effect. Interestingly, expression of the C–terminal half of hRpn13 in HeLa 
cells appears to induce cell death77 and hRpn13 is upregulated in several carcinoma cell lines 
and multiple types of solid tumors87,93,94. This property may involve interactions of hRpn13 
with Uch37 and proteasomes, although it may have other functions that are yet to be 
discovered. Double knockout of the two non–essential components Rpn10 and Rpn13 in yeast 
shows a synthetic growth defect, indicating overlapping function of the two proteins95 and 
recent data suggests that Rpn13p and the proteasome–associated Rpn14p are involved in the 
stable formation of 26S proteasome and the recognition of the ubiquitinated Gcn4p in 
proteasomal degradation96. Gcn4 is a typical eukaryotic transcriptional activator, which is 
degraded by proteasome97,98 and its stability seems to be increased in the deletion strain of 
Rpn13. 
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1.2.6  Goals of this study 
 
The ubiquitin–dependent proteasomal degradation represents a complex pathway and is based 
on the interplay of a variety of different proteasomal subunits and associated factors. 
Although a large number of subunits have been studied genetically, the composition and 
function of the 19S regulatory complex is hardly understood. The main goal of this study was 
the structure determination of the domain architecture of base subunit Rpn13 and the structure 
based functional analysis. This should be achieved by the establishment of a suitable 
expression system to obtain soluble recombinant Rpn13 for crystallization, the determination 
of the unknown phases by SeMet derivatization with subsequent structure solution and 
refinement. Furthermore, it was aimed to investigate interactions between Rpn13 and its 
binding partners Rpn2 and Uch37 as well as to reveal the underlying mechanisms of binding 
to monoUb (ubiquitin) and Ub-chains. In this study, pull-down assays and NMR spectroscopy 
should shed light on the interaction of the N-terminal domain of Rpn13 with ubiquitin and 
mutational analysis of interacting amino acid residues of Rpn13 should further support 
structural data. Additionally, NMR shift perturbation analysis should map the putative Rpn2 
binding site on Rpn13. For the investigation of the interaction between the C-terminal 
domains of mammalian Rpn13 and Uch37, the two proteins had to be coexpressed and 
purified. Thereby, the design of various truncated variants of Rpn13 and Uch37, which are 
based on secondary structure prediction, could lead to the localization of their interaction 
module. A part of the results of this study was published in Schreiner et al. 20081. 
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1.3  Results 
 
1.3.1 Cloning, expression and purification of Rpn13 
 
Mammalian Rpn13 could be divided in three main parts: the N–terminal domain (called Pru 
domain for Pleckstrin–like receptor for ubiquitin), a linker region and the C–terminal domain. 
In yeast, Rpn13 consists only of the N–terminal domain. To gain more insight into the domain 
architecture of Rpn13, different variants of the protein from Saccharomyces cerevisiae, Mus 
Musculus and Homo sapiens were cloned, expressed and purified (variants are listed in 
Table 1.1) preceding further investigations like crystallization, binding assays, NMR 
spectroscopy and structure determination of the N–terminal Pru domain of murine Rpn13. 
 
Variant Amino acid residues Organism
Expression 
vector 
MM 
(kDa) Comments 
1 1–156 S.c. pRSET–GST–PP 18.1 
full length yeast 
protein, highly 
expressed 
2 1–123 S.c. pRSET–GST–PP 14.4 truncated yeast protein, highly expressed 
3 1–407 M.m. pRSET–GST–PP 42.2 
full length mouse 
protein, highly 
expressed 
4 1–150 M.m. pRSET–GST–PP 16.8 highly expressed, crystals obtained 
5 151–407 M.m. pRSET–GST–PP 25.7 
N–terminal truncated 
mouse protein, highly 
expressed 
6 202–407 H.s. pRSET–GST–PP 21.1 
N–terminal truncated 
human protein, 
expressed 
7 202–407 H.s. Bicistronic vector 21.1 
N–terminal truncated 
human protein, 
expressed 
8 267–407 H.s. pRSET–GST–PP 15.2 
N–terminal truncated 
human protein, no 
expression 
Table 1.1: Different expressed Rpn13 variants. 
 
The cDNAs encoding Rpn13 variants were subcloned into E. coli expression vector pRSET–
GST–PP using BamHI restriction sites (for details see Materials and Methods). The BamHI 
and EcoRI cleaved PCR product encoding Rpn13 variant 7 (Table 1.1) was inserted into a 
bicistronic vector. All constructs were tested by restriction analysis and sequencing. The 
expression conditions were optimized in small scale expression tests.  
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As the first purification step, the GST–fused protein variants were purified from bacterial 
lysate by affinity chromatography using Glutathione Sepharose. Recombinant protein was 
eluted from the glutathione beads by cleavage with PreScission Protease (PP) and the eluted 
protein was further purified using a two step size exclusion chromatography (see Materials 
and Methods). The purity was analyzed after each step by SDS–PAGE. The gels and the 
chromatogram of the purification of Rpn13 variant 4 are depicted in Figure 1.6. 
 
 
Figure 1.6: Purification of Rpn13 variant 4. (a) Coomassie stained SDS–PAGE (16%) of  
affinity purification. 1=uniduced, 2=induced, 3=sup, 4=pellet, 5=flow through, 6=wash, 
7=elution with PP (PreScission Protease). (b) Chromatogram of a Superdex 200 run. 
(c) After first run with Superdex 200 gel filtration column.  1=load, 2–6=fractions. (d) After 
gel filtration second run. 1–4=fractions. 
 
 
 
18 
Results  Chapter 1 
1.3.2  Investigation of the domain architecture of Rpn13 
 
1.3.2.1 Primary sequence analysis of Rpn13 
 
An important step in investigating the domain architecture of Rpn13 is primary sequence 
analysis. PredictProtein was used for sequence analysis and the prediction of secondary 
structure and domain function. It returns multiple sequence alignments, PROSITE sequence 
motifs, low–complexity regions (SEG), prediction of secondary structure, transmembrane 
helices, coiled–coil regions, disulfide–bonds (DISULFIND), subcellular localization, and 
functional annotations.  
Based on its interaction with different binding partners, mammalian Rpn13/Arm1 could be 
divided into a N–terminal Pru domain, binding to Rpn2 and ubiquitin, a serine–rich (approx. 
22% serine) linker region, and the C–terminal domain interacting with the hydrolase Uch37. 
Interestingly in yeast, which lack Uch37, Rpn13 only consists of the N–terminal domain. 
Predictions with the program SEG exhibited an extended low complexity region in murine 
Rpn13 sequence which is located between residues 135–254, thereby supporting the postulate 
of a flexible linker domain.  
Murine Rpn13 contains six cysteines and according to DISULFIND, a program predicting 
disulfide bonding state, none of the cysteines is disulfide–bonded. Same is true for the two 
cysteines of yeast Rpn13. 
The secondary structures of Rpn13 from S. cerevisiae and M. musculus were predicted by 
PROFsec, an advanced method of PHDsec. It works by a system of neural networks rating at 
an expected average accuracy >82% for the three states helix, strand and loop. PROFsec has 
an improved accuracy through evolutionary information from multiple sequence alignments 
than methods using only single sequence information and also an improved β–strand 
prediction through a balanced training procedure. The prediction for murine (mRpn13) and 
yeast Rpn13 (scRpn13) are shown in Figures 1.7 and 1.8.  
 
  ....,....10...,....20...,....30...,....40...,....50...,....60 
AA  MTTSGALFPSLVPGSRGSSTKYLVEFRAGKMSLKGTTVTPDKRKGLVYIQQTDDSLIHFC 
PROF_sec                 EEEEEEE EEEE   EEE      EEEEEE    EEEEE 
Rel_sec   924332033436666466641267865112331352320256630688884577437777 
SUB_sec     L..........LLLL.LLL...EEEEE.......L.....LLL..EEEEE.LLL..EEEE 
 
  ....,....70...,....80...,....90...,....100..,....110..,....120 
AA  WKDRTSGTVEDDLIIFPDDCEFKRVPQCPSGRVYVLKFKAGSKRLFFWMQEPKTDQDEEH 
PROF_sec         EE          EEEE    EEEEEE     EEEEEEEE    EEEEEEE       HHH 
Rel_sec   411478874331588336421433200356606888872378537775414787777788 
SUB_sec     ....LLLL....EEE..L..........LLL.EEEEEE..LLL.EEEE...LLLLLLHHH 
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  ....,....130..,....140..,....150..,....160..,....170..,....180  
AA  CRKVNECLNNPPMPGSLGASGSSGHELSALGGEGGLQSLLGNMSHSQLMQLIGPAGLGGL 
PROF_sec         HHHHHHHH          
Rel_sec   999877514787776445565666665566665542333467664544444566656655 
SUB_sec     HHHHHHH..LLLLLL..LLLLLLLLLLLLLLLL......LLLL.L.....LLLLLLLLLL 
 
  ....,....190..,....200..,....210..,....220..,....230..,....240 
AA  GGLGALTGPGLASLLGSSGPPASSSSSSSRSQSAAVTPSSSTSSARATPAPSAPAAASAT 
PROF_sec                  
Rel_sec   555556676655556677777777777666666533567676666667777777666677 
SUB_sec     LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL..LLLLLLLLLLLLLLLLLLLLLLLL 
  
  ....,....250..,....260..,....270..,....280..,....290..,....300 
AA  SPSPAPSSGNGTSTAASPTQPIQLSDLQSILATMNVPAGPGGSQQVDLASVLTPEIMAPI 
PROF_sec             
Rel_sec   778777766667777788777665310000123677777777665553212363111201 
SUB_sec     LLLLLLLLLLLLLLLLLLLLLLLL.........LLLLLLLLLLLLLL.....L....... 
 
  ....,....310..,....320..,....330..,....340..,....350..,....360 
AA  LANADVQERLLPYLPSGESLPQTADEIQNTLTSPQFQQALGMFSAALASGQLGPLMCQIG 
PROF_sec            HHHHHHHH         HHHHHHH    HHHHHHHHHHHHHH     HHHHH 
Rel_sec   477356664420178766765406788764157105677878888753278631555215 
SUB_sec     .LL.HHHH.....LLLLLLLL..HHHHHH..LL..HHHHHHHHHHHH..LLL..HHH..L 
  
  ....,....370..,....380..,....390..,....400..,.. 
AA  LPAEAVEAANKGDVEAFAKAMQNNAKSDPKEGDTKDKKDEEEDMSLD 
PROF_sec           HHH       HHHHHHHHHH                HHHH  
Rel_sec   66010121244636889998640256774234533354534304679 
SUB_sec     LL.........L.HHHHHHHH...LLLL....L...L.L.....LLL 
 
Figure 1.7: Secondary structure prediction of mRpn13. PROFsec: predicted secondary 
structure in three states: helix H, sheet E, rest L. RELsec: reliability index for secondary 
structure prediction (0 = low to 9 = high). SUBsec: subset of the prediction, for all residues 
with an expected average accuracy >82%. 
 
The secondary structure prediction of mRpn13 reflected the domain architecture of 
mammalian Rpn13 (Figure 1.7). The PROFsec prediction showed clearly the defined 
secondary structure of the conserved N–terminal Pru domain (21–130) which was determined 
by X–ray crystallography in this study (see section 1.3.3) and the canonical order of its 
structural components, the seven β–strands followed by the C–terminal α–helix. In contrast, 
the C–terminal domain (301–407) exhibited solely helical structure and as expected from low 
complexity calculations, the serine–rich linker domain (131–300) lacks secondary structure 
elements. Prediction of scRpn13s secondary structure demonstrated the same pattern of seven 
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β–strands and α–helix for the N–terminal Pru domain in yeast (1–130) (Figure 1.8). In 
contrast to yeast Rpn13, the mammalian homolog contains a N–terminal extension of 20 
amino acids, where secondary structure elements are also missing.  
 
  ....,....10...,....20...,....30...,....40...,....50...,....60 
AA  MSMSSTVIKFRAGVCEYNEDSRLCTPIPVQGEIEIKPNEEEELGFWDFEWRPTEKPVGRE 
PROF_sec              EEEEEE  EEEE     EEE      EEEEEE       EEEEEEE 
Rel_sec   975440477630035405775223034564168886425566641677763256776676 
SUB_sec     LLL....EEE....E..LLLL......LL..EEEEE..LLLLL..EEEEE..LLLLLLLL 
 
  ....,....70...,....80...,....90...,....100..,....110..,....120 
AA  LDPISLILIPGETMWVPIKSSKSGRIFALVFSSNERYFFWLQEKNSGNLPLNELSAKDKE 
PROF_sec              EEEE    EEEEE      EEEEEEE    EEEEEEE                HH 
Rel_sec   663205884275147752135676378888617852788753157778764213632068 
SUB_sec     LL...EEE..LL..EEE...LLLL.EEEEEE.LLL.EEEEE..LLLLLLL....L...HH 
 
  ....,....130..,....140..,....150..,. 
AA  IYNKMIGVLNNSSESDEEESNDEKQKAQDVDVSMQD 
PROF_sec         HHHHHHHHH       HHHH          
Rel_sec   899998762688676203202456766666654368 
SUB_sec     HHHHHHHH.LLLLLL.......LLLLLLLLLL..LL 
 
Figure 1.8: Secondary structure prediction of scRpn13. PROFsec: predicted secondary 
structure in three states: helix H, sheet E, rest L. RELsec: reliability index for secondary 
structure prediction (0 = low to 9 = high). SUBsec: subset of the prediction, for all residues 
with an expected average accuracy >82%. 
 
 
1.3.2.2 Limited proteolysis of yeast Rpn13 
 
In this study limited proteolysis was used as a tool for the investigation of the protein 
structure and domain architecture of Rpn13. In order to retrieve structural information by 
localization of stable domains through proteolytic digestion it is necessary to limit the 
enzymatic reaction for example in either concentration of the protease or incubation time. 
In this experiment Rpn13 variant 1 (Table 1.1) from S. cerevisiae was digested with the three 
proteases Trypsin, Chymotrypsin and Carboxypeptidase Y. Trypsin cleaves peptide bonds C–
terminal to basic amino acids, lysine and arginine, whereas Chymotrypsin prefers bulky 
nonpolar and aromatic side chains like phenylalanine, tyrosine and tryptophane. 
Carboxypeptidase Y exhibits broader amino acid specificity, and is able to release every 
amino acid including proline from the carboxyl–terminus of peptides, although glycine and 
aspartic acid are released much more slowly than other residues. The influence of the tertiary 
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structure is expected to be more pronounced for proteases with broader specificity such as 
Carboxypeptidase Y. Rpn13 variant 1 was incubated with different concentrations of each 
protease and the results of the digestion were monitored by SDS–PAGE analysis 
(Figure 1.9a).  
 
 
 
Figure 1.9: Limited proteolysis of Rpn13 variant 1 from S. cerevisiae. (a) Coomassie stained 
SDS–PAGE (16%) of variant 1 digested with the proteases Trypsin, Chymotrypsin and 
Carboxypeptidase Y in different concentrations. 10 µg of Rpn13 was used in each lane. A 
stable fragment at 14 kDa (variant 2) occurred (b) Mass spectrometrical analysis of the 
proteolytic digestion of variant 1. The digested fragment exhibits the size of 14385 Da in 
comparison to the 18066 Dalton of the unprocessed protein. (c) Sequence of full length 
protein Rpn13 variant 1 and of the shorter variant 2 (aa 1–123) found by limited proteolysis. 
The cleavage site and the deleted sequence are marked red. (d) Coomassie stained SDS–Page 
of purified variant 1 and 2. 
 
SDS–PAGE analysis exhibited a processed fragment of 14 kDA, which seemed to be quite 
resistant to proteolytic treatment and which was also present as a degradation product of the 
untreated protein. The experiment was repeated using 12.5 ng of Trypsin with 10 µg of 
variant 1 and the sample was analyzed by mass spectrometry as depicted in Figure 1.9b. The 
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determination of the exact molecular mass of 14385 Da for the fragment allowed localization 
of the cleavage site, which is C–terminal of asparagine 123. This result led to the design of a 
new variant 2 for crystallization (Figure 1.9c and d). 
Both variants were often present as double bands arising from the fact that the four N–
terminal residues GPGS, which were residual from cleavage with PreScission Protease and 
the BamHI restriction site, were removed by endogenous proteases during purification 
procedure (see less intensive peaks in Figure 1.9b). Variant 2 was cloned and purified 
according to Section 1.3.1 and also subjected to crystallization trials. Figure 1.9d shows SDS–
PAGE of purified variant 1 and variant 2 in comparison, but none of the proteins crystallized. 
The crystal structure of the mammalian homologue, which was solved in this study (see 
Section 1.3.3), and the sequence alignment (Figure 1.13) propose that variant 2 is truncated in 
the middle of the C–terminal α-helix of the Pru domain, which might explain problems in 
crystallization. Additionally, NMR data suggested low structural order of this helix as it was 
absent in NMR structural analysis. This low structural order could result in the observed 
accessibility of the α–helix for protease treatment. 
 
 
1.3.3  Crystal structure of the Pru domain of Rpn13 
 
1.3.3.1  Crystallization and structure determination of the N–terminal 
Pru domain of Rpn13 
 
It has been recently shown that Rpn13 is a subunit of the 19S regulatory particle, being 
involved in contact of the 19S regulator with several other proteins, such as Uch37, Rpn2 as 
well as mono– and polyUb1,76-78,86,99. The major aim of this study was to crystallize Rpn13 to 
gain new insights into its domain architecture and to reveal its structural and functional role in 
the 19S regulatory subunit. Different variants listed in Table 1.1 were expressed and purified 
as described (see Section 1.3.1). The purified proteins were subjected to crystallization and 
the crystal structure of Rpn13 variant 4, the N-terminal domain of murine Arm1/Rpn13 
(residues 1–150, hereafter termed Pru domain) was determined by X–ray crystallography. As 
described above, the Pru domain was fused to a PreScission Protease cleavable GST–tag, 
overexpressed in a soluble form in E. coli and purified by different chromatography steps to 
more than 95% purity (Figure 1.10a). The typical yield of purified soluble Rpn13 Pru from 3 l 
of culture was approximately 4 mg. Size exclusion chromatography revealed that this domain 
forms monomers, which was consistent with the structural results.  
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Initial crystallization trials were performed with the purified mRpn13 Pru domain by hanging 
drop vapour diffusion method using commercial screening solutions (see Materials and 
Methods) and crystals appeared at 20°C within two days. After optimization the protein was 
crystallized using equal volumes of protein (5 mg/ml) and reservoir solution (15% (w/v) PEG 
4000, 200 mM NaOAc, 1 mM DTT, 100 mM Tris–HCl, pH 8.5) and grew to the size of 
500x 200x 200 µm3 (Figure 1.10b). Addition of DTT was critical for growth and diffraction 
quality of the crystals. Before exposure to X–rays, crystals were soaked in a solution of 
mother liquor including 15% PEG 400 and subsequently frozen in a stream of cold nitrogen 
gas at 100 K. Crystals were then measured using synchrotron radiation at the BW6 beamline 
at the DESY–centre in Hamburg and native data were collected (Table 1.2) using a MarCCD 
detector. Crystals of Rpn13 Pru were well ordered and diffracted to 1.7 Å resolution 
(Figure 1.11). 
 
 
Figure 1.10: Crystallization of Rpn13 Pru domain (variant 4) from M. musculus. (a) SDS–
PAGE of purified Pru domain. (b) Crystals of the Rpn13 Pru domain. (c) Crystals of the 
SeMet derivative of variant 4. 
 
Data were processed with DENZO and SCALEPACK. The space group of Rpn13 Pru was 
P212121 with the unit cell dimensions a=42.4 Å, b=56.2 Å, c=63.2 Å.  
Phase determination was performed by crystal structure analysis of the Rpn13 Pru–SeMet–
derivative. For selenomethionine labelling the Pru domain was overexpressed in the 
methionine auxotroph E. coli strain B834(DE3) and cells were grown in New Minimal 
Medium (see Materials and Methods). Purification and crystallization of selenomethionine–
labelled protein was performed according to the same procedure as for native protein and 
relevance of DTT for crystallization was even more pronounced (Figure 1.10c). 
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Figure 1.11: X–ray diffraction image of Rpn13 
Pru crystals. 
 
 
 
 
 
 
SAD data were collected at 2.7 Å resolution using anomalous diffraction experiments 
(absorption wavelength scan of Se identified wavelength λ=0.9793 Å, see Table 1.2). Two 
Se–sites were localized using SHELXD100. Subsequent phasing with MLPHARE (the CCP4 
suite: programs for protein crystallography) and solvent flattening with DM101 resulted in an 
interpretable electron density map, which was traced and phase extended to the native data set 
at 1.7 Å resolution using ARP–WARP102. The model has been completed using the interactive 
three–dimensional graphic program MAIN103 and refined with REFMAC5104. Temperature 
factors were optimized with restraints between bonded atoms and between non–
crystallographic symmetry related atoms. The finalized structure revealed well defined 
electron density for the core domain of Rpn13 Pru domain, except for the first 21 N– and the 
last 20 C–terminal residues of the molecule which were structurally disordered (Figure 1.14). 
In successive rounds of model building and refinement, the model was completed and 
included 81 water molecules. Temperature factors were refined with restraints between 
bonded atoms and between non–crystallographic symmetry related atoms yielding R–values 
of Rwork = 19.9% and Rfree = 22.4% (Table 1.2). 
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 Rpn13 Pru Rpn13 Pru SeMet 
   
Crystal parameters   
Space group P212121 P212121
Cell constants  a=42.4 Å; b=56.2 Å; 
c=63.2 Å 
a=42.7 Å; b=56.4 Å; 
c=64.2 Å 
Heavy metal – 2 
   
Data collection   
Beamline BW6, DESY BW6, DESY 
Wavelength (Å) 1.05 0.9793 
Resolution range (Å)a 99–1.7 (1.70–1.67) 99–2.62 (2.7–2.66) 
No. observations 1007679 227878 
No. unique reflectionsc 25165 8927 
Completeness (%)b 99.5 (99.9) 98.9 (100) 
Rmerge (%)b, c 5.1 (27.2) 10.0 (35.3) 
I/σ (I)b 19.1 (2.9) 32.6 (11.4) 
   
Refinement (REFMAC5)   
Resolution range (Å) 15–1.7  
No. reflections working set 16267  
No. reflections test set 813  
No. non hydrogen 973  
Solvent water  106  
Rwork/Rfree (%)d 19.9 / 22.4  
Rwork/Rfree (2.74–1.70 Å ) (%)d 24.5 / 27.7  
rmsd bond lengths (Å) / (°)e 0.012 / 1.75  
Average B–factor (Å2) 30.67  
Ramachandran Plot (%)f 92.7 / 7.3 / 0.0  
   
Table 1.2: Data collection and refinement statistics. 
aThe values in parentheses of resolution range, completeness, Rmerge and I/σ (I) 
correspond to the last resolution shell. 
bFriedel pairs were treated as different reflections. 
cRmerge(I) = ΣhklΣj |[I(hkl)j – I(hkl)] |/[Σhkl Ihkl , where I(hkl)j is the jth measurement 
of the intensity of reflection hkl and <I(hkl)> is the average intensity. 
dR = Σhkl | |Fobs| – |Fcalc| |/Σhkl |Fobs|, where Rfree105 is calculated without a sigma 
cutoff for a randomly chosen 5% of reflections, which were not used for structure 
refinement, and Rwork is calculated for the remaining reflections. 
eDeviations from ideal bond lengths/angles. 
fNumber of residues in favoured region / allowed region / outlier region. 
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1.3.3.2 Rpn13 Pru adopts Pleckstrin Homology (PH) architecture 
 
Primary sequence alignment could not identify any sequence similarities of Rpn13 Pru with 
other proteins, and no predictions of domain structure of Rpn13 could be made by using 
pattern and profile search programs. Therefore, a new folding pattern of this protein class was 
expected. Surprisingly, the crystal structure of Rpn13 Pru revealed that the N–terminal 
domain of Rpn13 has the topology typical for the Pleckstrin Homology (PH) domain fold 
(Figure 1.12a, b). Thus, we named this domain Rpn13 Pru, for Pleckstrin–like receptor for 
Ub. The determination of the structure allowed comparison with the secondary structure 
prediction. Although pattern and profile search program did not identify the fold of the 
N-terminal domain, the PROFsec prediction in Section 1.3.2.1 detected all secondary 
structure elements of the PH fold pretty well. 
 
 
Figure 1.12: Crystal structure of murine Rpn13 Pru (variant 4) revealed typical Pleckstrin 
homology (PH) domain fold. (a) Ribbon drawings of Rpn13 Pru. The PH–fold consisting of 
seven–stranded β–sandwich structure (1–7) capped by the C–terminal α–helix (H), indicated 
in white. (b) Stereoview of the structural alignment of Rpn13 Pru (red) and the PH domain 
(green) from Pleckstrin (PDB accession code 1PLS)106. 
 
PH–domains are small modules (100–120 amino acids) found in a multitude of intracellular 
proteins with very widespread functions106-110. The N–terminal Pru domain of Rpn13 
represents the first identified example of a PH fold among subunits of the 26S proteasome. 
Being very divergent at their sequence level, all PH domains share a common β–sandwich 
topology. The PH fold of Rpn13 Pru is composed of a four–stranded twisted antiparallel β–
sheet (β1–4: residues 22–34, 45–52, 56–62, 71–74) which packs almost orthogonally against a 
second triple stranded β–sheet (β5–7: residues 80–85, 92–98, 103–110) (Figure 1.12 and 1.13). 
Rpn13 Pru also forms a hydrophobic core which is typical for PH domains. All conserved 
hydrophobic residues forming this core, such as Phe26 (S1), Val47 (S2), Ile49 (S2), Phe50 
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(S3), Phe82 (S5), Tyr94 (S6), Leu96 (S6), Phe107 (S7) and Met109 (S7) are located within 
secondary structure elements (β–sheets) and positioned towards the barrel of the core 
(residues are indicated by red boxes in Figure 1.13). One end of the β–sandwich is capped by 
a long C–terminal amphipathic α–helix (residues 117–128), which is stabilized by 
interactions between residues Val124 and Leu128, whereas the other corner of the 
hydrophobic core is closed by three loops formed by the residues located between strands 
S1/S2, S3/S4 and S6/S7 (Figure 1.12).  
 
 
 
Figure 1.13: Sequence alignment of Rpn13 Pru homologues from Mus musculus (Mm), Homo 
sapiens (Hs), Drosophila melanogaster (Dm), Caenorhabditis elegans (Ce), Arabidopsis 
thaliana (At), Schizosaccharomyces pombe (Sp) and Saccharomyces cerevisiae (Sc). Identical 
residues of Rpn13 Pru are highlighted against a yellow background, conserved residues 
against a grey background. Sequence stretches given in grey are disordered in the crystal 
structure. Residues involved in formation of the hydrophobic core of the PH fold are 
conserved among all eukaryotes and indicated by red boxes. Motifs (M1, M2 and M3) 
exhibiting the highest degree of identity among Rpn13 Pru species are marked by green boxes 
Secondary structure elements of Rpn13 Pru contributing to the topology of the PH fold are 
indicated in blue, remaining secondary structure elements in grey. 
 
 
28 
Results  Chapter 1 
 
These loops represent variable (in primary sequence and in fold) regions among PH domains. 
Although the PH domain family is very divergent at the sequence level, the overall 
architecture of the molecules is well conserved, with major differences found only in the 
composition of the loops. These differences might have functional significance, since variable 
loops were shown to play a central role in specific and selective interactions of PH domains 
with ligands and proteins110-114. Structural superposition of Rpn13 Pru with Pleckstrin 
revealed high consensus of the backbone of the β–sandwich and the α–helix (r.m.s. deviation 
1.7 Å)109,110, but significant differences between the loops (Figure 1.12b). 
We performed a structural similarity search in the protein Data Bank using the DALI server 
(http://www.ebi.ac.uk/dali/) to identify PH folds which share similar conformation of the 
loops. Two proteins were found to share the highest structural homology to Rpn13 Pru: the 
PH domain of Enabled/VASP Homology 1 protein (EVH1), which is binding to proline–rich 
motifs (PDB accession code 1EVH, Z–score of 11.3, average r.m.s. deviation calculated over 
111 equivalent Cα–positions, 2.5 Å)111 and DAPP1, which specifically binds to 
phophatidylinositolphosphates (PIPs) in cell membranes (PDB accession code 1FAO, Z–score 
of 10.6, average r.m.s. deviation calculated over 95 equivalent Cα–positions, 2.5 Å)113. 
Interestingly, despite their structural similarity, EVH1 and DAPP1 have entirely different 
functions and bind their specific ligands at different sites. This indicates that the PH domain 
fold is a robust, but at the same time functionally plastic structure which has enough potential 
versatility to bind a wide range of ligands. Therefore, results of the DALI search alone do not 
allow any conclusions about function and ligand specificity, as well as about location of 
putative binding sites in Rpn13 Pru.  
 
 
1.3.3.3 Rpn13 Pru is conserved in eukaryotes 
 
Proteins of the Arm1/Rpn13 family are highly conserved among mammals (human and mouse 
share 97% sequence identity) with less significant sequence similarities between high and low 
eukaryotes. Figure 1.13 shows the multiple sequence alignment of Rpn13 from different 
species. Having solved the crystal structure of the N–terminal Pru domain of murine Rpn13 
and considering significant homology of the N–terminal domain among higher eukaryotes 
(about one third of the residues forming the β–sheets are strictly conserved), we conclude that 
all eukaryotic Rpn13 homologues possess a PH domain fold at their N–terminus. Flanking 
regions of the PH core structure are not conserved in length and charge among species (the 
first 21 N– and the last 20 C–terminal residues of the molecule were structurally disordered). 
Although the PH fold of Rpn13 from fungi (S. cerevisiae and S. pombe) shows lower 
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sequence similarity to murine Rpn13 Pru, residues involved in formation and stabilization of 
the hydrophobic core are absolutely conserved, providing another indication that the N–
terminal domains of Rpn13 from low eukaryotes also contain a PH fold (Figure 1.13). NMR 
data from cooperation partners revealed that the yeast homologue follows similar topology99. 
Rpn13 from yeast represents the shortest member of the family, since it has only 5 residues 
preceding the N–terminal PH domain and completely lacks the linker and the C–terminal 
domain, which was shown to be essential for Uch37 binding. Since yeast does not contain 
Uch37, there is apparently no need for the C–terminal domain. It has been shown that the first 
132 amino acids from human Rpn13 are sufficient for the protein to form a stable complex 
with subunit Rpn2 of the 19S regulatory particle78, which together with structural data would 
indicate that two distinct domains of Rpn13 might act independently of each other. Rpn13 Pru 
is able to bind simultaneously to mono– or polyUb chains99, as well as to Rpn2 of the 19S 
regulatory particle, thus acting as a mediator for Ub attachment to the proteasome. The fact 
that yeast lacks the C–terminal part of Rpn13 indicates that it is the sole function of the PH 
fold to bind both Rpn2 and Ub, leaving the C–terminus to perform other functions such as 
binding of deubiquitinating enzymes (DUBs). 
 
 
1.3.4 Ubiquitin docking at the proteasome via the PH domain 
interaction of Rpn13 Pru 
 
1.3.4.1 Investigation of the Pru interaction with ubiquitin by chemical 
shift perturbation analysis. 
 
Functional studies from cooperation partners indicated that the N–terminal Pru domain of 
Rpn13 is able to specifically bind to ubiquitin and therefore might represent a novel ubiquitin 
receptor in the 19S regulatory subunit of the proteasome. For this reason, the domain was 
named Pleckstrin–like ubiquitin receptor (Pru). 
In cooperation with the group of Walters (University of Minnesota, USA) NMR spectroscopy 
was used to confirm an interaction between Rpn13 and ubiquitin and to determine how 
hRpn13 binds ubiquitin. Towards this aim, we performed optimized triple resonance 
experiments to assign chemical shift values to hRpn13 Pru’s backbone (N,HN,Cα,C’) and Cβ  
atoms. Chemical shift assignments were made by using 3D HNCA/HNCOCA and HNCACB 
experiments on 0.6 mM 15N–, 13C– and 70% 2H–labelled hRpn13 Pru. A 15N dispersed 
NOESY spectrum (200 ms mixing time) acquired on 15N–, 50% 2H–labelled human Rpn13 
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Pru confirmed that human Rpn13 Pru in solution has similar topology and architecture as 
murine Rpn13 Pru in the crystal. Moreover, the first 21 and last 20 amino acids of the hRpn13 
Pru are similarly disordered in solution. This spectrum was used to aid in the identification of 
intermolecular NOE (nuclear Overhauser enhancements) interactions between hRpn13 Pru 
and Ub, as it was compared to an 15N dispersed NOESY experiment acquired under identical 
conditions on 15N, 13C– and 70% 2H–labelled hRpn13 Pru mixed with an equimolar ratio of 
unlabelled Ub. For this experiment, no 13C or 2H decoupling was implemented to enable the 
ready identification of intermolecular NOE interactions (Figure 1.15).  
To determine how Rpn13 binds ubiquitin, the chemical shift perturbation analysis and the 
NOESY experiments were used to directly detect intermolecular contacts. For the chemical 
shift perturbation analysis, three sets of experiments were performed. In particular unlabelled 
monoUb or tetraUb was added to 15N labelled hRpn13 Pru (Figure 1.14a) or alternatively 
unlabelled hRpn13 Pru was added to 15N labelled monoUb (Figure 1.14b). In each case, the 
15N labelled protein was observed by 1H, 15N HSQC experiments as it bound its unlabelled 
binding partner. The amide nitrogen and hydrogen chemical shift changes for each residue 
were mapped according to Equation 1 (see Materials and Methods). 
 
 
Figure 1.14: Conserved loops of Rpn13 Pru bind ubiquitin’s β–strand face. (a) Chemical 
shift perturbation analysis revealed residues within Rpn13 Pru that bind mono– (black) and 
K48–linked tetraubiquitin (red). For this analysis, the amide chemical shift values of Rpn13 
alone were compared to values with equimolar quantities of unlabelled ubiquitin (black) or 
K48–linked tetraubiquitin (red) present. Residues that were significantly affected by mono– or 
tetraubiquitin are labelled. L73 and R104, which exhibited significant shifting only when 
Rpn13 binds to K48–linked tetraubiquitin, are labelled in purple. (b) Analysis of the amide 
chemical shift values of free and Rpn13–bound ubiquitin were compared at equimolar 
concentration, as described in (a). Resonances that shifted significantly are labelled and 
those that undergo severe broadening are marked with asterisks and labelled with an arrow. 
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This information was complemented with twelve intermolecular NOE interactions to define 
the interaction surface precisely (see Materials and Methods). 
The chemical shift perturbation analysis and intermolecular NOEs indicated that Rpn13 binds 
ubiquitin using a surface formed by the S2–S3, S4–S5, and S6–S7 loops. More specifically, 
S55, L56, I75, F76, D79, F82, L96, F98 and G101 all exhibited significant amide chemical 
shift perturbations as Rpn13 bound ubiquitin (Figure 1.14a, black). In addition, explicit 
intermolecular NOE interactions were detected between F76, D78, D79, F98, A100, G101, 
K103, and R104 of hRpn13 and ubiquitin (Figure 1.15). 
 
 
 
Figure 1.15: Representative interactions identified between Rpn13 Pru and ubiquitin. Each 
panel contains a selected region of an 15N dispersed NOESY experiment recorded on 15N, 13C 
and 70% 2H–labelled human Rpn13 mixed with equimolar quantities of unlabelled ubiquitin. 
All of the resonances displayed in this panel could be unambiguously assigned as 
intermolecular NOE interactions with ubiquitin. Ubiquitin and Rpn13 Pru assignments are 
provided at the top and bottom of the expanded regions, respectively.   
 
The amino acids within these three loops form a contiguous surface with the sequence 
76FPD78 located at the surface’s centre. This motif is strictly conserved in higher eukaryotic 
Rpn13 proteins (Figure 1.13). Furthermore, in all Rpn13 species, the neighbouring residue of 
D79 is either an aspartic or glutamic acid. Interestingly, the residues within these loops share 
little sequence homology between mammalian and yeast Rpn13. P77, however, is strictly 
conserved. It is worth noting that prolines are excluded from amide chemical shift 
perturbation analysis; however, P77 introduces a turn in the loop connecting S4 and S5, and 
thereby plays an important role in defining the architecture of this region (Figure 1.16).   
The Ub–binding surface of Rpn13 is rich in hydrophobic residues and therefore was expected 
to bind to Ub’s hydrophobic patch, a β–strand surface that includes L8, I44, and V70 and is 
involved in binding most Ub receptors115-117 including proteasome component Rpn10/S5a118. 
This hypothesis was validated by explicit intermolecular NOE interactions between Rpn13 
Pru and L8, F45, A46, Q49, H68, and V70 of Ub (Figure 1.15). K48 of Ub is proximal to A46 
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and Q49 and exhibited significant chemical shift changes upon hRpn13 addition 
(Figure 1.14b). Altogether, these data suggest it to be within the Rpn13–binding surface. Ub 
chains formed by K48 linkages serve as effective signals for proteasomal degradation119,120, 
this finding was pursued further, and described in Section 1.3.4.5. 
 
 
1.3.4.2 Novel Ub binding mechanism of Rpn13 Pru 
 
Only five amino acid residues differ between the N–terminal Ub–binding domain of human 
and murine Rpn13 Pru (Figure 1.13). None of these are implicated by the NMR data as 
binding Ub and three of these, A18, N20, and A136, are located in the structurally disordered 
regions. As described above, the 15N dispersed NOESY experiment confirmed that hRpn13 
Pru in solution is similar to the crystal structure of mRpn13 in terms of topology and 
architecture, as well as in the disordered state of the N–terminal 21 and C–terminal 20 amino 
acids. Therefore, the mRpn13 Pru crystal structure (Figure 1.12a) was used as a starting 
structure along with the NMR data on hRpn13 to determine the structure of the mRpn13 
Pru:Ub complex (Figure 1.16). mRpn13 Pru:Ub complexes were generated by using 
HADDOCK1.3 (High Ambiguity Driven protein–protein DOCKing)121 in combination with 
CNS122 as described in Materials and Methods. Intermolecular NOE interactions between 
hRpn13 Pru and Ub were obtained by comparing the 15N–dispersed NOESY experiments 
recorded on hRpn13 Pru alone with that of the hRpn13 Pru:Ub complex. In addition, chemical 
shift assignment of Ub sidechain atoms was obtained by following the assigned resonances of 
the free protein upon addition of increasing molar ratios of unlabelled hRpn13 Pru. All atom 
pairs exhibiting an intermolecular NOE interaction were constrained to be within 1.8–6.0 Å of 
each other. In addition, the constraints from the hydrogen bonds published for Ub (PDB code 
1D3Z)123 were used to maintain its fold, as the protein does not undergo any gross structural 
change upon binding. For the first step of rigid–body energy minimization, 1000 structures 
were generated. 200 structures having the lowest energy from the rigid–body docking were 
subjected to semi–flexible simulated annealing in torsion angle space followed by refinement 
in explicit water. During semiflexible simulated annealing, atoms at the interface were 
allowed to move but constrained by the AIRs and unambiguous NOE–derived distance 
constraints. After water refinement, the resulting structures were sorted according to 
intermolecular energy and clustered using 1.5 Å cut–off criterions. This treatment resulted in 
an ensemble of 200 structures with the average RMSD of 0.94 ± 0.31 Å for all backbone 
atoms and 0.75 ± 0.23 Å for the backbone atoms at the interface. The ten lowest energy 
structures in the lowest energy cluster were evaluated according to the following criteria: all 
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intermolecular hydrophobic contacts between heavy atoms being less than 3.9 Å, 
intermolecular hydrogen bond distances between proton–acceptor and donor–acceptor pair 
being within 2.7 Å and 3.35 Å, respectively, and minimum angles of 90° for donor–hydrogen 
acceptor, hydrogen–acceptor–acceptor antecedent, donor–acceptor–acceptor antecedent atoms 
of hydrogen bonds124. 
 
 
 
Figure 1.16: Structure of Rpn13 Pru:Ub complex defines a novel Ub–binding motif.  Stereo 
representation of the mRpn13 Pru:Ub complex oriented with Ub at the top. At the interaction 
surface secondary structural elements of Ub and Rpn13 Pru are displayed in green and blue, 
respectively. Residues at the contact surface with intermolecular NOEs are in yellow (Ub) or 
red (Rpn13 Pru) whereas those suggested to be at the contact surface only by the NMR 
titration experiments are displayed in purple (Ub) or cyan (Rpn13 Pru). 
 
The structure of the mRpn13 Pru:Ub complex reveals a novel Ub binding mode in which 
residues of the S2–S3, S4–S5, and S6–S7 loops capture Ub (Figure 1.16). Neither Rpn13 Pru 
nor Ub undergoes structural rearrangements to bind each other: the r.m.s. deviations between 
the free and complexed state of Rpn13 Pru and Ub are 0.91 and 0.75 Å for backbone atoms 
and 1.20 and 1.15 Å for all non–hydrogen atoms, respectively. Slight changes were observed 
in Ub’s S1–S2 loop to enable interaction between one of L8’s methyl groups and the Cβ 
group of Rpn13 Pru’s D78. This interaction is reflected in the NMR data, as an NOE 
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crosspeak was observed between D79’s amide group and L8’s methyl group in Ub 
(Figure 1.15). In addition, congruent chemical shift changes were observed for this loop and 
the adjoining strands (Figure 1.14b). Human Rpn13 Pru’s interaction with Ub occurs 
predominantly through residues in the S4–S5 and S6–S7 loops (Figure 1.16). In this region, 
D78’s Oδ1 and D79’s Oδ2 form hydrogen bonds with Ub’s Nε2 and Nδ1 of H68, 
respectively, whereas F76 is engaged in hydrophobic interactions with I44, Q49, and V70 of 
Ub (Figure 1.17a).  
 
 
Figure 1.17: Structure of Rpn13 Pru:Ub complex defines a novel Ub–binding motif.  (a) 
Zoomed view of Figure 1.16 to highlight several key hydrophobic (green dashed lines) or 
hydrogen bond (red dashed lines) interactions. Several contact residues from Ub (yellow) or 
Rpn13 (red) are displayed. (b) Zoomed view of Figure 1.16 rotated by 90° to display relative 
location of Ub’s K48 (purple) and mRpn13 Pru’s L73, K103 and R104 (pink). Additional 
contact residues from Rpn13 (pink) or Ub (yellow) are also highlighted. 
 
These contacts are enabled by the strictly conserved P77, which causes the S4–S5 loop to 
turn. The resulting change in direction positions F76, D78 and D79 of Rpn13 Pru in an 
orientation favourable for Ub binding, and generates the core of the Ub–binding surface. The 
importance of D79 is supported by the strong reduction in binding observed after its 
substitution to asparagine (see Section 1.3.4.3). A series of additional hydrophobic contacts 
between Rpn13 Pru and Ub were observed. In particular, the sidechain methyl group of A100 
and the Cα group of G101 partially bury Ub’s F45, which is solvent–exposed in the free 
protein. Rpn13’s strictly conserved F98 located on S6 also becomes less solvent accessible 
through interactions with A46 and G47 of Ub (Figure 1.17a). Moreover, the methyl sidechain 
of L56 (S2–S3 loop), which is conserved in higher eukaryotes, contacts Ub’s Q49 and is in 
proximity to R42 and R72 (Figure 1.17b). In agreement with the NMR data, mutation of L56 
to alanine significantly reduced Rpn13 Pru binding to Ub (see Section 1.3.4.3). Calculation of 
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the electrostatic potential of mRpn13’s Ub binding surface indicates that a hydrophobic 
region containing L56 and F76 is available to interact with Ub’s L8, I44 and V70 (Figure 
1.18).  
 
 
Figure 1.18: Representation of the electrostatic 
surface potential of mRpn13 Pru’s Ub–binding 
surface with several of its key Ub–binding 
residues labelled in black. The surface is colour 
coded according to electrostatic potential, 
contoured from –25kT/e (intense red, negative 
charges) to +25kT/e (intense blue, positive 
charges). A ribbon representation of Ub is 
displayed with certain contact residues in balls–
and–sticks representation and labelled in green. 
 
Complementary electrostatic interactions between Rpn13 Pru and Ub also stabilize the 
complex, including interactions of D78 and D79 of Rpn13 Pru with Ub’s H68, as well as D53 
and D54 with Ub’s R42 and R72. In total, the contact surface of Rpn13 Pru and Ub comprises 
1256 Å2, which is large for Ub binding receptors. 
 
 
1.3.4.3 Mutational analysis of Pru domain binding to ubiquitin 
 
The NMR data acquired on hRpn13 implicated the S2–S3, S4–S5, and S6–S7 loops as 
forming the Ub recognition surface, but these regions share only 22% sequence identity with 
the homologue from yeast. To analyze the significance of specific residues for Rpn13 binding 
to Ub, several amino acid substitutions were made, based either on the NMR Ub binding data 
or their conservation among all Rpn13 species. Amino acid substitutions within N–terminal 
(1-150), wildtype mRpn13 (R27A, F107A, M109A, Q110R, S55E, L56A, I75R, F76R, 
D79N, and F98R) were created in cooperation with the group of Dikic (Goethe University 
Medical School, Frankfurt) by in vitro mutagenesis. The protein products were expressed as 
GST–fusions and used in GST pull-down assays. The results support and extend the NMR 
experiments since they revealed specific residues in the S2–S3 (L56A), S4–S5 (I75R, F76R, 
D79N), and S6–S7 (F98R) loops to be essential for Ub binding as their amino acids 
substitutions abolished binding to 4 x Ub in the pull down assays (Figure 1.19a).  
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Figure 1.19: Identification of Rpn13 Pru residues critical for Ub binding. (a) Specific amino 
acid substitutions were made within the S2–S3, S4–S5, and S6–S7 loops of mRpn13 Pru by in 
vitro mutagenesis and the protein products were expressed as GST–fusions and used in GST 
pull-down assays to highlight the importance of these loops for tetraUb binding. (b) 
Experiments that parallel (a) were performed to demonstrate the importance of a subset of 
conserved residues for the structural integrity of the hydrophobic core and the PH fold.  
 
Furthermore, NMR experiments on mRpn13 with the incorporated L56A, F76R or D79N 
mutations indicated that the loss of Ub binding was not caused by loss of structural integrity 
(Figure 1.20).  
 
 
Figure 1.20: The L56A, F76R and D79N point mutations do not compromise the structural 
integrity of the mRpn13 Pru domain. Only local effects are observed in superimposed 1H, 15N 
HSQC spectra of 15N labelled mRpn13 Pru wild–type (black) and L56A (cyan), F76R (red), or 
D79N (green) protein. Shifted resonances are labelled in black. 
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The results also highlight the importance of structural integrity of the PH fold for Ub binding, 
since amino acid substitutions that disturbed the PH structure were unable to support Ub 
binding and those residues that are most conserved among Rpn13 species are important for 
structural integrity (Figure 1.13 and 1.19b). More specifically, sequence analysis identified 
three motifs, E25–K30 (M1), G91–F98 (M2), and F106–E111 (M3), as exhibiting the highest 
degree of identity among Rpn13 species (Figure 1.13, green boxes). The structural integrity of 
Rpn13 was readily compromised by substitutions in M3. For example, alanine substitution of 
F107 yielded unstable protein that bound only weakly to Ub (Figure 1.19b). F107 is not 
surface exposed and is directly involved in forming the Rpn13 hydrophobic core (Figure 
1.21a, see also Section 1.3.3.2). 
 
 
 
Figure 1.21: (a) Location of key mutated residues of mRpn13 Pru from Figure 1.19a and b 
displayed in red and yellow, respectively; Ub–binding loops are in blue. (b) Superposition of 
1H, 15N HSQC spectra of wild type (black) or M109A (red) mRpn13 Pru indicates that 
residues remote from M109 were significantly shifted by its mutation suggesting that the 
architecture of the PH domain was distorted. Shifted resonances are labelled in black.  
 
Similarly, substitution of M109 (M109A) or Q110 (Q110R) largely abolished Ub binding 
(Figure 1.19b). These residues are also located within the hydrophobic core (Figure 1.21a) 
and a 1H, 15N HSQC experiment was used to evaluate the structural consequences of the 
M109A mutation in mRpn13 Pru. This experiment provided evidence of structural 
rearrangements in Rpn13, as a large number of residues shifted dramatically, including R27, 
Y48, F82, K83, Y94, and C121 (Figure 1.21b). Altogether, the data suggest that F107, M109 
and Q110 abolished Rpn13’s Ub binding capacity by disrupting its structural integrity and 
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thereby highlight the importance of the PH fold for Rpn13 Ub binding. In contrast, 
substitutions located in the loop regions abolished binding to Ub but did not harm the 
structural integrity. 
 
 
1.3.4.4 Rpn13 binds proteasome subunit Rpn2 independently of Ub 
 
To function as a proteasomal Ub receptor, Rpn13 must bind Ub and proteasome components 
simultaneously. In both yeast and mammals, Rpn13 binds to Rpn2 through its Pru 
domain80,92,93. To confirm these specific binding requirements of Rpn13 Pru for Ub and Rpn2 
a subset of N–terminal deletion mutants of human Rpn2/PSMD1 (aa695–953, aa797–953, 
aa881–953, and aa902–953) were designed and subcloned into pEGFP–C1 and pGEX–4T1 
vectors. The deletion mutants were expressed as GST–fused proteins and tested for their 
ability to bind mRpn13 (1–150) transiently expressed as myc–tagged protein in HEK293T 
cells (Figure 1.22).  
 
 
Figure 1.22: Interaction of Rpn13 Pru with base subunit hRpn2/PSMD1. (a) Different 
deletion mutants of hRpn2 (695–953, 797–953, 881–953 and 902–953) were expressed as 
GST–fused proteins and tested for their ability to bind mRpn13 (1–150) transiently expressed 
as myc–tagged protein in HEK293T cells. All deletion mutants of hRpn2 could bind mRpn13, 
indicating that the last 52 amino acids of hRpn2 are sufficient for mRpn13 binding. (b) Two 
deletion mutants of Rpn2 (881–953 and 902–953) were transiently expressed as GFPtagged 
proteins in HEK293T cells and tested for their ability to bind GST–mRpn13 (1–150).  
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Additionally, two deletion mutants of Rpn2 (881–953 and 902–953) were expressed as 
GFPtagged proteins in HEK293T cells and tested for their ability to bind GST–mRpn13 
(1-150). All deletion mutants of hRpn2 could bind mRpn13, showing that the last 52 amino 
acids of hRpn2 are sufficient for mRpn13 binding (Figure 1.22). 
Using NMR spectroscopy, we could map the surface of Rpn13 Pru for Rpn2 binding which is 
distinct from the Ub binding site (Figure 1.23a). More specifically, only Ub, and not hRpn2 
(797–953), bound to residues in the S2–S3, S4–S5, and S6–S7 loops of hRpn13, as apparent 
from chemical shift data for residues S55, F76, and D78 (Figure 1.23a). In contrast, M31, 
C88, and E111 were not affected by Ub binding, but shifted after hRpn2 (797–953) addition. 
Furthermore, when both Rpn2 and Ub were added, S55, F76, and D78 contacted Ub while 
M31, C88, and E111 contacted Rpn2 (Figure 1.23a), indicating that the two binding surfaces 
are largely independent. M31, C88, and E111 are conserved in mRpn13 (Figure 1.23b) and 
map to S1, the S5–S6 loop, and the region linking S7 to H1, respectively.  
 
 
Figure 1.23: Rpn13 Pru binds simultaneously Ub and Rpn2. (a) Ub (blue), hRpn2 (797–953) 
(green), or Ub and hRpn2 (797–953) (red) were added to hRpn13Pru domain, which was 
monitored by 1H, 15N HSQC experiments. Comparison with the spectrum acquired on the 
protein alone (black) indicates that S55, F76 and D78 bind Ub in a manner that is 
independent of hRpn2 (797–953), whereas M31, C88 and E111 bind hRpn2 in a Ub–
independent manner. (b) The hRpn2–binding surface of mRpn13 was mapped from NMR 
titration experiments. The sidechain residues attenuated by Rpn2 (797–953) are displayed in 
green, and those of M31, C88, and E111 highlighted in red. The Ub binding loops, which are 
remote from the Rpn2–binding residues, are indicated in blue. Location of key mutated 
residues in mRpn13 Pru from Figure 1.19a and b displayed in red and yellow, respectively; 
Ub–binding loops are in blue. 
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Mutational analysis of these three amino acid residues would provide further insight about the 
Rpn13:Rpn2 interaction. 
To define the Rpn2–binding surface more precisely, hRpn2 (797–953) was added to 15N 
labelled hRpn13 and its amide resonances were monitored. At least nineteen hRpn13 
crosspeaks were shifted or attenuated, corresponding to residues within the S1–S2 and S5–S6 
loops, as well as at the C–terminal end of S7 and the beginning of H1. They form a 
contiguous surface opposite to the Ub binding loops and include conserved (V85, R92, V93, 
E111, and E119) and strictly conserved (W108) residues. Overall, binding surfaces of both 
the Rpn13 Pru and Rpn2 contain many charged amino acid residues, with charges being most 
likely distributed in a complementary fashion to facilitate binding. 
 
 
1.3.4.5 K48–linked tetraUb binds hRpn13 Pru 
 
26S proteasomes exhibit high affinity for polyubiquitinated substrates125. Ub chains linked via 
isopeptide bonds between K48 and the C–terminal glycine of neighbouring Ub molecules are 
known to trigger proteasomal degradation of the labelled protein1,120,121. Chemical shift 
perturbation analysis, shown in Section 1.3.4.1 (Figure 1.14a, red) revealed that Rpn13 Pru 
binds K48–linked tetraUb. Importantly, K48–linked tetraUb affected hRpn13 residues in a 
manner comparable to that of monoUb (Figure 1.14a, red versus black). More specifically, 
tetraUb and monoUb caused chemical shift changes to the same hRpn13 residues, including 
L56, F76, and F98, and shifted them almost identically. It was demonstrated that hRpn13 
binds diUb elements of K48–linked tetraUb99 and the comparison in Figure 1.14a therefore 
indicates that one of the Ub moieties within a diUb element binds hRpn13 in a manner similar 
to monoUb. Only two residues in hRpn13 exhibited changes that were specific to K48–linked 
tetraUb, namely L73 and R104 (Figure 1.14a). These residues and the sidechain atoms of 
neighbouring K103 are proximal to each other and in the mRpn13:monoUb structure directed 
towards K48’s sidechain atoms (Figure 1.17b). This arrangement is congruent with Rpn13 
forming interactions with K48–linked tetraUb that are not present in the monoUb complex, as 
suggested by the chemical shift perturbation data. To gain further insight into how Rpn13 
binds neighbouring ubiquitins in K48–linked chains, the Rpn13:monoUb structure was used 
to build a model with diUb (Figure 1.24). In this model, the Rpn13 bound Ub is conjugated to 
another Ub molecule by an isopeptide bond, which is positioned to avoid steric clashes and 
the resulting complex is energy minimized.  
 41 
Results  Chapter 1 
 
Figure 1.24: Model of mRpn13 Pru complexed with diUb. White and grey ribbon diagrams 
display the proximal and distal Ub, respectively, whereas a balls–and–sticks representation is 
used for the K48–G76 isopeptide bond linkage. Rpn13 Pru is coloured in yellow and loops 
recognizing Ub in blue, whereas L73, K103 and R104 are displayed in red. DiUb was created 
by Insight II software based. 
 
As expected, the model revealed putative interactions between the Ub–linker region and 
Rpn13’s L73 and K103. In particular, when the proximal Ub binds Rpn13, the K48–G76 
isopeptide bond is located <4 Å away from Rpn13’s L73, which becomes partially buried. 
The separation of the Cδ groups of Ub’s linked K48 and Rpn13’s L73 is reduced by ~1 Å as 
compared to in the complex with monoUb, due to rotations in the K48 sidechain that avoid 
steric clashes between the distal Ub subunit and Rpn13. This rotation similarly places K103’s 
sidechain atoms within 4 Å of the carbonyl oxygen of the isopeptide bond, suggesting 
possible electrostatic interaction. To summarize, the data indicate that Rpn13 readily binds 
K48–linked chains and most likely affects the configuration of the linkage between 
conjugated ubiquitins. 
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1.3.5 Investigation of the interaction of Rpn13 Pru with PIPs 
 
As has been reported recently, a small fraction of human Rpn13 was found to be membrane 
associated, similar as has been shown for 26S proteasomes86. Interestingly, PH domains are 
best known for their ability to recruit proteins to membranes through their association with 
membrane phosphatidylinositolphosphates (PIPs)111,113, although they can simultaneously 
function as general protein–binding modules, like the GLUE domain which can bind to Ub 
and PIP independently126,127. A protein–lipid overlay assay was performed using PIP StripsTM 
membranes containing different phosphatidylinositides and lipids to test whether mRpn13 Pru 
can bind to PIPs. As shown in Figure 1.25, GST tagged Rpn13 Pru did not specifically bind to 
PIPs. In contrast, the GLUE domain, which is a PH domain known to bind PIPs, exhibited 
signals for PIP binding. 
 
 
Figure 1.25: Protein–lipid overlay assay of mRpn13 Pru using PIP StripsTM membranes 
containing 100 pmol of phospholipids. The membranes were incubated with GST alone, GST–
tagged Rpn13Pru and GST–tagged GLUE. Membranes were decorated with GST antibody 
and bound protein was detected by chemiluminescence. In contrast to GST–GLUE as positive 
control, GST (negative control) and GST–tagged Rpn13 did not show any signal. 
 
We compared structures of Rpn13 Pru and other PH domains bound to PIPs in order to get 
insights about structural requirements for binding to PIPs. 
Most PH domains bind PIPs at a canonical site located between the S1–S2 and S3–S4 loops. 
A typical example is DAPP1 with PIP bound to the canonical site (PDB accession code 
1FAO)113. Rpn13 Pru shows a similar architecture of the putative PIP binding grove as found 
at the PIP binding site in DAPP1:PIP complex (Figure 1.26). In DAPP1 it is the loop between 
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strands S1 and S2 which is mainly responsible for the interaction, and which is strictly 
conserved among PH domains binding PIPs110. Although the conformation of the loop 
between S1 and S2 in Rpn13 Pru is similar to that of DAPP1, the overall charge distribution 
on the surface of the Rpn13 Pru differs from the positively charged profile of DAPP1:PIP 
binding site (Figure 1.26). The positively charged surface of the molecule is essential for 
binding the negatively charged phosphate side chains of PIPs. Additionally, this region is not 
conserved among members of the Rpn13 family, thus excluding a possibility that these 
molecules carry a canonical PIP binding site. Together with the result from the protein–lipid 
overlay experiment, it is very unlikely that the Pru domain can specifically interact with PIPs. 
 
 
 
 
Figure 1.26: Structural comparison of Rpn13 Pru and DAPP1 bound to inositol 1,3,4,5–
tetrakisphosphate (P5I) (PDB accession code 1FAO). Electrostatic potential surface 
representations of Rpn13 Pru and DAPP1 are colour coded according to their electrostatic 
potential, contoured from –25kT/e (intense red, negative charges) to +25kT/e (intense blue, 
positive charges). Ribbon presentations of molecules in the same orientation are shown as 
insets. 
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1.3.6 Interaction of Rpn13 with the Ubiquitin C–terminal 
hydrolase (UCH) 37 
 
The C–terminal part of Rpn13 is supposed to recruit the deubiquitinating enzyme Uch37 to 
the ubiquitinated substrates for subsequent release of the polyUb chains and therefore might 
also function in processing of substrate proteins. Rpn13 is not only reported to bind to the C–
terminus of Uch37, but was also shown to significantly stimulate the enzymatic activity of the 
enzyme upon binding76-78.  To structurally investigate the interaction of Rpn13 with Uch37, 
different C–terminal variants of Rpn13 were expressed and subjected to crystallization. The 
Rpn13 variants 5, 6, 7 and 8 listed in Table 1.1 were cloned and expressed as described in 
Section 1.3.1. Truncated versions of Uch37 (aa 6–228, aa 6–325) were cloned in pGEX–6P–1 
vector and purified according to the same procedure as Rpn13. So far, no crystals were 
obtained. 
To gain more insight into the interaction modus of Rpn13 with Uch37 the two proteins were 
coexpressed using a bicistronic expression system. Therefore, a vector with a bicistronic 
operon was constructed by introducing a second ribosomal binding site (RBS) and a second 
open reading frame (ORF2) into the pGEX–6P–1 vector (Figure 1.27a) as described in 
Materials and Methods. The C–terminal domain of Rpn13 was cloned into the first ORF1, 
thereby introducing a PreScission Protease cleavable GST–tag, whereas Uch37 was cloned 
into the second ORF2. Both proteins were expressed and purified from bacterial lysate by 
affinity chromatography using Glutathione Sepharose and eluted with PreScission Protease 
according to the same procedure as in Section 1.3.1. The complex was further purified via 
size exclusion chromatography (see Materials and Methods) and subjected to crystallization. 
Rpn13 and Uch37 formed a stable complex in vitro, since only Rpn13 carried an affinity tag 
and the complex remained stable upon gel filtration.  Figure 1.27 shows the Rpn13 (aa 202–
407):Uch37 (aa 230–325) construct as an example for the copurification. The DNA sequence 
encoding this Uch37 construct contains an unexpected Shine–Delgarno sequence in proximity 
to the transcription start, which led to the additional expression of a shorter version of Uch37 
(marked with an asterisk). First results indicate that this shortened version (aa 249-325) is still 
able to bind to Rpn13. As demonstrated in Section 1.3.2.1 (Figure 1.7), the linker domain in 
Rpn13 lacks secondary structure elements and is rather unlikely to be involved in interaction 
with Uch37. Therefore, a shortened variant (300–407) of hRpn13 was constructed, which was 
sufficient for binding to Uch37 and represents the shortest known Uch37–interaction module 
on Rpn13 so far. In future, further truncation mutagenesis has to be performed to specifically 
map the interaction module and to improve crystallization tendency. 
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Figure 1.27: Bicistronic expression and purification of Rpn13:Uch37 complex. (a) Schematic 
view of the constructed bicistronic expression vector based on pGEX–6P–1. Rpn13 was 
cloned into ORF1 and carried a cleavable GST–tag, whereas UCH37 was cloned into ORF2. 
(b) Coomassie stained SDS–PAGE (17.5%) of purification of the Rpn13(202–
407):Uch37(230–325) complex with Glutathione–Sepharose. 1=after sonification, 2=pellet, 
3=flow through, 5=wash, 6=elution with PP. The asterisk marks a Shine–Delgarno product 
of Uch37. (c) The Rpn13 (202–407):Uch37 (230–325) complex after run with Superdex 200 
gel filtration column, 1–4=fractions. 
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1.4  Discussion 
 
1.4.1  The N–terminal Pru domain of Rpn13 
 
The structure of the CP has been solved by X–ray crystallography11-13, whereas structural 
insights on the RP are limited. The complexity of substrate recognition by the proteasome has 
hindered the development of general mechanistic models for how protein degradation is 
triggered and regulated. Proteasomal Ub receptors are well characterized, with the structures 
of proteasomal subunit Rpn10/S5a118,128 as well as UBL/UBA family members129-132. This 
study could identify Rpn13 as a novel Ub receptor for the proteasome, which is unrelated to 
Rpn10 and the three UBL/UBA proteins, and moreover defines a new class of Ub recognition 
surface. 
The Ub–binding region of Rpn13 adopts a PH fold and the complex structure of Rpn13 Pru 
with Ub unveiled a new Ub–binding mode. The PH fold is present in a remarkably large 
number of proteins110, but Rpn13 Pru is the first example of a PH domain structure within the 
26S proteasome. NMR structural analysis of Rpn13 from yeast99 revealed that it adopts a PH 
fold despite its low sequence identity with Rpn13 from higher eukaryotes (Figure 1.13 and 
1.28). Residues that are conserved between fungi (S. cerevisiae and S. pombe) and eukaryotic 
Rpn13 are largely involved in forming and stabilizing the typical PH hydrophobic core 
(Figure 1.13).  
 
 
Figure 1.28: Stereo representation of the structural superposition of murine (grey) and yeast 
(red) Rpn13 Pru. Ub binding loops for murine and yeast Rpn13 are coloured in blue and 
yellow, respectively99. 
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Structural superposition of secondary structure elements of murine and yeast Rpn13 resulted 
in an r. m. s. deviation of 2.55 Å (Figure 1.28). Since scRpn13 is the most divergent in 
primary sequence from mRpn13, we conclude that all Rpn13 homologues contain N–terminal 
PH topology. 
 
 
 
1.4.2  Comparison of Rpn13 from mouse and yeast 
 
Rpn13 from budding yeast is the smallest member of the family, with only five residues 
preceding the N–terminal PH domain and no C–terminal Uch37–binding domain76-78. No 
Uch37 homologue has been identified in yeast, consistent with the omission of the C–terminal 
domain in scRpn13. Rpn13 proteins from mouse and yeast bind Ub using the S2–S3, S4–S5, 
and S6–S7 loops, which are 22% identical in primary sequence. The S6–S7 loop plays an 
important role in binding Ub for both species, with F91, S93 and R96 of scRpn13 expected to 
perform analogous roles to F98, G101 and R104 of mRpn13. By contrast, the S4–S5 loop in 
mRpn13 is conserved in mammals, but not in S. cerevisiae, in which it is shortened and 
directed towards the structural core rather than the Ub binding surface (Figure 1.28). 
Moreover, important interactions are lost between this loop and Ub in scRpn13; for example, 
D78, which in mammals forms a hydrogen bond with H68, is replaced with G71 in scRpn13. 
It is tempting to speculate that mammals take better advantage of Ub’s H68. Such differences 
between scRpn13 and mRpn13 correlate with the significantly higher affinity of hRpn13 for 
Ub as compared to scRpn1399. This alteration in Rpn13, together with the difference in its 
association with Uch37, suggests interesting evolutionary adjustments of the role of Rpn13 in 
proteasome function, the details of which remain to be described. 
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1.4.3  Rpn13 loops bind Ub 
 
Rpn13, like many other Ub receptors, binds to the L8, I44, and V70 hydrophobic pocket of 
Ub. However, the Pru domain of Rpn13 is the first to bind this region using exclusively loops 
(Figure 1.29). Ubiquitin-binding domains, which complex structures with ubiquitin were 
solved, are listed in Table 1.3. 
 
Ub-binding domain Full name Source protein PDB ID 
UBA ubiquitin-associated Dsk2  1WR1 
  hHR23A 1ZO6 
  Mud1 1Z96 
  Ede1 2G3Q 
CUE 
coupling of ubiquitin conjugation 
to endoplasmatic reticulum 
degradation 
Vsp9 1P3Q 
  Cue2 1OTR 
GAT 
Golgi-localized, gamma-ear-
containing, ADP-ribosylation-
factor-binding protein and target of 
myb 
GGA3 1YD8 
   1WR6 
  TOM1 1WRD 
UEV Ubc E2 variant Vps23 1UZX 
  Tsg101 1S1Q 
Ubc ubiquitin-conjugating enzyme UbcH5 2FUH 
UIM ubiquitin-interacting motif Vsp27 1Q0W 
   1O06 
  S5a 1YX5 
   1YX6 
DUIM double-sided UIM Hrs 2D3G 
MIU motif interacting with ubiquitin Rabex-5 2FID, 2FIF 
   2C7N 
NZF Npl4 zinc finger Npl4 1Q5W 
A20 ZnF A20 zinc finger Rabex-5 2FID, 2FIF 
   2C7N 
ZnF UBP zinc finger ubiquitin-specific processing protease Isopeptidase T 2G45 
GLUE GRAM-like ubiquitin binding in ELL-associated protein 45 Vsp36/EAP45 2HTH 
   2DX5 
PH Pleckstrin homology Rpn13 2Z59 
Table 1.3: Ubiquitin-binding domains. Protein data bank codes (PDB ID) are only listed for 
co-ordinates containing ubiquitin-binding domains complexed with ubiquitin. 
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Most of the Ub receptors characterized to date use α–helices to bind this surface of Ub, 
including UBA, CUE, UIM, DUIM, MIU and GAT133. Among them, the UBA and CUE 
domains are structurally homologous showing common 3–helical bundle architecture. The 
CUE domain of Cue2–1 binds Ub through the α1 and α3 helices (Figure 1.29b)116, whereas 
the UBA–domain of Dsk2 uses the loop between α1 and α2, as well as the C–terminal part of 
α3 (Figure 1.29c)131. M342 of Dsk2`s UBA and M19 of Cue2–1`s CUE domain play an 
integral role in recognizing Ub by forming hydrophobic contacts with its I44–centred pocket 
and a hydrogen bond to G47116,131. Structural characterization of the UIMs demonstrated that 
a single α–helix is sufficient for binding this region of Ub118,134,135. The UIM helix includes a 
conserved alanine neighboured by a bulky hydrophobic residue, each of which packs against 
Ub’s I44 as demonstrated in the S5a UIM1/Ub complex (Figure 1.29d)118. The MIU/IUIM 
domain of Rabex–5  (Figure 1.29e)136,137 and the pol η UBZ domain138 similarly bind this 
region in Ub through a single α–helix, with a contact surface formed by hydrophobic residues 
proximal to a central invariant alanine. In this special case the helix is in the reverse 
orientation. The GLUE domain of ESCRT–II EAP45, which exhibits a split pleckstrin–
homology topology, is the only previously known Ub–binding PH domain139. However it 
binds Ub in a different manner: the I44 containing surface of Ub is contacted by residues 
within secondary structural elements including the EAP45 C–terminal helix corresponding to 
H1 in Rpn13139 (Figure 1.29f). Moreover, although the longer S6–S7 loop of EAP45 is 
involved in binding Ub, the S2–S3 and S4–S5 loops are not; instead, contacts are formed by 
residues from S5 and S6. Like these other receptors, Rpn13 binds the I44 hydrophobic patch 
of Ub, but does so using three loops to generate a relatively large buried surface area, which 
comprises 1256 Å2 for both molecules in complex. Thus, the relatively high affinity of 
7.5 µM for Rpn13 binding to monoUb99 is explained by the enlarged contact surface as 
compared to that of EAP45 GLUE (1000 Å2 in total)140. Published values for the total buried 
surface of Cue2–1cue and Dsk2UBA upon Ub binding are even smaller: 960 and 800 Å2, 
respectively116,131. 
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Figure 1.29: Structural comparison of Ub receptors complexed with Ub. (a)–(f) Complex 
structures of Ub and specific receptors displayed with Ub in the same orientation (grey) and 
Ub’s I44 shown in black sticks. Each receptor has unique colour coding: (a)Rpn13 Pru (red), 
(b) Cue2–1CUE (PDB code 1OTR; light green), (c) Dsk2UBA (PDB code 1WR1; dark green), 
(d) S5a–UIM1 (PDB code 1YX5; light blue), (e) Rabex–5 MIU/IUIM (PDB code 2FIF; dark 
blue), (f) EAP45 GLUE domain (PDB code 2HTH; yellow). All structures are compared by a 
best–fit superposition of bound Ub (grey). In (c), L1 denotes the loop connecting α1 and α2. 
51 
Discussion  Chapter 1 
1.4.4 The first proteasomal Pleckstrin Homology domain 
 
As shown in this work, Rpn13 Pru adopts the fold typical for Pleckstrin Homology (PH) 
domains, which are present in a remarkably large number of proteins from yeast to humans110. 
So far, Rpn13 is the first example which adopts a PH topology within the 26S proteasome. PH 
domains are small modules (100–120 amino acids) found in a multitude of intracellular 
proteins with very widespread functions106-110. Although PH domains show low homology at 
the primary sequence level and have diverse cellular functions as well as ligand/protein 
binding properties, their overall architecture and composition of the hydrophobic core are 
well conserved. Each PH domain is electrostatically polarised, with variable loops forming a 
charged surface. These loops are supposed to determine variability and specificity of 
protein:protein and protein:ligand interactions of different PH domains and indeed, binding of 
Rpn13 Pru to ubiquitin is exclusively mediated by its loops. Wide distribution and functional 
diversity of the PH domain family originates from their ability to bind to virtually any target 
by simple adaptation of their molecular surface and by displaying highly variable residues 
throughout the protein surface. This feature of surface adaptation is comparable to the 
modularity of other protein binding scaffolds like the ankyrin–repeat141 or the 
immunoglobulin fold. The NMR data showed that Rpn13 Pru binds to Rpn2 and Ub from 
opposite directions, thus displaying another example of the protein adaptor functions of PH 
domains. The very high degree of flexibility in PH domains makes it rather difficult, to 
predict putative interaction partners or binding motifs of Rpn13 by comparison with 
homologous PH domains. The GLUE domain of ESCRT–II EAP45, which is so far the only 
identified PH domain known to bind Ub139,140 in contrast to Pru, forms a split pleckstrin–
homology domain, but binds ubiquitin along the S5 edge of the β–sandwich139. Rpn13’s 
ubiquitin binding mode is novel, and it will be interesting to learn whether other receptors use 
this unique binding mode. 
Many PH–domains act in pathways of membrane trafficking and were shown to bind 
phosphatidylinositolphosphates (PIPs) through a conserved and positively charged 
pocket110,142. Additionally, it has been shown that a small fraction of Rpn13, like proteasome, 
appears to be membrane associated86. However, protein–overlay assay and the structural 
superposition performed in this study exclude an interaction of Rpn13 Pru with PIPs. 
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1.4.5  Rpn13 and its neighbours in the proteasome 
 
Rpn1 and Rpn2, which abut the hexameric ATPase complex, have been proposed to play 
scaffolding roles in the RP, as they bind multiple proteins involved in Ub chain docking and 
processing, including deubiquitinating enzyme Ubp6143, Ub ligase Hul5144, the arsenite–
inducible factor AIRAP145 and UBL/UBA family members41. Rpn10 may also reside in this 
region of the proteasome77,144. The extent of coordinate action on an Ub chain will depend on 
its length, but, given the presence of both an Ub ligase and two deubiquitinating enzymes in 
this assembly, chain length is likely to be highly dynamic for any conjugate docked in this 
area. The proteasome is typically viewed as a molecular machine with hard–wired 
connections between discrete parts whose movements are driven by the energy of ATP 
hydrolysis. However, the Ub receptors and Ub chain processing enzymes lack any obvious 
ATPase motifs. Many (perhaps most) contain notably flexible segments118,130, which may 
allow their active sites to explore large spaces in the periphery of their docking site in the 
proteasome. Such flexibility may enable several enzymes to work simultaneously on a given 
Ub chain. The identification of a new Ub receptor in this region of the proteasome, together 
with its intimate linkage with a deubiquitinating enzyme, emphasizes the importance of this 
region as well as the significance of Ub chain dynamics for substrates docked here. Rpn13 has 
a unique Ub binding preference for diUb elements within K48–linked chains99 and most 
likely interacts directly with the isopeptide bond within an Ub chain. This Ub binding mode is 
consistent with the functional relationship of Rpn13 with Uch37, which it adds to this 
region’s collection of chain processing enzymes76-78. Binding to Rpn13 both facilitates the 
deubiquitinating activity of Uch3776,77 and links Uch37 to the proteasome, suggesting that 
Rpn13 plays a major role in Ub chain disassembly at the proteasome. We propose that, in 
docking Ub conjugates at the proteasome, Rpn13 performs two functionally distinct but 
related roles. The substrate component of the conjugate is exposed to an unfolding site in the 
proteasome, while, perhaps at the same time, the Ub component is presented to a chain 
disassembly site. The unfolding site is presumably the hexameric ATPase ring composed of 
Rpt1–6, while the disassembly site is proposed to be Uch37. These components are all found 
clustered within the base subassembly of the proteasome. Our findings suggest that the Ub 
receptor function of Rpn13 does not serve simply to enhance Uch37 activity, but, as other Ub 
receptors, it promotes protein degradation by participating in the substrate docking step. 
Uch37 has an explicit enzymatic directionality whereby it only deconjugates chains from the 
distal end, removing one Ub moiety at a time74. This strict cleavage specificity complements 
that of Ubp6 and Rpn11, as Ubp6 can deconjugate multiple Ub’s in a single cleavage event143 
and Rpn11 performs “en bloc” deubiquitination from the proximal end54,55. Deubiquitinating 
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activities, particularly Ubp6, are antagonized by another Rpn2–bound protein, the chain 
elongation factor Hul5144. With so many receptors and chain–processing enzymes bound to 
Rpn1 and Rpn2, some of them mutually antagonistic, the detailed pathway by which a 
substrate is degraded may be subject to many stochastic variations. Whether this 
unanticipated design promotes high substrate flux through the proteasome is unclear, but it 
seems well suited to allow the cell to fine–tune proteasome activity143,145. 
 
  
1.4.6  Rpn13 recruits Uch37 to the proteasome 
 
Uch37 was proposed to function as an “editing isopeptidase”74 and to disassemble chains 
bound to the proteasome, and, given that it removes one Ub at a time from the substrate–distal 
tip of the chain, to complete the removal of short chains more rapidly than long ones. In this 
way, Uch37 could help to suppress the degradation of oligoubiquitinated substrates by 
proteasomes, thereby functioning in a proofreading process. The attrition of long chains by 
Uch37 may have a more modest effect on their affinity for the proteasome, because they 
arrive with more Ub groups than are needed to maintain interaction with proteasomal Ub 
receptors. Recent studies76-78 showed that Rpn13 recruits Uch37 to the proteasome and acts as 
a facilitator of Uch37 by the stimulation of its catalytic activity. If the Ub receptor activity of 
Rpn13 simply served to present chains to Uch37, then Rpn13 would likewise serve only as an 
antagonist of degradation. However, Rpn13 seems to be a positive regulator in this 
process71,77,96. The ubiquitin–binding data suggests that, by binding to Rpn13, Uch37 is 
brought into the proximity of a high–affinity complex involving Ub, and thus activated. Other 
mechanisms of activation by Rpn13 may also operate, and it has been postulated that Uch37’s 
C–terminal region acts as a competitive inhibitor, as its deletion enhances Uch37 
deubiquitinating activity and binding of Rpn13 to this C–terminal domain of Uch37 relieves 
its autoinhibition. Additionally, the presence of Rpn13 might just enhance Uch37 catalytic 
activity principally by serving as a bridge between Uch37 and Ub.  
Altogether the data1,99 confirm that Rpn13 binds diUb elements of K48–linked Ub chains and 
engages interactions with K48 and G76 that are linked by an isopeptide bond as shown by 
NMR spectroscopy. We propose that by abrogating interactions between the Ub moieties of a 
diUb unit and by changing the orientation of the isopeptide linker region, the cleavage site of 
Uch37, Rpn13 facilitates substrate recognition by Uch37. This model is similar to one 
proposed for substrate ubiquitination, whereby an E3 enzyme can align the E2–Ub thiolester 
in a favourable orientation146. Whereas Uch37 exhibits distal end cleavage specificity, the 
interaction of Rpn13 with the Ub linker is likely to place it preferentially at the penultimate, 
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rather than most distal Ub subunit of a chain (Figure 30). This localisation of Rpn13 to the 
more proximal Ub subunit is supported by NMR data using diubiquitin in which either the 
proximal or distal subunit is 13C labelled. This was then monitored by 1H, 13C HMQC 
experiments as hRpn13 Pru was added and indeed, hRpn13 Pru binds to the proximal and not 
the distal subunit. Consequently, the preferred cleavage site when Rpn13 is bound to the 
penultimate subunit would be at the distal end of the chain (Figure 1.30). 
 
 
Figure 1.30: Model for Rpn13–mediated activation of Uch37 by Ub binding. Ub–P, 
penultimate Ub, Ub–D; distal Ub. Proposition that Uch37–mediated deubiquitination occurs 
through a 2–step processive mechanism, in which it cleaves first the distal (a) and then the 
initially penultimate (b) linkage as the chain remains stationary on the proteasome. 
 
With the exception of yeast, Rpn13 homologues from all organisms contain a linker region 
which connects the PH domain with the C–terminal Uch37 binding domain. In contrast to the 
N–terminal parts of hRpn13 and hUch37, secondary structure prediction of the C–terminus of 
both proteins shows solely helical secondary structure elements. Indeed, coexpression of the 
two interaction partners in this study revealed that the interaction module is limited to these 
helical domains located at the end of both polypeptide chains. Moreover, the amino acid 
residues from 300 to 407 on Rpn13 and from 230 to 325 on Uch37 appear to be sufficient for 
interaction. 
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1.5  Materials and Methods 
 
1.5.1  Materials 
 
1.5.1.1 Oligonucleotides 
 
The following oligonucleotides were used as primers to amplify different constructs of Rpn13 
and Uch37 from Saccharomyces cerevisiae, Mus Musculus and Homo sapiens. For the 
ligation of the amplified genes into the vectors pRSET–GST–PP, pGEX–6P–1 and pGEX–
bicistron, all primers carried specific restriction sites. These sites were BamHI (forward and 
reverse) in case of pRSET–GST–PP, BamHI (forward) and EcoRI (reverse) for pGEX–6P–1. 
Primers used for cloning into pGEX–bicistron vector carried the restriction sites 
BamHI/EcoRI and NdeI/NotI for the open reading frames 1 and 2. Additionally, all primers 
were designed to have an overhang to ensure high cleavage efficiency. The primers are 
synthesized and purified from Metabion international AG. 
 
Name         Enzyme Organism 
 
Rpn13 
mmRpn13_1_fo  5`–GCG GAT CCA TGA CGA CTT CAG GCG BamHI  Mus musculus
       CTC TG–3`    
      
mmRpn13_150_re 5`–GCG GAT CCT CAC AGT GCT GAA AGC  BamHI  Mus musculus 
     TC–3`       
 
mmRpn13_151_fo 5`–GCG GAT CCG GCG GTG AGG GTG GCC–3`BamHI  Mus musculus 
 
             
mmRpn13_407_re 5`–GCG GAT CCT CAG  TCT AGA CTC ATA BamHI  Mus musculus 
     TCT TCT TC–3` 
        
scRpn13_1_fo  5`– AAA AAA GGA TCC AGT ATG AGT TCA BamHI  Saccharomyces  
 ACT GTA ATT AAA TTC –3`    cerevisiae
    
scRpn13_156_re  5`– AAA AAA GGA TCC TTA ATC TTG CAT  BamHI  Saccharomyces 
ACT AAC ATC CAC–3`     cerevisiae 
  
scRpn13_123_re  5`– AAA AAA GGA TCC TTA ATT GTA AAT  BamHI  Saccharomyces 
TTC TTT ATC TTT CGC AC–3`    cerevisiae 
 
hsRpn13_202_fo  5`– AAA AAA GGA TCC GGG AGC AGC TCC BamHI  Homo sapiens 
 TCC TCC –3`       
 
hsRpn13_267_fo  5`– AAA AAA GGA TCC CTC CAG AGC ATC  BamHI  Homo sapiens 
CTG GCC –3`       
            
hsRpn13_407_re  5`– AAAcAAA GGA TCC TTA GTC CAG GCT BamHI  Homo sapiens 
 CAT GTC CTC C –3`     
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Rpn13_407_re_bicis 5`– AAA AAA GCG GCC GCC ATA TGT ATA NotI  Homo sapiens 
 TCT CCT TCT TAA AGT TAA ACA AAA TTA 
 TTG TCG ACG GAG CTC GAA TTC TTA GTC 
 CAG GCT CAT GTC CTC C–3`     
        
UCH37 
hsUch37_6_fo  5`– AAA AAA GGA TCC GGG GAG TGG TGC BamHI  Homo sapiens 
 CTC ATG–3`   
  
hsUch37_228_re  5`– AAA AAA GAA TTC TTA TTT TCT GTC EcoRI  Homo sapiens 
 AGA CAC AAT GGC –3`    
  
hsUch37_325_re  5`– AAA AAA GAA TTC TTA AGC TTT CTT EcoRI  Homo sapiens 
 TGC GTT CTG TTT TTC–3`     
 
hsUch37_234_fo_bicis 5`– AAA AAA CAT ATG ATA TAT GAG CAG NdeI  Homo sapiens 
 AAG ATA GCA G–3      
 
hsUch37_407_re–bicis 5`– AAA AAA GCG GCC GCT TAA GCT TTC NotI  Homo sapiens 
 TTT GCG TTC TGT TTT TC –3`      
 
 
1.5.1.2 Vectors 
 
1.5.1.2.1 pRSET–GST–PP  
 
The expression vector pRSET–GST–PP was derived from the pRSET vector (Invitrogen) by 
cutting out the MCS (Multiple Cloning Site) with restriction enzymes NdeI and BamHI and 
insertion of the DNA encoding GST–tag followed by a PreScission Protease (PP) cleavage 
site. Rpn13 constructs (see Table 1.1, 1.3.1) were ligated with BamHI restriction sites into the 
pRSET–GST–PP vector, which carries a T7 promoter, ampicillin resistance (Ampr) and a lac 
operator, allowing gene expression to be induced by IPTG (isopropyl–b–D–
thiogalactopyranosid). Finally, a protein expressed with this vector could be purified by 
affinity chromatography via the GST–tag which can be cleaved off with PreScission Protease. 
 
 
1.5.1.2.2 pGEX–6P–1 and pGEX–4T–1  
 
The pGEX–6P–1 vector (Amersham Biosciences) was used for expression of Uch37 variants, 
which did not express in the pRSET system and also as a platform for construction of the 
bicistronic vector. Similar to pRSET–GST–PP vector, this vector contains a GST–tag 
followed by a PreScission Protease site for cleavage of the tag (vector map is shown in 
Figure 1.31). Uch37 constructs were inserted with the restriction sites BamHI and EcoRI of 
the MCS. The vector carries ampicillin resistance (Ampr) and expression is under the control 
of the tac promoter, which is induced by the lactose analogue IPTG.  
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Figure 1.31: Vector map of 
expression vector pGEX–
6P–1 (Amerham 
Bioscience).  
 
 
 
 
 
 
 
The pGEX–4T–1 vector was used for expression of GST–fused tetraUb and different point 
mutants of Rpn13 Pru domain. It is very similar to pGEX–6P–1 except that it carries a 
thrombin cleavage site instead of the PP cleavage site. Different deletion mutants of hRpn2 
(aa695–953, aa797–953, aa881–953, and aa902–953) were also subcloned into pGEX–4T–1 
using BamHI restriction sites and additionally into pEGFP–C1 (Clontech) verified by 
sequencing. All pGEX vectors are also engineered with an internal lacIq gene. The lacIq gene 
product is a repressor protein that binds to the operator region of the tac promoter, preventing 
expression until induction by IPTG, thus maintaining tight control over expression of the 
insert. 
 
 
1.5.1.2.3 Bicistronic vector system 
 
Based on the pGEX–6P–1 vector (Figure 1.31), an expression vector with a bicistronic operon 
for simultaneous expression of two different proteins was constructed (Figure 1.32). 
Therefore, the Rpn13 gene was inserted with the restriction enzymes BamHI and NotI using a 
reverse primer, which contains several restriction sites, a second ribosomal binding site (RBS) 
and the second open reading frame (ORF2) resulting in a vector system with an ORF1 
bordered by BamHI at the 5`–end and EcoRI at the 3`–end and an ORF2 bordered by NdeI 
and NotI. A GST–tag with PP cleavage site is preceding ORF1. In case of coexpression of the 
two proteins, Rpn13 and Uch37 were cloned into ORF1 and ORF2, respectively. 
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 pGEX–6P–1 
  BamHI  EcoRI      SacI            SalI     
          
GST_PPCTGGGATCCORF1GAATTC/GAGCTCCGTCGACAATAATTTTGTTTAACTTT 
 
pGEX–6P–1 RBS       NdeI         NotI 
 
AAGAAGGAGATATACATATG ORF2GCGGCCGC 
 
Figure 1.32: Inserted sequence of bicistronic expression vector pGEX–bicistron. Rpn13 was 
cloned in the ORF1 and carries a cleavable GST–tag, whereas Uch37 was cloned into ORF2. 
 
 
1.5.1.3 Bacteria 
 
The following E. coli strains were used for molecular biological working and for the 
expression of the variants of Rpn13 and Uch37. The strains were ordered from Stratagene, 
Heidelberg. 
 
Strain Genotype Application 
XL–1 blue strain a 
 
 
 
recA1 endA1 gyrA96 thi–1 hsdR17 
supE44 relA1 lac{F’ proAB 
laclqZM15Tn10(Tetr)} 
non inducible promoter 
Preparation of high–quality plasmid 
DNA. 
BL21–CodonPlus(DE3)–RIL 
 
 
B F–ompT hsdS(rB– mB–) dcm+ Tetr 
galλ (DE3) endA Hte {argU ileY leuW 
Camr), extra copies of argU, ileY and 
leuW tRNA genes on a ColE1–
compatible plasmid with canamycine 
resistance marker, protease deficiency, 
chromosomal T7–polymerase gene 
Induced high–yield protein expression 
with, especially with T7 promoter. 
 
 
 
 
 
B834(DE3) F–ompT gal hsdSB (rB–mB–) met dcm 
lon _DE3 
Methionine auxotroph expression 
host; labelling of proteins with 
selenomethionine 
Table 1.4: Different E. coli strains which were used in this study. 
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1.5.1.4  Enzymes 
 
Name Company 
Taq Polymerase New England Biolabs, Schwalbach 
Pfu Polymerase Promega 
Shrimp Alkaline Phosphatase Roche 
T4 DNA Ligase New England Biolabs, Schwalbach 
Restriction Enzymes (BamHI, EcoRI…..) New England Biolabs, Schwalbach 
Trypsin  SIGMA, Saint Louis, MI, USA 
Chymotrypsin SIGMA, Saint Louis, MI, USA 
Carboxypeptidase Y  Worthington Biochemical Corp., 
Lakewood, NJ 
PreScission Protease self-made 
Table 1.5: List of used enzymes. 
 
 
1.5.1.5  Equipment and chemicals 
 
ÄKTA Explorer, ÄKTA Purifier and Amersham Biosciences, Freiburg 
ÄKTA Prime Chromatography Systems   
Amicon Ultra 10K, 30K device   Millipore, Bedford, MA, USA 
Autoklav Bioclav     Schütt 
Autoklav Varioklav     H+P Labortechnik GmbH 
Balance MC1 AC210P    Sartorius, Göttingen 
Balance CPG22     Sartorius, Göttingen 
Branson Sonifier 250     G. Heinemann 
Centrifuges: Avanti J–25, Avanti J–20 XP  Beckman Instruments   
Centrifuge 5810 R     Eppendorf 
22 mm x 0.96 mm thick Plain circle cover slides Hampton R., Laguna Niguel, CA,US  
22 mm Circular Cover Slides  (siliconized)  Jena Bioscience 
Cups (1.5 ml and 2.0 ml)    Sarstedt 
ThermoTubeTM PCR Tubes 0.2 ml   Peqlab Biotechnology GmbH 
Digital Camera     Sony 
Econo–Column Chromatography Column  Biorad 
Electrophoresis Power Supply   Consort 
Electrophoresis Power Supply EPS 601  Amersham Biosciences 
Freezer –20 °C     Liebherr 
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Freezer –80 °C Forma Scientifie, Life Sciences 
International GmbH 
Fridge 4 °C      Liebherr 
Fraction collector Frac 100    Amersham Pharmacia, Freiburg 
GDS–7900 System Transilluminator   UVP 
(Agarose gel documentation) 
Gel chambers workshop, Institut für Physiologische 
Chemie, München 
Gel Drying Film     Promega Corp., Madison, WI, USA 
Glas ware      Schott, Duran 
Grease       Hampton R., Laguna Niguel, CA, USA 
Greiner 96 well plates    Greiner und Söhne, Frickenhausen 
Incubators for molecular biology   Heraeus Christ 
Incubator for crystallisation    RUMED 
Microscope      Carl Zeiss AG, Oberkochen, Germany 
Mikro 22 R centrifuge    Hettich 
Mikrowave      Bosch 
Mono Q HR 10/10     Amersham Pharmacia, Freiburg 
Multichannel Pipette Research Pro 10 and 300 Eppendorf 
Multitron II shaker     Infors AG, Bottmingen 
Nanosep Centrifugal Devices (3 and 10K)  Pall Life Sciences (New York, USA)  
NMR spectrometer Varian 
Overhead shaker workshop, Institut für Physiologische 
Chemie, München 
Mastercycler gradient  (PCR)    Eppendorf 
Petriplates      Greiner und Söhne, Frickenhausen 
Peristaltic–Pump P–1    Amersham Biosciences 
pH–Meter CG 822     Schott 
Photometer Gene Quant pro    Amersham Biosciences 
Photometer Ultrospec 10    Amersham Biosciences 
Pipettes 2, 20, 100, 200, 1000 µl   Gisco 
Primus (PCR)      MWG Biotech 
PP–Test tubes, 15 and 50 ml (falcons)  Greiner 
Quarz precision cuvettes 105.201–QS  Hellma Müllheim 
Röntgen films NewRX    Fuji 
Sterile benches     BDK, Genkingen 
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Superdex 200 HR 10/30    Amersham Pharmacia, Freiburg 
Table centrifuge 5415 D    Eppendorf–Netheler, Hamburg 
Thermomixer compact    Eppendorf 
VDX™ 24 well plate (greased)   Hampton R., Laguna Niguel, CA, US 
Vortex Mixer      Bender&Hobein, Zürich 
 
Unless stated otherwise all chemicals were from the following companies in p.A. 
quality. 
●Amersham Biosciences, Freiburg 
●Applied Biosystems, Weiterstadt  
●Fluka, Neu–Ulm  
●Fermentas, St.Leon–Rot  
●Merck, Darmstadt  
●New England Biolabs, Schwalbach/Taunus  
●Qiagen, Hilden 
●Promega 
●Roth, Karlsruhe 
●Serva, Heidelberg 
●Sigma Aldrich, Deisenhofen 
 
 
1.5.1.6 Media and Buffers 
 
All solutions and media used for microbiological work were sterilized either by autoclaving 
or filtration. Buffers were prepared using bidestillized water (ddH2O, Millipore). 
 
NAME PRESCRIPTION 
E. coli Media 
LB 10 g Trypton, 5 g Yeast Extract, 10 g NaCl, ad 1 l ddH2O (for culture plates ad. 1.5% 
w/v Agar) 
Selenomethionine labelling of proteins 
New Minimal Medium 7.5 mM (NH4)2SO4, 8.5 mM NaCl, 55 mM KH2PO4, 100 mM K2HPO4, 20 mM 
glucose, 50 µg/l of each amino acid,  0.1% CaCl2, 0.1% FeCl2, 1 µg/l(w/v) trace 
elements (each),  10 mg/l thiamine, 10 mg/l biotin, 0.25 mM selenomethionine 
Preparation of M9 Minimal Medium 
10xM9 salts 479 mM Na2HPO4, 220 mM KH2PO4, 86 mM NaCl 
M9 Minimal Medium 10 % (v/v) 10xM9 salts, 1 mM MgSO4, 19 mM NH4Cl, 17 mM glucose, 0.1 mM 
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CaCl2, 1% Gibco MEM Vitamin solution 
Competent Cells 
electrocompetent 10% Glycerol (v/v) 
chemical competent 0.1 M CaCl2  
Isolation of plasmid DNA 
Resuspension buffer 50 mM Tris–HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNAse 
Lysis buffer 200 mM NaOH, 1.0% (w/v) SDS 
Neutralization buffer 3 M potassium acetate, pH adjusted to 5.5 with acetic acid 
Agarose gels 
5xSample Buffer 50 mM EDTA, 0.05% Bromphenolblue (w/v), 0.05% Xylencyanol (w/v), 30% 
Glycerol (v/v) 
1xTAE –
Electrophorese–Buffer 
40 mM Tris/Acetat, 20 mM Natriumacetat, 1 mM EDTA, pH 7.5 
  
Antibiotics 
Ampicillin 100 mg/ml H2O 
Chloramphenicol 30 mg/ml Ethanol 
Tetracyclin 12.5 mg/ml Ethanol 
SDS–PAGE 
4xSample Buffer 40% Glycerol (v/v), 240 mM Tris–HCl pH 6.8, 0.02% Bromphenolblue (w/v), 20% 
β-Mercaptoethanol (w/v), 8% SDS (w/v) 
10xSDS Runningbuffer 248 mM Tris–Cl, 1.9 M Glycine, 10% SDS(w/v) 
Western Blot 
Transfer buffer 20 mM Tris–Cl, 150 mM Glycine, 20% (v/v) Methanol, 0.08% (w/v) SDS 
Ponceau S solution 0.2% (w/v) Ponceau S in 3% (w/v) Trichloracetic acid 
Staining of Protein gels 
Coomassie Stain 40% Ethanol (v/v)., 10% Acetic acid (v/v), 0.2% Coomassie Brilliant Blue R–250 
(w/v) 
Coomassie Destain 30% Methanol (v/v), 10% Acetic acid (v/v) 
Immunodecoration 
TBS 10 mM Tris–Cl pH 7.5, 135 mM NaCl 
ECL reagent 0.1 M Tris–Cl  pH 8.5, 2.5 mM 3–Aminophtalhydrazide, 0.4 mM Pcumaric acid,  
0.0113% H2O2  
Limited proteolysis 
Reaction Buffer 100 mM NaCl, 20 mM Tris–Cl pH 8.0 
Protein purification 
Lysis Buffer 100 mM NaCl, 20 mM Tris–Cl pH 8.0, 1mM DTT 
Glutathione–Sepharose  column 
Wash Buffer Lysis Buffer 
Elution Buffer Lysis Buffer plus PreScission Protease or plus 10 mM red. Glutathione  
TCA precipitation 
Precipitant 72% Trichloracetic acid 
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TCA wash buffer 100 mM Tris Tris–Cl pH 8.8, 70% (v/v) Ethanol, small amount (spatula tip) 
Bromphenolblue 
Mono Q Column 
Low salt buffer 20 mM Hepes pH 7.0, 1 mM DTT 
High salt buffer Low salt buffer with 1 M NaCl 
Size Exclusion Chromatography 
Gel filtration buffer  20 mM Tris–Cl pH 8.0,  40 mM NaCl, 1 mM DTT 
Crystallisation 
Nextal Screen System see manufacturer`s buffer composition table 
Crystallisation condition 
for mRpn13 Pru 
15 % (w/v) PEG 4000, 200 mM NaOAc, 1 mM DTT, 100 mM Tris–HCl, pH 8.5 
Protein overlay assay 
Blocking buffer 10 mM Tris–Cl, pH 8.0, 150 mM NaCl and 0.1% (v/v) Tween–20, 0.1% ovalbumin 
(w/v) 
NMR spectroscopy 
Buffer C 20 mM NaPO4 pH 6.5, 30 mM NaCl, 2mM DTT, 0.1% (w/v) NaN3, and 10% (v/v) 
D2O 
Biochemical pull down assay 
Thrombin cleavage 
buffer 
20 mM Tris–Cl pH 8.4, 150 mM NaCl, 2.5 mM CaCl2, 1 mM DTT 
Incubation buffer Thrombin cleavage buffer plus 10% Glycerol and 1% Triton X–100. 
Table 1.6: Media and buffers. 
 
 
1.5.1.7 DNA Isolation and Preparation Kits 
 
Name       Application 
 
Pure YieldTM Plasmid MidiPrep System Isolation of plasmid DNA from E .coli.  
 
Wizard® SV Gel and PCR Clean Up System Purification of PCR–products and 
extraction of DNA from agarose gel 
 
Company: Promega Corp., Madison, WI, USA. 
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1.5.1.8 Columns 
 
NAME VOLUME 
V0 = void 
volume 
LOADING 
RANGE 
MMW–
Range 
TECHNIQUE
Mono Q 5/50 
GL 
1 ml  50 mg  
Anion 
exchange 
Superdex 200 
HR 10/30 
24 ml 7.77 ml  10 – 600 kDa Size exclusion
Table 1.7: Columns. 
 
 
1.5.1.9 Bioinformatics 
 
DNA and protein sequences were obtained from the „National centre for Biotechnology 
Information” (http://www.ncbi.nlm.nih.gov) and SWISS–PROT (http://www.expasy.ch). 
Primary sequence predictions were obtained from PredictProtein. PredictProtein is an Internet 
service (accessible via SWISS–PROT portal) for sequence analysis and the prediction of 
protein structure and function. Users submit protein sequences or alignments and 
PredictProtein returns multiple sequence alignments, PROSITE sequence motifs, low–
complexity regions (SEG), nuclear localisation signals, regions lacking regular structure 
(NORS) and predictions of secondary structure, solvent accessibility, globular regions, 
transmembrane helices, coiled–coil regions, structural switch regions, disulfide–bonds 
(DISULFIND), sub–cellular localization, and functional annotations. For all services, users 
can submit their query either by electronic mail, or interactively from World Wide Web. The 
secondary structure prediction was made by PROFsec, an advanced method of PHDsec. 
The computation of various physical and chemical parameters for a given protein by entering 
its sequence was performed by the ProtParam tool (SWISS–PROT portal). The computed 
parameters include the molecular mass, theoretical pI, amino acid composition, atomic 
composition, extinction coefficient, estimated half–life, instability index, aliphatic index and 
grand average of hydropathicity (GRAVY) 
 
 
 
 
 
 
 65 
Materials and Methods  Chapter 1 
1.5.2  Methods 
 
1.5.2.1 Primer design 
 
The length of the primers varied from 26 to 94 bases and the primers had at least one G or C 
at the 3`–end to obtain better binding and elongation. They were designed to have a melting 
temperature of approximately 60°C to allow sufficiently high annealing temperatures and 
contained the required restriction sites. In case of the pRSET–GST–PP, pGEX–6P–1 and 
pGEX–bicistron vector (for ORF2 a start codon was necessary) no start codon had to be 
introduced because it is already included in the vector. For all constructs the reverse primers 
had to contain a stop codon (TGA) before the restriction site (see Section 1.5.1.1). 
 
 
1.5.2.2 Methods in molecular biology 
 
1.5.2.2.1 Polymerase chain reaction (PCR) 
 
Since the beginnings of the PCR new applications were constantly found for this method, 
which allows amplifying DNA sequences of any sequence. For the PCR two oligonucleotide 
primers complementary to sequences at the ends of the required DNA, a mixture of all four 
dNTP`s and a for high temperature stable polymerase with the suitable buffer and the right 
concentrations of salt are required. After the denaturizing of the dsDNA (denaturizing), the 
primers hybridize with the complementary DNA (annealing) and the polymerase elongates the 
ssDNA construct starting with the 3`–end of the primer (elongation). Thus, the number of 
dsDNA constructs increases exponentially with each cycle. Either the enzymes Taq or Pfu 
were used as polymerases. 
 
Reaction mixture: 
 Substance         Volume 
1) DNA template (approx. 0.5 µg/µl)      1 µl 
2) Forward primer (100 pmol/µl)      0.5 µl 
3) Reverse primer (100 pmol/µl)      0.5 µl 
4) dNTP`s (5 mM per nucleotide)      2 µl 
5) Taq or Pfu buffer (10x)       5 µl 
6) ddH2O sterile         40 µl 
7) Taq (5 U/µl) or Pfu polymerase (3 U/µl)     1 µl 
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The reaction mixture was pipetted into 500 µl PCR tubes and PCR reaction was carried out in 
a thermocycler. 
 
PCR program: 
 Temperature        Time 
1) 95 °C         10 min 
2) a) 92 °C         1 min 
    b) 58 °C         1 –2 min 
    c) 72 °C (Taq)/ 75 °C (Pfu)      1 min 
Step 2 was repeated thirty times. 
3) 72 °C (Taq)/ 75 °C (Pfu)      10 min 
 
Annealing temperature (2b) and elongation time (2c) of the reaction can be varied and had to 
be adjusted to the respective reaction. PCR products were analyzed by agarose gel 
electrophoresis and purified using the Wizard® SV Gel and PCR Clean Up System. To check 
for positive clones by PCR on E. coli colonies, colonies were picked with a sterile tip and 
resuspended in 10 µl of sterile ddH2O. The reaction volume was then only half of the above 
mixture, Taq was used as polymerase and the resuspended colony as template. The forward 
primer of the insert and a reverse primer annealing in the vector served as primers. The 
mammalian expression vector pcDNA3.1/myc–his containing the full–length cDNA of 
mRpn13 was kindly provided by Dr. Lamerant, Centre de Biophysique Moléculaire, 
France,147 and served as template for cloning of mRpn13 constructs. A pGEX–4T–1 vector 
containing DNA of human Uch37 (kindly provided by Ivan Dikic, Institute of Biochemistry 
II, Goethe University Hospital, Frankfurt (Main)) was used as a template for all Uch37 
cloning. 
 
 
1.5.2.2.2 Digestion of DNA with restriction endonucleases 
 
For analytical and preparative purposes plasmid DNA and PCR products were digested with 
restriction endonucleases, which digest the DNA at specific, mostly palindromal sequences. 
All used enzymes produced an overhang, thus only ligation of sticky ends occurred. The 
incubation time, temperature and the buffer conditions were applied according to the 
manufacturer’s recommendations. The obtained fragments were analyzed by agarose gel 
electrophoresis. Before the final sequencing of the resulting plasmid DNA, an additional 
restriction digestion was carried out to see whether the clone contained the required insert. 
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PCR product Vector Control Restriction 
5 µl PCR construct 
5 µl BSA (10x) 
0.5 µl Enzyme 1 
0.5 µl Enzyme 2 
5 µl 10xBuffer 
3 µg vector 
5 µl BSA (10x) 
0.5 µl Enzyme 1 
0.5 µl Enzyme 2 
5 µl 10xBuffer 
ad 50µl H2O steril 
2 µl vector 
2 µl BSA (10x) 
0.5 µl Enzyme 1 
0.5 µl Enzyme 2 
2 µl 10xBuffer 
13 µl H2O sterile 
Table 1.8: Restriction digestion of PCR product or vector as well as control restriction. 
 
All constructs for insertion into the pRSET–GST–PP/pGEX–4T–1 vector as well as the vector 
were digested solely with BamHI, whereas all constructs for ligation into pGEX–6P–1 vector 
were digested with endonucleases BamHI/EcoRI. According to Figure 1.27, constructs for 
ORF1 and ORF2 of the pGEX–bicistron vector were digested with the enzymes 
BamHI/EcoRI and NdeI/NotI, respectively. The analysis of the desired DNA fragments and 
cleaved vectors was done by gel electrophoresis (see 5.2.2.3).  
Self ligation of the linearized plasmid was suppressed by dephosphorylating the 5`–end using 
salmon alkaline phosphatase (SAP). Therefore 1 µl of SAP (10 U/µl) and the appropriate 
amount of 10 fold SAP buffer were added to the purified, digested vector and incubated for 
one hour at 37 °C. The reaction was stopped through gel electrophoresis or purification with 
Wizard® SV Gel and PCR Clean Up System. This reaction was not used in all cases because 
the dephosphorylation could reduce the number of positive clones after transformation. 
 
 
1.5.2.2.3 Ligation 
 
If PCR products and vector are restricted with the same restriction enzymes the desired DNA 
construct can be inserted into the open plasmid and ligated with T4 DNA ligase. Linearized 
DNA vector and an approximately 10 fold molar excess of DNA fragment to be inserted were 
incubated with T4 DNA Ligase and buffer. The ligation mixture was prepared on ice and 
incubation was performed either at RT for 1 h or at 4°C over night. The self ligation of the 
vector served as negative control. 0.5 to 1 µl of this mixture were used for transformation into 
competent E. coli cells. 
 68 
Materials and Methods  Chapter 1 
Ligation Negative–Control 
1 µl 
10 x molar excess 
2 µl 
1 µl 
vector 
PCR–construct 
10xLigase–buffer 
T4–DNA–Ligase 
1 µl 
16 µl 
2 µl 
1 µl 
vector 
H2O sterile 
10xLigase–buffer 
T4–DNA–Ligase 
Table 1.9: Ligation mixture. 
 
 
1.5.2.2.4 DNA agarose gel electrophoresis 
 
The agarose gel electrophoresis was used to separate and analyze DNA fragments between 
0.1 and 8 kb. Voltages were in the range of 80 to 120 V and the concentration of agarose 
between 1–2%. Detection was done by the DNA intercalating dye ethidium bromide which 
can be observed in the ultraviolet. In case of 1% (2%) agarose gel, 1 g (2 g) of agarose was 
solved under heat in 100 ml 1xTAE–buffer and supplemented with 1:10000 fold dilution of 
ethidium bromide (Sigma). The rigid gel was placed in a gel chamber and covered with TBE–
buffer. Samples were mixed with 5 x sample buffer and loaded onto the gel. For the marker a 
1kb or a 100bp DNA ladder (New England Biolabs) was used. DNA constructs and linearized 
vectors that were utilized for ligation were excised from the gel under UV light (λ = 254 nm) 
and purified with the Wizard® SV Gel and PCR Clean Up System. 
 
 
1.5.2.2.5 Competent E. coli cells 
 
1.5.2.2.5.1 Chemical competent E. coli cells 
 
500 ml LB medium supplemented with tetracycline (XL1blue) or chloramphenicol (BL21–
(DE3)–RIL) were inoculated with 5 ml of over–night culture of the desired E. coli strain. The 
cells were grown at 37°C to OD600 of 0.4. After incubation on ice for 15 minutes cells were 
centrifuged for 15 minutes at 2580 x g (4000 rpm, JA10 rotor) and 4°C. All following steps 
were done at ≤4°C. The pellet was resuspended in 40 ml 0.1 M CaCl2, incubated on ice for 
30 min and harvested by centrifugation at 2580 x g and 4°C for 15 min. This pellet was 
resuspended in 20 ml 0.1 M CaCl2 supplemented with 4 ml of glycerol. After an additional 
incubation on ice for 2 h, the suspension was dispensed in 200 µl aliquots and after shock–
freezing in liquid nitrogen stored at –80°C. 
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1.5.2.2.5.2 Electro–competent E. coli cells 
 
500 ml LB media supplemented with tetracycline (XL1blue) or chloramphenicol (BL21–
(DE3)–RIL) were inoculated with 5 ml of over–night culture of the desired E. coli strain. The 
cells were grown at 37°C to OD600 of 0.5 and then harvested by centrifugation for 15 minutes 
at 2580 x g (4000 rpm, JA10 rotor) and 4°C. All following steps were done at ≤4°C. The 
pellet was washed three times with 500, 250 and 50 ml 10% (v/v) glycerol. After the washing 
steps, cell pellet was resuspended in 500 µl 10% (v/v) glycerol, dispensed in 40 µl aliquots 
and after shock–freezing in liquid nitrogen stored at –80°C. 
 
 
1.5.2.2.6 Transformation 
 
Transformation of plasmid DNA into chemical competent E. coli cells was mostly done with 
the heat shock method. Therefore 100 µl of the competent cells were thawed on ice, mixed 
with 4–10 µl of the ligation suspension (or 1 µl of purified plasmid) and incubated on ice for 
10–30 minutes. Afterwards, cells were heated at 42°C for 1 min. After a short recovery on ice 
for 2 minutes, 500 µl of fresh LB medium were added and the mixture was shaken at 37°C for 
45 min. Finally, the bacteria were harvested by centrifugation, resuspended in 200 µl of fresh 
LB media and plated on a selective media (LB/Ampr for all used vectors). The plates were 
incubated at 37°C over night. 
For the transformation of plasmid DNA into electrocompetent cells 0.5–1 µl of ligation 
suspension (or purified plasmid) were added to 40 µl of thawed competent cells. The 
suspension was transferred to a pre–cooled cuvette and the cuvette was introduced in an 
electroporation apparatus (settings: 2.0 kV, 400 Ω, 25 µF, time constant 8–9 ms). After a brief 
application of a high electric voltage, the suspension was diluted with 800 µl LB–medium, 
and shaken for 30–60 min at 37°C. The experiment proceeded according to the transformation 
into chemical competent cells (see above).  
 
 
1.5.2.2.7 Isolation of plasmid DNA from E. coli 
 
To analyse whether the PCR constructs have been properly inserted into the vector, the 
plasmid DNA was isolated from XL1blue cells and digested with restriction enzymes. 
Alternatively, E. coli colonies were tested for the right insert by PCR as described in 5.2.2.1. 
To isolate plasmid DNA, colonies were picked with pipet tips from the selective media plate, 
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transferred into 2 ml LB media containing the suitable antibiotic (at a dilution of 1:1000) and 
placed into a 37°C-shaker over night. 
The cultures were transferred to a 2 ml reaction tube, harvested by centrifugation for 1 min at 
16,000 g. Plasmid DNA was isolated according to the following procedure: 
 
1) Resuspension of cell pellet in 300 µl of resuspension buffer. 
2) Addition of 300 µl of lysis buffer and incubation at RT for 5 min. 
3) Neutralization with 300 µl of neutralization buffer 
4) Centrifugation at 21900 x g for 10 min. 
5) Precipitation of DNA by mixing supernatant of centrifugation with 600 µl 
isopropanol. 
6) Centrifugation at 21900 x g for 10 min and 4°C. 
7) Washing with 500 µl of ice–cold 70% ethanol. 
8) Drying of DNA pellet at 50°C for at least 10 min. 
9) Dissolving of DNA in 30 µl of sterile ddH2O. 
 
For large scale plasmid DNA isolation from 50 ml of culture media the Pure YieldTM Plasmid 
MidiPrep System from Promega was used.  
 
 
1.5.2.2.8 Mutagenesis 
 
Point mutants within full–length, wild–type mRpn13 R27A, R92A, F107A, F107S, W108A, 
M109A, M109C, F107A/W108A, S55E, L56A, I75R, F76R, D78N, D79N, F98R, G101F, 
K103R, R104A were created by in vitro mutagenesis using the QuickChange Site–directed 
Mutagenesis Kit (Stratagene) and verified by sequencing. 
 
 
1.5.2.2.9 DNA sequencing 
 
The concentration of isolated plasmid DNA was determined at 260 nm using a photometer 
and send to Eurofins Medigenomix GmbH for sequencing. 
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1.5.2.3 Methods in protein biochemistry 
 
1.5.2.3.1 Gene expression 
 
After transformation of the desired plasmid DNA in E. coli BL21–(DE3)–RIL cells, 100 ml of 
LB media containing ampicillin (100 µg/ml) and chloramphenicol (30 µg/ml) were inoculated 
with the transformed cells (500 µl suspension, see 5.2.2.6) and incubated over night in a 
37°C-shaker. Three litres of LBAmp,Cam medium were inoculated with the preculture at a ratio 
of 1:40 and incubated at 37°C. After cell density reached OD600 0.6 to 0.8, expression was 
induced with 0.5 mM IPTG (end concentration). The cells were incubated at 24°C over night 
and harvested by centrifugation at 4°C and 2580 x g (4000 rpm, JLA 8.1000 rotor) for 10 min. 
Finally the supernatant was discarded and the resulting pellet was gently resuspended in cold 
lysis buffer at 1/100 of the culture volume. For storage, the suspension was frozen and stored 
at –20 °C. For test expressions 100 ml of LB media as well as different expression times and 
temperatures were used (normally 3 h at 37°C, O/N at 37°C and O/N at 24°C). 
 
 
1.5.2.3.2 Cell lysis 
 
The thawed suspended cells were disrupted on ice using an appropriately equipped sonicator 
for the suspended volume (parameters: big tip, pulse maximum and duty cycle 60) for 10 min. 
After centrifugation at 24000 x g (20000 rpm in Beckman JA20 rotor) and 4°C for 20 min, the 
supernatant including the protein of interest was used for further purification steps like 
affinity chromatography. An aliquot of the cleared lysate and the remaining pellet, which was 
treated with 8 M urea, were saved for analysis by SDS–PAGE. 
 
 
1.5.2.3.3 Purification of GST-fused proteins 
 
GST–fused proteins were purified from bacterial lysate by affinity chromatography using 
Glutathione Sepharose 4B (Amersham Biosciences). Therefore, an appropriate amount of 
Glutathione Sepharose 4B suspension (mostly 5 ml for 3 l culture volume) was transferred to 
a Biorad column and washed with 50 ml of cold lysis buffer. The cleared bacterial lysate was 
mixed with the equilibrated beads and shaken at 4°C for 1 h under skaking. After this 
incubation the mixture was transferred to the column and washed with 4 x 50 ml of cold lysis 
buffer. The flow through and the washing fractions were collected and analyzed by SDS–
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PAGE analysis. Recombinant protein was eluted from glutathione beads by cleavage with 
PreScission Protease at 30 °C for 1 h in 10 ml of lysis buffer (alternatively over night at 4°C). 
To analyze protein, which is still bound to the Glutathione Sepharose after treatment with 
PreScission Protease, the beads were incubated for 5 min with lysis buffer supplemented with 
10 mM of reduced glutathione. Samples for SDS–PAGE analysis were taken of both elutions. 
If PreScission Protease was not able to cleave the fusion protein on the resin, the protein was 
eluted with reduced glutathione and the GST–tag was removed in solution. In this case, the 
protein was separated from GST via anion exchange chromatography. 
 
 
1.5.2.3.4 Anion exchange chromatography (MonoQ) 
 
The principle of ion exchange chromatography is the interaction between charged proteins 
and the contrarily charged groups of the column matrix. The binding of the proteins to the 
anion exchange column occurs under low salt conditions and the bound protein can be eluted 
under high salt conditions. Therefore, eluted protein from the Glutathione Sepharose column 
was loaded on the equilibrated MonoQ column in low salt buffer using an Äkta 
Chromatography System, washed with 5 CV (column volumes) of low salt buffer and eluted 
with increasing salt concentration using a linear gradient spanning 25 CV. The purification 
was monitored by UV spectrum at 280 nm and collected fractions containing the eluted 
protein were analyzed by SDS–PAGE. 
 
 
1.5.2.3.5 Size exclusion chromatography  
 
The protein of interest was further purified in gel filtration buffer on a Superdex 200 gel 
filtration column. Size exclusion chromatography is used to separate proteins according to 
their size. The column material consists of a cross–linked network of sugar molecules so that 
larger proteins migrate faster through the column than smaller ones, additionally depending of 
the shape of the protein. Thus, the elution volume (Ve) from the column is a characteristic 
property of each protein. Eluted protein fractions from glutathione sepharose or anion 
exchange columns were pooled and concentrated by centrifugation using Amicon Ultra 
devices (Millipore). 500 µl of the concentrated protein solution were injected on the 
preequilibrated Superdex 200 column via an Äkta Chromatography System. After elution 
with 1.2 CV, the target protein containing fractions were pooled and either purified by an 
additional gel filtration run or directly used for crystallisation trials. Through comparison with 
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marker proteins which were run on Superdex 200 under the same conditions as the purified 
protein, this method also gives information about the approximal size and oligomerisation of 
the examined protein. 
 
 
1.5.2.3.6 Expression and purification of selenomethionine labelled protein 
 
For selenomethionine labelling Rpn13 Pru was overexpressed in the methionine auxotroph 
E .coli strain B834(DE3) (Novagen). The gene expression took place in New Minimal 
Medium (NMM)148 supplemented with selenomethionine and ampicillin. All stock solutions 
for the medium were either autoclaved or sterile filtered. For the 10x amino acid stock, 0.5 g 
of each amino acid except Tryptophan and Tyrosin were mixed. Tryptophan and Tyrosin had 
to be dissolved in 1 M HCl. The New Minimal Medium was prepared as follows:  
 
Preparation of 1 l New Minimal Medium (5.1.6): 
 
1) Mix together in autoclaved Fernbach culture flasks: 
 
7.5 ml  1 M (NH ) SO4 2 4  
1.7 ml 5 M NaCl  
55 ml  1 M KH2PO4    
100 ml  1 M K2HPO4  
9 ml 40% glucose  
1 ml  1 mg/ml CaCl2  
1 ml 1 mg/ml FeCl2  
1 ml  10 mg/ml thiamine    
10 ml  10 mg/ml biotin  soluble at slightly basic pH (with NaOH) 
9 ml 40% glucose  
1 ml 100x trace element stock Ca2+, Zn2+, Mn2+, MoO4– in H2O 
0.85 g 10x amino acid stock  
10 ml 0.5% Tryptophan dissolved in 1 M HCl 
10 ml 0.5% Tyrosin dissolved in 1 M HCl 
ad 1 l sterile ddH2O  
 
2) Set pH between 7.4 and 7.0. 
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3) Add 1 ml of 1000x ampicillin. 
 
4) Add 50 mg of selenomethionine. 
 
100 ml of overnight cultures of LB medium were harvested at 3000 x g for 10 min, washed 
with 50 ml of NMM supplemented with 100 mg/l Ampicillin. Pellets were resuspended in 3 L 
of NMM, supplemented with 0.25 mM selenomethione and 100 mg/l ampicillin. After cells 
were grown at 37 °C to an OD600nm of ~0.6, expression was induced with 0.5 mM IPTG. 
Incubation was continued at 24°C over night. The purification of selenomethionine–labelled 
protein was performed according to the same procedure as for unlabelled protein. 
 
 
1.5.2.3.7 Transfer of proteins to nitrocellulose membrane (Western–blot) 
 
Proteins separated via SDS–PAGE were transferred onto nitrocellulose membrane using the 
semi–dry blotting method149,150. The gel, the membrane, and six sheets of Whatman filter 
paper (3MM) were incubated in transfer buffer. Three sheets of filter paper were placed on 
the anode electrode followed by the membrane and on top of it the gel. This was covered with 
other three filter papers and with the cathode electrode. The transfer was performed at 200 
mA for 1.5 h. To verify transfer efficiency, the nitrocellulose membranes were reversibly 
stained with Ponceau S solution. Afterwards, the membrane was immunodecorated. 
 
 
1.5.2.4 Detection and quantitative determination 
 
1.5.2.4.1 SDS–Polyacrylamide gel electrophoresis (SDS–PAGE) 
 
Proteins can be separated according to their molecular mass by discontinuous 
sodiumdodecylsulfat polyacrylamide gelelectrophoresis (SDS–PAGE) as described151. 
Smaller proteins migrate faster through the gel towards the negative pole than larger ones. 
Although the electrophoretic mobility depends not only on molecular mass but also on the 
shape and the charge of the protein, the molecular mass could be estimated through 
comparison to a marker because the protein solution is denaturized under reducing conditions 
(β–mercaptoethanol) by adding SDS (it binds to the unfolded peptide and has a high charge).  
Two different electrophoresis systems were used. Normally, big gels were used (running gel: 
9 x 15 x 0.1 cm; stacking gel: 1 x 15 x 0.1 cm) and in some cases Mini gels (Mini–PROTEAN 
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II, Bio–Rad) (running gel: 7 x 7.2 x 0.075 cm; stacking gel: 1 x 7.2 x 0.075 cm). The 
concentration of acrylamide and bis–acrylamide in the separating gel was chosen according to 
the molecular size of the proteins to be separated (mostly 16 or 17.5%). For the big gels, glass 
plates of 160x140 mm and spacers of 1 mm thickness were used. The samples were dissolved 
in appropriate volumes of 4 x sample buffer and incubated at 95°C for 5 min, before loading. 
The electrophoresis was performed at 25–45 mA for 1–3 h (30–60 min for mini gels) in 1 x 
SDS running buffer. Protein molecular mass standards were used in each gel.  
 
Bottom gel  
Separating gel 
Separating gel 16% (w/v) acrylamide, 0.16–
0.33% (w/v) bis–acrylamide, 380 mM Tris–
HCl (pH 8.8), 0.1% (w/v) SDS, 0.05% (w/v) 
APS, 0.035% (v/v) TEMED. 
Stacking gel 
Stacking gel 5% (w/v) acrylamide , 0.1% 
(w/v) bis–acrylamide, 60 mM Tris–HCl (pH 
6.8), 0.1% (w/v) SDS, 0.05% (w/v) APS, 
0.035% (v/v) TEMED 
Table 1.10: Composition of a SDS–PA gel. 
 
 
1.5.2.4.2 Staining SDS–PA gels with Coomassie brilliant blue 
 
To visualize the protein on the gel, Coomassie Brilliant Blue dye was used, which allows 
detection of protein amounts down to 0.1 µg. After SDS–PAGE and removal of the bottom 
and stacking gels, the separating gel was heated in Coomassie stain for 1 min using a 
microwave for, incubated for 20–40 min at room temperature, subsequently washed with 
water and destained in Coomassie destain until distinct bands became visible against a clear 
background. The gel was scanned and then dried overnight between two gel–drying films. 
 
 
1.5.2.4.3 Immunodecoration 
 
To visualize the immobilized proteins on PVDF or nitrocellulose membrane, 
immunodecoration with specific antibodies was carried out. Membranes were first incubated 
for 1 h in 5% (w/v) milk powder in TBS to block all non–specific binding sites. The 
immunodecoration was done for 1 h at RT or over night at 4°C, with specific antiserum 
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(1:200 to 1:1000 dilutions in milk/TBS). The membrane was then washed 3 times (each wash 
lasts 5 min), with TBS, TBS/0.05% (w/v) Triton X–100 and again with TBS, and incubated 
for 1 h with horseradish peroxidase coupled to secondary goat anti–rabbit–IgG (diluted 
1:10.000 dilutions in milk/TBS). The membrane was again washed (as above) and treated 
with ECL reagents (H2O2 was added fresh). The luminescence reactions were detected with 
Röntgen films.  
 
 
1.5.2.4.4 Determination of the protein concentration by Bradford assay 
 
The Bradford assay is based on the fact that the absorption of Coomassie–Brilliant Blue dye 
shifts from 465 nm to 595 nm when it binds to protein. Its sensitivity allows to measure 
protein concentrations between 0.1 mg/ml and 30 mg/ml per ml Bradford solution. Protein 
concentration was determined using the “Bio–Rad–Protein assay” reagent152. Protein solution 
was mixed with 1 ml reagent (1:5 dilution) and incubated for at least 5 min at RT. To increase 
the accuracy of the assay six samples were measured (twice 2.5 µl, 5 µl and 7.5 µl of the 
diluted protein solution). The absorbance was measured at 595nm using a 10 mm path length 
microcuvette. Finally, the protein concentration was calculated according to a standard curve 
(Bovine from IgGs (Biorad) was used as standard protein). 
 
 
1.5.2.4.5 Determination of the protein concentration by UV spectroscopy 
 
Protein concentration could be also determined by measuring the absorbance at 280 nm using 
a photometer. Therefore, the extinction of an appropriate dilution of 150–200 µl of the protein 
solution was measured in a quartz cuvette with the buffer solution as blank value. The 
theoretical extinction coefficient was calculated by the ProtParam tool (5.1.9) and used for the 
determination of the protein concentration. 
 
 
1.5.2.4.6 Concentration of proteins 
 
For crystallization high protein concentrations were required. Protein was concentrated by 
centrifugation using Amicon Ultra 10K or 30K devices or Nanosep Centrifugal Devices (3 
and 10K) according to the manufacturer`s instructions.  
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1.5.2.4.7 Protein precipitation 
 
Sometimes the concentration of a protein fraction was less than is required for SDS–PAGE. 
Therefore, the protein was precipitated with 1/5 volume of 72 % trichloracetic acid (TCA), 
incubated on ice for 10 min and centrifuged at 14000 rpm for 1 min. The precipitate was 
washed with 0.5 ml of TCA wash buffer, and dried at 56 °C for 10 min. The precipitated 
protein was dissolved in 1 x sample buffer and analysed by gel electrophoresis. 
 
 
1.5.2.5 Limited proteolysis 
 
Trypsin, Chymotrypsin and Carboxypeptidase Y were used for the proteolytic assay. For the 
digestion 10 µg of protein were mixed each with different concentrations (100 ng, 50 ng, 
25 ng, 12.5 ng) of the respective protease in reaction buffer (total volume of 30 µl) and 
incubated at 25 °C for 20 min. The reaction was stopped by addition of 10 µl of 4 x sample 
buffer and samples were analyzed by SDS–PAGE. The experiment shows the stability of a 
protein variant to proteolytic treatment and degradation products might appear, which 
represent a stable domain of the protein. 
 
 
1.5.2.6 Mass spectrometry 
 
Promising fragments which were found by limited proteolysis were produced by protease 
treatment as described in 5.2.5 and analysed further by mass spectrometrical analysis. 
Therefore the enzymatic reaction was stopped by addition of 5 mM PMSF and the solution 
was sent to the “core facility” in the Max Planck Institute for Biochemistry in Munich. The 
determination of the molecular mass of the proteolytic fragment mostly allowed localization 
of the putative cleavage site and mapping of the domain corresponding to the degradation 
band in the gel. 
 
 
1.5.2.7 Crystallization 
 
Highly purified and concentrated protein was subjected to crystallisation trials. Initial 
screening for the right conditions was done by the sitting drop method at 20 °C using the 
Nextal Screening system. Therefore, 80 µl of each screening solution were transferred with a 
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multichannel pipette from the master block to the reservoir well of a 96well plate (if DTT was 
necessary for crystallization, 1 µl of 100 mM DTT was added to each well). In the next step 
1 µl of the protein solution (for the first screens, protein concentration was adjusted between 5 
and 20 mg/ml) was provided into the sitting drop well using a dispenser and 1 µl of each 
reservoir solution was added and mixed. After sealing with tape the plate was incubated at 
20°C and analyzed under the microscope in regular periods. For each protein several plates 
using different screens from Nextal (e.g classics suite, PH clear I and II suites) were set up. 
Normally, crystals grew after several days and to improve crystal quality, fine screens to 
optimize the conditions were performed by hanging drop vapour diffusion. 1–2 µl of the 
concentrated protein solution were mixed on a plastic cover slide with the same volume of 
reservoir solution. The slide was placed over a well containing 300 µl reservoir solution (if 
necessary supplemented with 1 mM DTT) on a 24–well plastic plate and hermetically sealed 
with grease. Additive screens from Hampton Research were used to improve crystal growth 
and quality by addition of 0.28 µl of each additive to the hanging drop solution. 
Rpn13 Pru crystals grew within two days to the size of 500 x 200 x 200 µm3. The drops 
contained equal volumes of protein (5 mg/ml) and reservoir solution (15 % (w/v) PEG 4000, 
200 mM NaOAc, 1 mM DTT, 100 mM Tris–HCl, pH 8.5). Crystals of the SeMet derivative 
occurred under the same conditions. 
 
 
1.5.2.8 Structure determination 
 
Before exposure to X–rays, crystals were soaked in a solution of mother liquor including 15% 
PEG 400 (cryo protectant) for 5 min and subsequently frozen in a stream of cold nitrogen gas 
at 100 K (Oxford Cryosystems). Single anomalous dispersion (SAD) methods were 
performed using synchrotron radiation at the BW6 beamline at the DESY–centre in Hamburg, 
Germany. Native data to 1.7 Å resolution were collected (Table 1.2) using a MarCCD 
detector. Data were processed with DENZO and SCALEPACK153. The space group of Rpn13 
Pru was P212121 with unit cell dimensions of a=42.4 Å, b=56.2 Å, c=63.2 Å. Phase 
determination was performed by crystal structure analysis of the Rpn13 Pru–SeMet–
derivative. SAD data were collected at 2.7 Å resolution using absorption peak wavelengths 
(0.9793 Å). Two Se–sites were localized with SHELXD100. Subsequent phasing with 
MLPHARE (The CCP4 suite: programs for protein crystallography) and solvent flattening 
with DM101 resulted in an interpretable electron density map, which was traced and phase 
extended to the native data set at 1.7 Å resolution using ARP–WARP102. The model has been 
completed via the interactive three–dimensional graphic programs MAIN103 and refined with 
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REFMAC5104. Temperature factors were refined with restraints between bonded atoms and 
between non–crystallographic symmetry related atoms. Rcrys and Rfree have been refined to 
0.202 and 0.227, respectively105. The final model comprises fully defined residues 21–131 of 
Rpn13 Pru, whereas the N– and C–terminal parts of the molecule are structurally disordered. 
 
 
1.5.2.9 Protein–lipid overlay assay 
 
The protein–lipid overlay assay was performed to test Rpn13 Pru domain for binding to 
lipids, especially to phophatidylinositolphosphates (PIPs). Therefore, PIP StripsTM 
membranes (Molecular Probes) containing 100 pmol of phospholipids were blocked in 
blocking buffer for 1 h at RT. The membrane was then incubated for 1 h with 0.1 µg/ml of 
purified GST–tagged protein in the same solution. After washing 3 times over 30 min, the 
membranes were incubated for 1 h with 1:1000 dilution of anti–GST polyclonal serum 
(Sigma). The membranes were washed as before, then incubated for 1 h with 1:10000 dilution 
of goat–anti–rabbit–horseradish peroxidase conjugate (Biorad). Finally, the membranes were 
washed 3 times over 30 min in blocking buffer and the interaction of GST–tagged proteins 
was detected by chemiluminescence. 
 
 
1.5.2.10 NMR spectroscopy 
 
1.5.2.10.1 15N, 13C and 2H labelling of proteins 
 
The following protocol has been used to 15N, 13C or 2H label the proteins used for NMR 
spectroscopy in the standard expression system. The desired plasmid DNA was transformed 
in E. coli BL21–(DE3)–RIL cells and gene expression took place in M9 Minimal Medium 
similar to expression in LB medium (see Section 1.5.2.3.1). Expressed proteins were labelled 
by replacing ammonium chloride, glucose or H2O with 15N ammonium chloride, 13C glucose 
or D2O respectively as needed. Preparing M9 minimal media begins with preparing an 
autoclaved 10x stock solution of M9 salts and M9 Minimal Medium was prepared as follows:  
 
M9 Salts: 
Na2HPO4   Dibasic sodium phosphate 
KH2PO4   Monobasic potassium phosphate 
NaCl    Sodium chloride 
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Preparation of 1 l M9 Minimal Medium (5.1.6): 
 
1) Use autoclaved or sterile filtered solutions 
 
2) Mix together: 
 
100 ml 10xM9 salts  
1 ml 1M MgSO4  
1 g  NH4Cl   Use 15N ammonium chloride for 15N 
labelling 
3 g  glucose  Use 13C glucose for 13C labelling 
1 ml 100 mM CaCl2  
10 ml GibcoMEM 
Vitamin Solution  
 
ad 1l H2O  Use D2O for 2H labelling 
 
2) Set pH between 7.4 and 7.0 
 
3) Transfer into autoclaved Fernbach culture flask. 
 
 
1.5.2.10.2 NMR spectra 
 
NMR spectra were acquired at 25°C on a Varian NMR spectrometer operating at 800 MHz 
with a cryogenically cooled probe. Processing was performed in NMRPipe154 and the 
resulting spectra visualized with XEASY155. All NMR samples were dissolved in buffer C. 
Optimized triple resonance experiments were performed to assign chemical shift values to 
hRpn13 Pru domain’s backbone (N,HN,Cα,C’) and Cβ  atoms. Chemical shift assignments 
were made by using 3D HNCA/HNCOCA and HNCACB experiments on 0.6 mM 15N–, 13C– 
and 70% 2H–labelled hRpn13 Pru in buffer C. An 15N dispersed NOESY spectrum (200 ms 
mixing time) acquired on 15N–, 50% 2H–labelled human Rpn13 Pru was used to confirm the 
assignments and that the secondary structural elements match those of the crystal structure. 
This spectrum was also used to aid in the identification of intermolecular NOE interactions 
between hRpn13 Pru and Ub, as it was compared to an 15N dispersed NOESY experiment 
acquired under identical conditions on  15N–, 13C– and 70% 2H–labelled hRpn13 Pru mixed 
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with equimolar ratio of unlabeled Ub. For this experiment, no 13C or 2H decoupling was 
implemented to enable the ready identification of intermolecular NOE interactions.  
 
hRpn13 Pru 
HN
Ub 
F76 Hγ2 of Q49 
D78 Hγ2 of V70 
D79 
    Hδ2 of L8 
Hε1 of H68 
F98 Hβ of A46 
A100 
Hβ of A46 
Hα of A46 
G101 
Hβ of A46 
Hδ of F45 
Hε of F45 
K103 Hβ of A46 
R104 Hβ of A46 
Table 1.11: List of NOE–derived distance constraints between hRpn13 Pru and Ub. None of 
these observations were violated in any of the 200 calculated structures. 
 
 
1.5.2.10.3 Chemical shift perturbation analysis 
 
To determine how Rpn13 Pru binds Ub, chemical shift perturbation analysis and NOESY 
experiments were used to directly detect intermolecular contacts. Chemical shift perturbation 
data for Rpn13 Pru binding to ubiquitin and K48–linked tetraubiquitin were obtained for each 
amino acid residue by comparing the amide chemical shift values of Rpn13 Pru alone and 
with equimolar quantities of ubiquitin or K48–linked tetraubiquitin. Therefore, three sets of 
experiments were performed. In particular unlabeled monoUb or tetraUb was added to 15N 
labelled hRpn13 Pru or alternatively unlabeled hRpn13 Pru was added to 15N labelled 
monoUb. In each case, the 15N labelled protein was observed by 1H, 15N HSQC experiments 
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as it bound its unlabeled binding partner. The amide nitrogen and hydrogen chemical shift 
changes were mapped for each residue according to Equation 1: 
 
CSP = 0.2∆δN2 + ∆δH2  
 
In this equation ∆δN and ∆δH represent the changes in the amide nitrogen and proton chemical 
shifts (in parts per million), respectively. 
 
 
1.5.2.10.4 Docking protocol 
 
Rpn13 Pru/Ub complexes were generated by using HADDOCK1.3 (High Ambiguity Driven 
protein–protein DOCKing)121 in combination with CNS122. The atomic coordinates for Ub 
were obtained from PDB entry 1D3Z123. All of the residues with chemical shift perturbation 
values greater than one standard deviation value above the average and with main chain or 
sidechain accessibility above 50% were defined as “active” residues (Table 1.12). Neighbours 
of these residues with greater than 50% accessibility were defined as “passive.” During 
docking, Ambiguous Interaction Restraints (AIRs) were defined that restrict each active 
residue to be within 2.0 Å of any atom of the binding partner’s active or passive residues. All 
active and passive residues localized to distinct surfaces in hRpn13 Pru and Ub that were also 
identified as the contact surface by intermolecular NOE interactions. “Flexible” segments 
(Table 1.12) were allowed to move their side chains upon complex formation and defined 
according to the “active” residues, as described121. Intermolecular NOE interactions between 
hRpn13 Pru and Ub were obtained by comparing the 15N–dispersed NOESY experiments 
recorded on hRpn13 Pru alone with that of the hRpn13 Pru:Ub complex. In addition, chemical 
shift assignment of the sidechain Ub atoms was obtained by following the assigned 
resonances of the free protein upon addition of increasing molar rations of unlabeled hRpn13 
Pru. All atom pairs exhibiting an intermolecular NOE interaction were constrained to be 
within 1.8 – 6.0 Å of each other (Table 1.11). In addition, the constraints from the hydrogen 
bonds published for Ub (PDB code 1DZ3) were used to maintain its fold, as the protein does 
not undergo any gross structural change upon binding. For the first step of rigid–body energy 
minimization, 1000 structures were generated. 200 structures having the lowest energy from 
the rigid–body docking were subjected to semi–flexible simulated annealing in torsion angle 
space followed by refinement in explicit water. During semiflexible simulated annealing, 
atoms at the interface were allowed to move but constrained by the AIRs and unambiguous 
NOE–derived distance constraints. After water refinement, the resulting structures were 
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sorted according to intermolecular energy and clustered using 1.5 Å cut–off criterions. This 
treatment resulted in an ensemble of 200 structures with the average RMSD of 0.94 ± 0.31 Å 
for all backbone atoms and 0.75 ± 0.23 Å for the backbone atoms at the interface. The ten 
lowest energy structures in the lowest energy cluster were evaluated according to the 
following criteria: all intermolecular hydrophobic contacts between heavy atoms being less 
than 3.9 Å, intermolecular hydrogen bond distances between proton–acceptor and donor–
acceptor pair being within 2.7 Å and 3.35 Å, respectively, and minimum angles of 90° for 
donor–hydrogen–acceptor, hydrogen–acceptor–acceptor antecedent, donor–acceptor–acceptor 
antecedent atoms of hydrogen bonds124. 
 
Protein Active residues Passive residues Flexible segments 
hRpn13 
Pru 
55,76,78,99,101,104 53,54,74,77,81,83,100,102,103 51–57,72–85,97–106 
Ub 47,48,49,68 6,8,9,10,11,12,16,42,46,51,72 4–18,40–53,66–74 
Table 1.12: List of active and passive residues defined in hRpn13 Pru and Ub as defined by 
CSP plots for HADDOCK 
 
 
1.5.2.11 Modelling of mRpn13 Pru:diUb complex 
 
The model structure of mRpn13 Pru:diUb was built from the structures of the 
mRpn13 Pru:Ub complex and Ub (PDB entry 1D3Z) by using Insight II (Accelrys, Inc). For 
diUb, the two monoUb molecules were conjugated by forming the G76–K48 isopeptide bond 
and allowing rotations in the K48 sidechain of proximal Ub to avoid steric clashes between 
the distal Ub subunit and Rpn13. The structure was subsequently energy minimized by using 
SYBYL (Tripos, Inc.). 
 
 
1.5.2.12  Biochemical pull–down assays 
 
GST–fused tetraUb subcloned into pGEX–4T1 was coupled to Glutathione Sepharose TM 
4B, cleaved with thrombin 4 h at 4°C (Novagen) in Thrombin cleavage buffer. Thrombin was 
inactivated with addition of PMSF and GST bound to beads was removed by centrifugation. 
Supernatant containing tetraUb was further used for GST pull–down with GST, GST–fused 
wildtype and different point mutants of Rpn13 Pru in incubation buffer. After 5 hours of 
incubation at 4°C, beads were washed three times with incubation buffer. Bound proteins 
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were boiled for 5 minutes in SDS sample buffer and analyzed by SDS–PAGE and 
immunoblotting. 
 
 
1.5.2.13 Rpn2 binding assays 
 
Different deletion mutants of hRpn2 (695–953, 797–953, 881–953, and 902–953) were 
amplified by PCR, subcloned into and pGEX–4TI, verified by sequencing and expressed as 
GST–fused proteins. The GST–tagged purified proteins were tested for their ability to bind 
mRpn13 (1–150), which was transiently expressed as myc–tagged protein in HEK293T cells. 
Two deletion mutants of Rpn2 (881–953 and 902–953) were transiently expressed as GFP–
tagged proteins in HEK293T cells and tested for their ability to bind GST–mRpn13 (1–150). 
The pull–down assays were done as described in Section 1.5.2.12. 
For mapping of the Rpn2 binding domain on Rpn13 Pru by NMR spectroscopy, Ub, hRpn2 
(797–953) or Ub and hRpn2 (797–953) were added to 15N labelled hRpn13 Pru domain, 
which was monitored by 1H, 15N HSQC experiments. Similar to Section 1.5.2.10.3 the amide 
nitrogen and hydrogen chemical shift changes were mapped for each residue according to 
Equation 1. 
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2 Crystallographic studies of the TOM core 
complex 
 
2.1  Abstract 
 
The translocase of the outer mitochondrial membrane TOM mediates transfer of 
mitochondrial proteins across the outer membrane and plays a fundamental role in the 
biogenesis of the organelle. Its crystal structure is expected to provide many deep insights for 
understanding the molecular basis of protein translocation across the outer mitochondrial 
membrane and membrane trafficking in general. 
In this study, we present purification and crystallisation of the TOM core complex from 
Neurospora crassa and preliminary crystallographic data. We have been able to determine 
space group and cell dimensions of crystals and calculate selfrotation, revealing asymmetry of 
the TOM core complex. Well ordered crystals are essential for the determination of protein 
structures by X-ray crystallography, and low diffraction qualities of the TOM core complex 
crystals (8Å) are so far the limiting factor for phase and structure determination. Temperature 
factor and degree of mosaicity are the most important parameters of crystal order and their 
improvement will certainly contribute to a better diffraction pattern and increased resolution. 
Different attempts to improve the diffraction quality have been undertaken including 
detergent exchange upon purification, usage of additives such as detergents, heavy metal 
compounds and lipids as well as direct manipulation of the crystals. Since co-crystallization 
of membrane proteins with monoclonal antibody fragments was reported to promote their 
crystallization, TOM-directed monoclonal antibody fragments were derived and co-
crystallized with TOM core complex. Based on the predicted β-barrel topology of the pore-
forming component Tom40, its recombinant expression and crystallization may represent a 
convenient alternative to the crystallization of the whole complex. We achieved expression 
and refolding of Tom40 from N. crassa, which further purification should result in 
crystallization-grade protein.  
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2.2  Introduction 
 
2.2.1  Mitochondria 
 
The mitochondrion is a membrane-enclosed dynamic organelle found in most eukaryotic 
cells156. These organelles range from 1 – 10 µm in size and are often described as “cellular 
power plants” since they generate most of the cell`s energy supply by oxidative 
phosphorylation in terms of adenosine triphosphate (ATP). In addition to providing energy, 
mitochondria are involved in several fundamental processes such as signalling, cellular 
differentiation, cell death as well as cell growth and cell cycle control157. Important reactions 
occurring in mitochondria include the citric acid cycle (Krebs cycle), heme biosynthesis, β-
oxidation of fatty acids, metabolism of certain amino acids and biogenesis of Fe/S clusters158. 
Their ancestry is not fully understood, but according to the endosymbiotic theory, 
mitochondria represent a relic of an ancient species of alphaproteobacteria, which were 
engulfed by the first eukaryotes more than a billion years ago159. In consistence with this 
theory, mitochondria possess, like chloroplasts and the nucleus, their own independent 
genome, which shows substantial similarity to bacterial ones. During evolution, the bacterial 
symbiont transferred most of its genome in a gradual process into the nuclear chromosomes160 
and consequently the majority of proteins functioning in the organelle are now coded on 
nuclear genes (about 99%). For example, the human mitochondrial genome is a circular DNA 
of about 16 kilobases encoding 37 genes: 13 for subunits of respiratory complexes I, III, IV, 
and V, 22 for mitochondrial tRNA, and 2 for rRNA161,162. The number of mitochondria in a 
cell varies widely by organism and tissue type. Many cells have only a single mitochondrion, 
whereas others can include several thousand of the organelle163,164. Growth and division of 
mitochondria are not linked to the cell cycle but are mainly dependent of the energy 
requirements of the cell. If the energy use is low, mitochondria are destroyed or inactivated. 
At cell division, they are distributed to the daughter cells randomly during division of the 
cytoplasm. Mitochondria divide by binary fission similar to bacterial cell division, but unlike 
to bacteria, mitochondria can also fuse165.  
Although some anaerobic unicellular eukaryotes contain mitochondria that are atypical with 
regard to organellar biochemistry and morphology, they all contain organelles with double 
membrane, whether they are called mitochondria, hydrogenosomes or mitosomes160. This 
double-membraned organization of mitochondria accounts for their partition into four distinct 
compartments (Figure 2.1): the outer mitochondrial membrane, the intermembrane space 
(IMS), the inner mitochondrial membrane and the matrix. 
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Figure 2.1: (a) Schematic representation of a mitochondrion showing its 
compartmentalization. (b) Electron micrograph of mitochondria from mammalian lung. 
 
The cristae space (Figure 2.1) is formed by infoldings of the inner membrane, which expand 
the surface area of the inner membrane, thereby enhancing its ability to produce ATP. These 
are not simple random folds but rather invaginations that can affect overall chemiosmotic 
function166,167. The outer mitochondrial membrane encloses the entire organelle and shows a 
protein-to-phospholipid ratio similar to that of the eukaryotic plasma membrane. It comprises 
large numbers of integral proteins called porins, which form channels that allow free diffusion 
of molecules with a molecular mass less than 5000 Da. In contrast, large proteins need 
specific signalling sequences to be transported through the outer membrane. The inter-
membrane space (IMS) is between the outer and the inner membrane. Due to the permeability 
of the outer membrane to small molecules, their concentrations are the same as in the cytosol, 
whereas the protein composition is different. The inner membrane is rich in the unusual 
phospholipid cardiolipin168 and comprises proteins that fulfil the following functions: redox 
reactions of the oxidative phosphorylation, generation of ATP (ATP synthase), regulation of 
metabolite passage through the membrane and protein import163. Unlike the outer membrane, 
the inner membrane lacks porins and is highly impermeable to all molecules. This 
impermeability enables the enzymes of the electron transport chain to maintain a membrane 
potential across the inner membrane. The matrix comprehends about 2/3 of the total 
mitochondrial protein content and is important in the production of ATP. It contains distinct 
enzymes, which major functions include oxidation of pyruvate and fatty acids as well as the 
citric acid cycle, special mitochondrial ribosomes, tRNA, and several copies of the 
mitochondrial genome163. 
With their central place in cell metabolism, dysfunction in mitochondria is an important factor 
in a wide range of human diseases. Mutations in the mitochondrial DNA (mtDNA) for 
example are associated with diseases such as cardiomyopathy, MELAS syndrome, Leber`s 
hereditary optic neuropathy and many others169. Nuclear genes encoding mitochondrial 
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proteins can be also mutated and be a cause of human diseases. In addition to the well-
documented diseases, several other common human diseases are accompanied by 
mitochondrial defects. For example, a major contributing factor to Parkinson`s and 
Altzheimer`s disease is reduced cellular ATP levels caused by mitochondrial dysfunction.  
 
 
2.2.2  Protein import into mitochondria 
 
The contribution of the mitochondrial genome to the mitochondrial proteome is very limited 
and does not exceed 1% of its total number of proteins. Since the vast majority of 
mitochondrial proteins is nuclear-encoded and synthesized in the cytosol, the biogenesis of 
mitochondria, therefore, depends on the import of these proteins from the cytosol into the 
organelle (Figure 2.2).  
 
 
Figure 2.2: Schematic representation of different import pathways in mitochondria. 
1=presequence import pathway, 2=carrier pathway, 3=intermembrane space import and 
assembly pathway, 4=outer membrane sorting and assembly pathway. 
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The processes of recognition and sorting of mitochondrial preproteins are mediated by protein 
translocase machineries present in both the outer and inner mitochondrial membranes. Most 
of the mitochondrial precursor proteins, if not all, are in an unfolded conformation and 
associated with chaperones, which maintain them in a translocation-competent conformation. 
They are delivered to the organelle by virtue of specific targeting signals, which are 
recognized by specialized receptor proteins170,171. All cytosolic precursor proteins are 
imported by the general entry gate, the translocase of the outer mitochondrial membrane 
(TOM, see Section 2.2.2.3). At least four classes of precursor proteins exist that contain 
distinct targeting signals and are directed to different import routes (Figure 2.2). This 
classification leads to the description of the following import pathways: the presequence 
pathway to matrix and inner membrane, the carrier pathway to inner membrane, 
intermembrane space import and assembly as well as outer membrane sorting and assembly 
(Figure 2.2)172. Additionally, some inner membrane proteins follow a conservative import 
pathway. They are fully imported into the matrix via TOM and TIM23 complexes (see 
2.2.2.1) and are then exported from the matrix into the inner membrane in a process that 
involves the OXA (oxidase assembly) complex170.  
 
 
2.2.2.1 Presequence import pathway 
 
The classic import pathway of mitochondrial matrix proteins involves a characteristic N-
terminal presequence that forms a positively charged amphipathic α-helix (MTS, matrix 
targeting signal) (Figure 2.2). These proteins were directed across both membranes into the 
matrix where the presequences are usually proteolytically removed by the matrix processing 
peptidase (MPP)172. After crossing the outer membrane through the TOM complex, the 
preproteins are transferred to the translocase of the inner mitochondrial membrane TIM23 
(also termed presequence translocase). The TIM23 complex can be structurally and 
functionally subdivided into the membrane-integrated translocation channel, including the 
components Tim17, Tim21, Tim23 and Tim50, and the matrix-faced import motor PAM (for 
presequence translocase-associated motor) which comprises at least five proteins, Tim14 
(Pam18), Tim16 (Pam 16), Tim44, Mge1 and mtHsp70 (mitochondrial heat-shock 
protein 70)170. Transport of the presequences through the TIM23 complex is driven by the 
inner membrane potential ∆ψ and the hydrolysis of ATP. ∆ψ performes a dual role: It 
activates the channel protein Tim23 and drives translocation of positively charged 
presequences by an electrophoretic mechanism173. Tim23 and Tim17 form the membrane-
embedded core of the translocase and share a related membrane domain consisting of four 
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transmembrane segments171,174. Tim50 is anchored into the inner membrane and, as Tim21, 
was found to participate in preprotein transfer from TOM to Tim23. Tim50 binds to the 
incoming polypeptide chains as they reach the trans site of the TOM complex and presumably 
passes them to TIM23174-177. Tim21 connects TOM and TIM complexes by direct but 
transient interaction with Tom22. The intermembrane space domain of Tim50 binds to Tim23 
and promotes closing of the channel in the absence of preproteins, thus preventing leakage of 
ions178.  
The import motor is driven by the ATP requirement of mtHsp70, which interacts with the 
unfolded preprotein in transit and, supported by membrane-associated co-chaperones, 
promotes their translocation to the matrix. Two current hypotheses for the mechanism of 
action of mtHsp70 exist: trapping of preproteins by a Brownian ratchet that prevents back-
sliding of the polypeptide chain, or active pulling by a motor (power stroke mechanism)179-184. 
Both models agree that mtHsp70 binds to the inner membrane through Tim44 in an ATP-
regulated manner. The identification of the Tim14:Tim16 complex revealed tight regulation 
of the ATPase activity of mtHsp70 and thereby of translocation185,186. 
Several integral inner membrane proteins are synthesized with an N-terminal presequence 
followed by a hydrophobic sorting signal. The sorting signal arrests translocation and induces 
lateral release of the protein into the inner membrane independently of the import motor170,172. 
This process involves Tim17 and Tim21 and is referred to as the stop-transfer 
pathway171,174,187. 
 
 
2.2.2.2 Carrier pathway 
 
Metabolite carriers such as ADP/ATP and the phosphate carrier form a large class of inner 
membrane proteins. The carrier or TIM22 pathway (Figure 2.2) is a sorting route selectively 
used by members of the solute carrier family and by the membrane-embedded TIM subunits 
Tim17, Tim22 and Tim23. All known substrates of the TIM22 complex represent membrane 
proteins with even-numbered transmembrane segments that expose their N and C termini to 
the IMS. Carriers contain usually six transmembrane segments without any cleavable 
presequence but with an internal targeting signal. However, presequence-carrying preproteins 
and carrier precursors are imported through the TOM channel, but the former are translocated 
as unfolded linear polypeptide chains, whereas the latter cross the outer membrane in a loop 
formation188. In the next step of this pathway, the small TIM proteins are employed. These 
chaperone complexes of the intermembrane space, namely the hexameric Tim9:Tim10 and 
Tim8:Tim13 complexes, shield the hydrophobic domains of carrier proteins and accompagny 
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them from the TOM to the TIM22 complex189-194. Finally, carrier proteins are taken over by 
TIM22 complex and inserted into the lipid bilayer of the inner membrane in a membrane 
potential-dependent manner171. A modified chaperone complex, which contains Tim12 in 
addition to Tim9 and Tim10, is located at the surface of the translocase. The core is built by 
the channel-forming Tim22, responsible for insertion, whereas the exact functions of the 
associated integral membrane proteins Tim54 and Tim18 are not known172,195. 
 
 
2.2.2.3 Intermembrane space import and assembly pathway 
 
Many proteins of the IMS are small (less than 20 kDa) and their folding is stabilized by 
cofactors or disulfide bridges. Systematic analysis led to the identification of a specific 
protein import and assembly machinery (Figure 2.2), which central component, the inner 
membrane protein Mia40, shows characteristic cysteine motifs. Following their translocation 
across the outer membrane, the precursor forms are recognized and specifically bound by 
Mia40 through mixed disulfide bonds196-199. Mia40 promotes the sequential formation of 
intramolecular disulfides in the imported proteins and thus initiates the assembly of imported 
proteins into oligomeric complexes199,200. Typical examples of this are the hexameric 
chaperone complexes formed by small Tim proteins. The activity of Mia40 relies on the 
function of the sulphydryl oxidase Erv1, an essential FAD-binding protein that directly 
interacts with Mia40 and maintains it in an oxidized, active state. The current model suggests 
a disulfide relay system with electrons being transferred from the precursor protein to Erv1 
through Mia40, and from there via cytochrome c to the respiratory chain201-203. It is now a 
matter of debate, if Erv1 has further roles and if additional factors might be involved.  
An alternative pathway to regulate the import of proteins into the IMS is the stabilization by 
cofactors. For example, cytochrome c is trapped in the IMS by the enzyme cytochrome c 
heme lyase, which inserts the heme factor into cytochrome c. This soluble holoform is then 
released into the IMS204-206. 
 
 
2.2.2.4 Outer membrane sorting and assembly pathway 
 
The outer membranes of mitochondria, chloroplasts and Gram-negative bacteria contain β-
barrel proteins, a special type of integral membrane proteins. A beta barrel is a large beta-
sheet that twists and coils to form a closed structure in which the first strand is hydrogen 
bonded to the last207. So far identified β-barrel proteins are porin (or VDAC), Tom40, Tob55 
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(Sam50), Mdm10 and Mmm2. Like all other mitochondrial outer membrane proteins, they are 
synthesized in the cytosol. The β-barrel precursors are imported by the TOM complex and 
inserted into the outer membrane by a translocase named TOB (topogenesis of mitochondrial 
outer membrane β-barrel) or SAM (sorting and assembly machinery) (Figure 2.2)208,209. 
Precursors of β-barrel proteins interact mainly with the receptor Tom20 of the TOM complex 
and are subsequently transported through the translocase to the trans side of the outer 
membrane, where TIM chaperone complexes guide the hydrophobic precursors to the TOB 
complex210,211. Its main component is the essential Tob55 (Sam50), which is homologous to 
the bacterial outer membrane protein Omp85208,212. Several partner proteins of Tob55, namely 
Tob38 (Sam35), Mas37 (Sam37) and Mdm10 (Mitochondrial distribution and morphology 
10), aid in membrane insertion and assembly of the β-barrel precursors. The exact function of 
Tob38 and Mas37 is not yet known. Mdm10 together with the two other morphology proteins, 
Mdm12 and Mmm1 (Maintenance of mitochondrial morphology 1) forms a complex that 
functions in the assembly pathway of β-barrel proteins downstream of the TOB complex213. 
The N-terminal hydrophilic region is exposed to the IMS and forms a characteristic structure, 
called POTRA (polypeptide translocation associated) domain214. The POTRA domain of 
Tob55 may be involved in the recognition of β-barrel precursors and might pass them on to 
the membrane-embedded C-terminal region of Tob55, which then facilitates membrane 
insertion and assembly of the β-barrel proteins171,215. 
 
 
2.2.3 The TOM complex 
 
The molecular machine translocating proteins across the mitochondrial outer membrane is the 
TOM complex (translocase of the outer mitochondrial membrane, Figure 2.2). This large 
multisubunit membrane protein is responsible for the initial recognition of precursor proteins 
in the cytosol and subsequent transfer of the polypeptides through pores. It also facilitates 
release of cytosolic-binding factors and contributes to the unfolding of cytosolic protein 
domains. The holo-TOM complex is composed of at least seven different subunits. Tom20 
and Tom70 are the major receptors that recognize preproteins, whereas the subunits Tom40, 
22, 7, 6 and 5 form the stable TOM core complex. Tom20 and Tom70 are both anchored with 
N-terminal transmembrane segments in the outer membrane and expose hydrophilic domains 
into the cytosol. They differ in their substrate specificity, but overlap in their function and can 
partially substitute each other. As shown in the crystal structure of Tom70216 it contains 
several conserved tetratricopeptide repeat (TPR) motifs, which are organized in a right-
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handed superhelix. These motifs form a peptide-binding groove for specific interaction with 
cytosolic chaperones like Hsp70, whereas the C-terminal part of Tom70 reveals a putative 
binding site for precursor proteins. Tom70 shows substrate preference for hydrophobic 
precursors that comprise internal targeting signals216,217. In contrast, Tom20 is the central 
receptor for N-terminal presequences and structural analysis by NMR demonstrated a binding 
groove for the hydrophobic face of the MTS (matrix targeting signal, see Section 2.2.2.1)218. 
The binding sites for precursor proteins on the cytosolic site are often referred to as cis-
binding sites, whereas the IMS-exposed binding surface of the TOM complex represents the 
trans-binding site171.  
Tom40 represents the pore-forming component of the complex and was proposed, based on 
theoretical predictions, to adopt a β-barrel fold (see Section 2.2.2.4). Even in the absence of 
other TOM subunits, purified Tom40 forms pores in artificial membranes that show 
characteristics to that of the entire TOM complex219-221. Tom22, Tom5, Tom6, and Tom7 
each have a single α-helical transmembrane segment that locks them tightly into position on 
Tom40222. Tom22 spans the outer membrane in a Nout-Cin orientation exposing a highly 
negatively charged N-terminal domain to the cytosol and a short C-terminal part to the IMS. It 
assists the transfer of substrate proteins from the receptors to the pore and may cooperate with 
Tom20 in the binding and unfolding of precursor proteins. In addition, Tom22 plays a critical 
role for the general integrity of the TOM complex171,223-226. The small TOM proteins (Tom5, 
Tom6 and Tom7) appear to function in regulating the stability of interactions within the 
complex, thereby assisting substrate protein transfer to and through the core translocase. The 
loss of individual small TOM subunits causes only minor effects, but simultaneous deletion of 
all three is lethal227-229. Mutational analysis in Neurospora crassa revealed that Tom6 plays a 
major role in TOM complex stability, whereas Tom7 has a lesser role229. The TOM holo 
complex (purified in the detergent digitonin) has a molecular mass of roughly 490-600 kDA 
and single-particle imaging of the negatively stained TOM holo complex showed particles 
with two or three pore-like structures, whereas the TOM core complex, which lacks Tom20 
and Tom70, contains two pores with a diameter of ~2.1 nm230-232. Isolated Tom40 alone is 
capable of forming homooligomeric structures, which reveal one cavity220,221,233. Further 
studies by electron microscopy report that Tom20 is selectively responsible for the presence 
of the three pore-like structure. Both subunits Tom22 and Tom20 appear to be critical for the 
assembly of Tom40 channel units232.
In addition to translocation of precursor proteins, the TOM complex is also involved in the 
integration of outer membrane proteins into the membrane, a process which is only partially 
understood171,234. The structural organization of the TOM machinery is still a subject of 
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debate and three-dimensional structures will shed light on its overall topology and import 
mechanism. 
 
 
2.2.4  Goals of this study 
 
In the outer membrane of mitochondria the TOM complex represents the main entry site for 
distinct types of mitochondrial precursor proteins. The complex interaction modes of receptor 
subunits with preproteins and subsequent translocation of unfolded substrate proteins through 
the membranes are actively investigated, but still very poorly understood. The filamentous 
fungi Neurospora crassa turned out to be an excellent model organism for studying the TOM 
complex due to its fast growth rate and simple manipulation procedures. The aim of this work 
was the improvement of crystals of the TOM core complex to get initial structural information 
of the translocase complex. Therefore, the purification strategy of TOM core complex had to 
be optimized and the crystal quality should be improved by additive screening and crystal 
manipulation approaches as well as by detergent exchange. Since crystallization in complex 
with antibody fragments could facilitate the crystallization and structure determination of 
membrane proteins, one major goal of this work was to derive TOM-directed monoclonal 
antibody fragments from classical hybridoma technology to accomplish amelioration of the 
diffraction quality by co-crystallization. Another aim of this study was the recombinant 
expression of the main TOM component Tom40 in E. coli and its subsequent refolding to 
obtain highly pure protein suitable for crystallization. 
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2.3  Results 
 
2.3.1  Isolation and purification of TOM core complex 
 
The TOM complex which consists of Tom70, 40, 22, 20, 7, 6, and 5 has been shown to be 
essential for biogenesis of mitochondria. This TOM holo complex can only be isolated in its 
native state from Neurospora crassa using the detergent digitonin, but since digitonin is not 
stable in water and precipitates in a crystalline form after a few days, this detergent is not 
suitable for protein crystallization. In contrast, the TOM core complex, which lacks the two 
receptor subunits of the holo complex, Tom70 and Tom20 (Figure 2.3a), was purified in the 
detergent n-dodecyl-β-D-maltoside (β-DDM)231. The filamentous fungus Neurospora crassa 
was used as model organism for investigating the TOM complex. 
 
 
Figure 2.3: Purification of TOM core complex from Neurospora crassa. (a) Schematic 
representation of TOM core complex and its subunits Tom40, 22, 7, 6, 5. (b) Chromatogram 
of a Superose 6 run. (c) Coomassie-stained urea-SDS-PA gel of highly purified protein 
showing the five subunits of the complex. The asterisk marks a degradation product of Tom6. 
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In this study, the TOM core complex was isolated from a Neurospora crassa strain (GR-107) 
that carried a version of Tom22 with a hexahistidinyl tag at its C-terminus (Figure 2.3). 
Growth of the cells and preparation of mitochondria were performed as described 
previously230,235. The TOM core complex was isolated according to Athing et al., 1999, with 
modifications in the protocol. Isolated mitochondria were solubilized using β-DDM, which 
removes the transiently bound receptor subunits Tom70 and Tom20 from the TOM holo 
complex. The core complex was purified from the clarified extract by affinity 
chromatography via Ni-NTA (for more details, see Materials and Methods). Further 
purification of the complex by anion exchange (Resource Q) and size exclusion 
chromatography (Superose 6) resulted in more than 95% pure and stable protein suitable for 
crystallization trials and functional studies (Figure 2.3). The gel filtration run on Superose 6 
and the Coomassie-stained urea-SDS polyacrylamide gel of purified TOM core complex are 
depicted in Figure 2.3. An average preparation of the protein started with ~1.5 kg of 
Neurospora cells (wet weight), which yielded in 3-5 g of mitochondrial protein and from 
about 10 mg of mitochondria 2-3 mg of purified TOM core complex were obtained. Isolated 
TOM core complex demonstrated channel activity231, was stable at higher temperatures 
(45 °C), in urea (4M) and relatively resistant to protease treatment. Upon gel filtration, the 
TOM core complex ran at a high molecular mass of ~400 kDa. The purified protein was 
subjected to crystallization and used to generate monoclonal antibodies, which are directed 
against TOM core complex (see below). The introduction of size exclusion chromatography 
as an additional purification step could improve the quality of the crystals (see below).  
 
 
2.3.2 Generation of murine monoclonal antibodies 
recognizing native epitopes of Tom core complex 
 
Crystallisation in complex with monoclonal Fv or Fab fragments has been reported to 
facilitate the crystallization of membrane proteins and to improve the diffraction quality of 
such crystals236. Therefore, monoclonal antibodies directed to TOM core complex were 
derived from murine cell culture using the highly purified, detergent solubilized TOM core 
complex. The scheme in Figure 2.4 shows the different steps to generate murine monoclonal 
antibodies (mABs). It started with the initial immunization of mice with purified TOM core 
complex. After preparation of spleen cells and their fusion with myeloma cells to obtain 
permanently living cells, the fusion was distributed in different dilutions on 96well plates and 
cultivated (see Materials and Methods). Only fused myeloma cells will survive in tissue 
culture upon HAT selection (for details, see Section 2.5.2.3.2). 
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Figure 2.4: Generation of TOM-directed monoclonal antibodies (mABs). Schemata showing 
the individual steps of the manufacturing of the mABs recognizing discontinuous epitops of 
TOM core complex. 
 
Screening of the supernatants of the resulting hybridoma clones for conformation-specific 
mABs was performed using an ELISA (enzyme-linked immunosorbent assay). Clones to be 
selected clones were isolated via dilution and further tested by ELISA (single cell cloning) to 
make sure to gain single hybridoma clones (Section 2.5.2.3.3). Positive clones were selected 
by sandwich ELISA as described in Section 2.5.2.3.5.  
Around 80 hybridoma clones were found that produced antibodies which exhibited a positive 
signal in the ELISA test. However, subtyping revealed that only eight of them produced 
antibodies of the requested IgG class (see Section 2.3.3.1). The diagram shows the average 
signal strength of the IgG antibody containing supernatants minus the average background 
value. Antibody P1C10 exhibited a much higher signal in the ELISA test than the other 
antibodies. Ni-NTA coated plates to which TOM core complex was bound via its His-tag, 
were also tested to improve the signal to noise ratio, but the ELISA signals were comparable 
to the signals of the sandwich approach. 
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Figure 2.5: Hybridoma clones producing murine IgG antibodies with elevated signal 
strength. The diagram shows the average ELISA signals of each antibody containing 
supernatant minus the average background value. Antibody P1C10 exhibits the strongest 
ELISA signal. 
 
 
2.3.3 Characterization of selected monoclonal antibodies 
 
2.3.3.1 Immunological subtyping of murine antibodies 
 
Immunological subtyping experiments were necessary to define the isotype of the 
immunoglobulines found. They showed that only 10% of all antibodies detected belonged to 
the IgG class and 90% to the IgM class of immunoglobulines. IgMs form pentamers and 
therefore reveal high signal strength because of their avidity, but are not suitable for 
copurification and cocrystallization with TOM core complex due to their lower affinity. To 
determine the Ig subtype, the mouse hybdridoma subtyping kit from Boehringer-Mannheim 
was used for ELISA experiments. The subtyping was possible using peroxidase conjugated 
secondary antibodies which were specific for the different subtypes of Igs and for the two 
subclasses of the light chain (IgA, IgG, IgG1, IgG2a, IgG2b, IgG3, IgM, λ- and κ-chain). The 
signal strength was detected by an ELISA reader. Table 2.1 shows the results of the subtyping 
for the eight positive IgG clones. 
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 Table 2.1: Subtyping of antibodies from hybridoma  
 supernatants showing positive signals in ELISA tests. All  
 four IgG classes are present  
  
  
     
     
Name Subtype 
P9E9 IgG1 
P4E4 IgG1 
P7C1 IgG2a 
P1C10 IgG2a 
P2C6 IgG2b 
P1 16 IgG2b 
P3H6 IgG3 
P4F9 IgG3 
The IgA isotype was absent, whereas all different IgG subclasses were present. The light 
chains of all IgG antibodies belonged to the κ subclass.     
 
         
2.3.3.2 Western Blot analysis for selection of conformation-specific 
antibodies  
     
Monoclonal antibody fragments that aid in crystallization should bind a discontinuous epitope 
on their target protein. Due to their high affinity of antibodies to the natively folded protein 
they generally exhibit no or only weak signals in Western Blot analysis, performed with 
unfolded proteins. The selected monoclonal IgG antibodies were tested by Western Blot 
analysis using the cell culture supernatants and an anti-mouse secondary antibody. TOM core 
complex was run on a gradient SDS gel, blotted onto nitrocellulose membrane and decorated 
with the supernatants of the positive hybridoma clones (for details see Materials and 
Methods). Except for the antibodies P3H6 and P1C10, which exhibited a very weak signal for 
Tom40, none of the tested antibodies showed activity in Western Blot. In general, all tested 
antibodies which revealed Western Blot activity appeared to be directed against the pore 
subunit Tom40. 
 
 
2.3.3.3 Pull-down assay with hybridoma supernatants 
 
Pull-down assays were useful to confirm the in vitro interaction of the antibodies from the 
hybridoma cultures with TOM core complex. Since TOM core complex carries a His-tag on 
Tom22, purified complex was bound to Ni-NTA magnetic agarose beads and utilized to 
capture TOM-directed monoclonal antibodies from cell culture supernatants. The eluted 
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protein mixture should contain the TOM core complex and the binding antibody, respectively. 
This was monitored by silver-stained SDS-PAGE as well as by Western Blot analysis 
(Figure 2.6).  
 
 
Figure 2.6: Ni-NTA pull-down of monoclonal antibodies with TOM core complex. (a) Silver-
stained gradient (4-12%) SDS-PAGE of elution fractions. Six hybridoma supernatants were 
deployed in this example. P1C10 is the only antibody, which seemed to bind to TOM core 
complex under the given conditions. The gel shows the heavy (H) and the light (L) chains of 
P1C10 with the size of about 62 and 26 kDa. M=marker, C=control.  (b) Similar experiment 
as in (a), but monitored by Western Blot analysis. P1C10 was clearly binding. (c) To (b) 
corresponding flow through fractions of the antibodies P1C10 and P9E9, analyzed by 
Western Blot and showing the use of a large excess of the antibodies. 
 
Under the conditions applied P1C10 was the only antibody that was clearly captured from the 
hybridoma supernatant by TOM core complex as depicted in Figure 2.6a and b. Both the 
heavy and the light chains (around 26 and 62 kDa) of P1C10 were present in the silver-stained 
SDS gel and in Western Blot. In comparison to P1C10, pull-down experiment with P9E9 
exhibited a very weak Western Blot signal (Figure 2.6b), indicating a possible interaction 
with TOM core complex, but one with low affinity. In all cases, a large excess of the 
antibodies was used for incubation with bound TOM core complex (Figure 2.6c) and analysis 
of the flow through fractions demonstrated that all antibodies were present in the hybridoma 
supernatant. 
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2.3.3.4 Purification of murine antibodies from hybridoma cell culture  
 
For production and subsequent purification of murine antibodies from hybridoma cell culture, 
the culture volume and the production rate was scaled up and each mAB (murine antibody) 
was purified from the supernatant using protein A affinity chromatography. Since the high 
concentrations of fetal calf serum (FCS) in the medium cause high grade of impurity by its 
elevated content of antibodies, the first task before purification was to adapt the hybridoma 
cells stepwise to FCS-free culture medium. Cells were grown on plates for several days and 
then transferred to cell culture flasks (for details see Materials and Methods), resulting in 
about 180 ml of culture medium per hybridoma clone with a typical protein concentration 
between 2 and 20 µg/ml. The supernatant was loaded onto protein A sepharose column to 
bind the mABs, which were then eluted at low pH (3-4).  Figure 2.7a shows the exemplary 
chromatogram of the antibody P3H6.  
 
 
Figure 2.7 Purification of the mABs from cell culture supernatant. (a) Chromatogram of the 
protein A purification of antibody P3H6. The first peak with high intensity represents the flow 
through fraction. (b) Chromatogram of the protein A purification of antibody P1C10. Elution 
of P1C10 showed a double peak. (c) Coomassie-stained gradient (4-12%) SDS-PAGE of the 
flow through and elution fractions of the antibodies P3H6, P1C10 and P7C1. M=marker, 
FT=flow through. 
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The peak with the high intensity at the beginning represents the protein content in the flow 
through fraction. In contrast to P3H6, which resembled the standard peak distribution for this 
kind of purification, the curve of P1C10 exhibited a double peak, indicating a possible 
disassembly of the antibody at the rather harsh elution condition (Figure 2.7 a and b).  
However, between 300 and 500 µg of highly purified mABs were obtained by this 
purification strategy (Figure 2.7) and subjected to binding studies with TOM core complex 
(see below). 
 
 
2.3.3.5 Binding studies via analytical gel filtration 
 
To investigate the in vitro binding behaviour of the monoclonal TOM-directed mABs and to 
find the optimal conditions for this interaction, binding assays were performed by analytical 
size exclusion chromatography. Therefore, the purified mABs (Section 2.3.4.4) were 
concentrated to 2.5 to 3 mg/ml and the buffer was adjusted to the TOM buffer conditions. The 
particular antibody and TOM core complex were mixed in a ration 4:1, incubated and run on 
a SMART-Superose 6 column. None of the tested antibodies was binding to TOM core 
complex upon gel filtration. No size shift for the TOM:antibody complex in comparison to 
uncomplexed TOM core could be observed and the antibody fractions ran as the unbound 
form at an approximate molecular mass of 150 kDa (Figure 2.8).  
 
 
Figure 2.8: Binding assays of TOM core complex with murine antibodies by analytical gel 
filtration. (a) Superimposed chromatograms of TOM core complex alone (red) and the 
mixture of TOM with antibody P7C1 (blue). The peak of TOM core complex did not shift and 
was separated from the antibody fractions. (b) Silver-stained SDS-PAGE analysis of the 
fractions reflecting the separated peaks of the chromatogram in (a). The first lane shows the 
purified antibody followed by the peak fractions. H=heavy chain; L=light chain. 
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SDS-PAGE analysis of the fractions revealed, that TOM core complex and the antibody were 
separated on the Superose 6 column (Figure 2.8). 
The mAB P1C10 which was the only binding murine antibody in the pull-down assay (see 
Section 2.3.3.3), eluted at much lower size than expected. Additional experiments using a 
Superdex 200 column showed that this antibody was unstable and exclusively present in the 
dissociated form, where the heavy and the light chains are disassembled. This finding is 
consistent with the protein A purification of P1C10, showing an unusual double peak in the 
elution (Section 2.3.3.4). Therefore, results from the binding behaviour based on analytical 
gel filtration are not significant for this antibody. 
 
 
2.3.4 The TOM core in complex with monoclonal antibody 
fragments 
 
2.3.4.1 Expression and purification of Fv fragments 
 
Recombinant Fv fragments consist of the variable domains of the heavy and the light chains. 
The monoclonal antibodies, which were directed against TOM core complex, were derived 
from murine cell culture as described above. The mRNA of the selected clones was isolated 
from the hybridoma cells and transcribed into cDNA. The corresponding genes of the heavy 
and the light chains, which sequences were unknown, were amplified by PCR using a set of 
related primers and cloned into the pDRIVE or the TOPO vector (for details, see Materials 
and Methods). After sequencing, the corresponding genes of the variable domain (Fv) 
(Figure 2.9a) of the mABs P1C10 and P9E9 were cloned in the bicistronic operon of the 
plasmid pASK68 allowing periplasmic coexpression of both chains in E. coli under the 
control of the inducible lac promoter237. The oxidizing environment in the periplasma should 
ensure proper folding and formation of the disulphide bonds. The antibody containing cleared 
lysate of the periplasmic fraction was prepared after expression in the E. coli strain JM83.  
Since the vector pASK68 provides a C-terminal fusion of strep-tag I to the heavy chain of the 
fragment, the Fv domains of P1C10 and P9E9 were purified by streptavidin affinity 
chromatography (Figure 2.9). The purification using the strep-tag yielded highly pure Fv 
complex (Figure 2.9b and d). The presence of the light chain (VL) was checked by Western 
Blot analysis as it carried a myc-tag (Figure 2.9c). 
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Figure 2.9: Purification of the Fv fragments of the antibodies P1C10 and P9E9. (a) 
Schematic representation of the structural composition of an immunoglobuline. The Fv 
fragment is the smallest binding part of the antibody. (b) SDS-Page of the purified Fv 
fragment of the antibody P1C10. Heavy VH and light chain VL were too similar in size to be 
resolved. (c) Western Blot against the myc-tag on VL showed a positive signal. (d) SDS-Page 
of the purified Fv fragment of the antibody P9E9. P=periplasma, E=elution. 
 
Both Fv fragments P1C10 and P9E9 revealed homogeneous peaks at the right size in gel 
filtration experiments with a Superdex 75 column. In contrast to P9E9, the expression rate of 
the Fv fragment of P1C10 turned out to be much lower. This very low expression rate of 
P1C10 accounted for expression of 48 l culture volume to obtain the required amount of 
protein necessary for copurification with TOM core complex. 
 
 
2.3.4.2 Copurification of Fv fragments with TOM core complex 
 
To crystallize TOM protein which is complexed with monoclonal antibody fragments both 
proteins were mixed and copurified. After the addition of excessive amounts (10:1 molar 
ratio) of purified Fv fragment to the purified TOM core complex, the resulting TOM:antibody 
complex was separated from unbound Fv fragment by size exclusion chromatography 
(Figure 2.10).  
The chromatogram of the mixture showed two peaks, corresponding to the TOM core:P1C10 
complex and the unbound antibody fraction (Figure 2.10b). It was not possible to define a 
pronounced size shift of TOM core complex due to its high molecular mass and the limited 
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resolution of the Superose 6 column. However, the Fv fragment was specifically bound to 
TOM core complex (Figure 2.10a). Addition of the antibody to the purified TOM complex in 
the molar ratio of 5:1 was not sufficient to saturate the complex, indicating the presence of 
more than one antibody binding site. The Fv fragment P9E9 did not bind to TOM core 
complex under these conditions, which is consistent with all other binding experiments using 
the corresponding antibody from cell culture (see above). P1C10 which exhibited the highest 
affinity in the ELISA experiment and which was binding to TOM core complex in the pull-
down assay appeared to be the only specific TOM-directed antibody from hybridoma culture. 
The other six antibodies were not tested, since their affinity to TOM core complex was even 
lower than for P9E9, according to the ELISA signals. 
 
 
 
Figure 2.10: Copurification of the Fv fragments P1C10 with TOM core complex (a) Silver-
stained SDS-urea polyacrylamide gel. The asterisk marks the dimer of the two antibody 
chains. (b) Chromatogram of the gel filtration using Superose 6. The first peak represents the 
TOM core:P1C10 complex, whereas the second peak contains the unbound excess of P1C10. 
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2.3.5  Crystallographic analysis of TOM core complex 
 
2.3.5.1 Crystallization of TOM core complex 
 
One aim of this study was to determine the three-dimensional structure of the TOM core 
complex by X-ray crystallography. Therefore, purified TOM core complex was subjected to 
crystallization experiments according to the protocol established by Simone Schmitt238. 
Improved crystals were obtained within 2 to 3 days with the optimized condition of 100 mM 
ammonium citrate pH 4.5, 50 mM Tris-Cl pH 7.2 and 22-28% PEG400 (Figure 2.11). The 
crystallization was done by the hanging drop vapour diffusion method mixing 1.5 µl of TOM 
core complex with a concentration of 14 mg/ml and 1 µl of the crystallization solution. The 
crystals contained all components of TOM core complex, but crystallization appeared to be 
selective for unprocessed Tom6, as the degradation product of Tom6 was absent in the 
crystals238. The concentration of PEG400 was critical for crystallization and had to be 
determined independently for each TOM preparation. Additive screens were used to increase 
the crystal quality, but almost none of the additives could improve the diffraction quality, 
although some could change the morphology of the crystals. Initially received TOM core 
complex crystals diffracted only to a resolution of less than 15 Å showing only weak 
individual reflection spots, however, the optimized purification strategy significantly 
improved resolution to 7 Å. The crystallization condition turned out to be already a cryo-
protectant, thus crystals were directly frozen in a stream of liquid nitrogen from their mother 
liquor. This procedure did not cause any damage to the crystals or any loss of resolution 
which was confirmed by measuring crystals grown in a capillary by counter diffusion 
(Figure 2.11c). Further improvement of the diffraction quality to 6 Å resolution was achieved 
by using specific detergent additives, allowing to determine the space group as well as the 
unit cell parameters (see below). 
 
 
Figure 2.11: Crystallization of the TOM core complex (a) Crystals in the standard condition 
plus 100 µM CuCl2 as additive. (b) Crystal catched in a cryo loop. (c) Crystals in capillary. 
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2.3.5.2 Optimization of the diffraction quality of the crystals 
 
2.3.5.2.1 Experiments to improve crystallization 
 
Since the resolution limit of 7-8 Å abolished elucidation of the three-dimensional protein 
structure of TOM core complex, the diffraction properties of the crystals had to be improved 
considerably. All additives from the detergent screens from Hampton Research were tested in 
the standard TOM crystallization condition and used at CMC (critical micelle concentration). 
For all additives, where crystal growth occurred (Table 2.2), fine screens were performed to 
find the optimal concentration of PEG400. Optimized crystals, which were large enough for 
measuring, were examined using synchrotron radiation. For most of the additives, the 
diffraction quality of the crystals became worse and the resolution limit was significantly 
higher than 8 Å (Table 2.2). For maltosides with shorter carbon chain length than n-Dodecyl-
β-D-maltoside, such as n-Undecyl-β-D-maltoside and n-Nonyl-β-D-maltoside (Figure 2.12), 
the resolution limit was comparable to DDM, although crystals in n-Undecyl-β-D-maltoside 
were smaller.  
 
Detergent MM (g/mol) CMC (mM) Type Synchrotron max. Resolution
C12E9 583.1 0.08 N Y >7 Ǻ 
C12E8 539.1 0.11 N Y >7 Ǻ 
n-Dodecyl-ß-D-maltoside 510.6 0.17 N Y 7 Ǻ 
Sucrose monolaurate 524.6 0.2 N N   
CYMAL®-6 508.5 0.56 N Y >7 Ǻ 
n-Decyl-ß-D-maltoside 482.6 1.8 N N   
ZWITTERGENT® 3-12 335.6 4.0 Z Y >7 Ǻ 
n-Hexadecyl-ß-D-maltoside 566.6 0.0006 N N   
n-Tetradecyl-ß-D-maltoside 538.6 0.01 N N   
n-Tridecyl-ß-D-maltoside 524.6 0.033 N N   
n-Undecyl-ß-D-maltoside 496.6 0.59 N Y 7 Ǻ 
n-Decyl-ß-D-thiomaltoside 498.6 0.9 N Y >7 Ǻ 
FOS-Choline®-12 315.5 1.5 Z Y <7 Ǻ 
1-s-Nonyl-ß-D-thioglucoside 322.4 2.9 N Y >7 Ǻ 
n-Nonyl-ß-D-thiomaltoside 484.6 3.2 N N   
n-Nonyl-ß-D-maltoside 468.4 6.0 N Y 7 Ǻ 
Table 2.2: List of detergent additives in which crystals grew still under the typical TOM core 
complex crystallization condition. N=nonionic, Z=zwitterionic. Yes and No in the column 
“Synchrotron” means, if the crystals were measured or not. 
 
In case of the detergents sucrose monolaurate, n-Decyl-ß-D-maltoside and the maltosides with 
longer carbon chains than DDM, crystals were too small for measuring. FOS-Choline®-12 
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seemed to be the only detergent of the additive screen, which slightly improved the diffraction 
quality of the TOM core complex crystals to a maximal resolution of ~6.5 Å (Table 2.2, 
Figure 2.12). 
 
 
Figure 1.12: Crystals of TOM core complex with different additives (a) C12E8. (b) FOS-
Choline-12. (c)  n-Nonyl-ß-D-maltoside. 
 
Since it was shown that copper ions can block channel activity of reconstituted TOM complex 
in conductivity measurements221, CuCl2 was tried as an additive for crystallization. A fraction 
of TOM core complex (10-14 mg/ml) mixed with CuCl2 is precipitating and if the mixture is 
used for crystallization, crystal grew to bigger size, but without any significant alteration of 
diffraction properties. 
All crystallized membrane protein complexes show defined lipid-protein contacts and lipid 
requirement may also be necessary for stabilization of membrane proteins. Therefore, 
different lipids were used as additives to enhance ordered crystallization of TOM core 
complex, but addition of the lipids L-α-phosphatidylcholine, L-α-phosphatidylethanolamine, 
L-α-phosphatidylinositol and cardiolipin prevented crystal growth of the protein under the 
original crystallization condition. 
Due to the thermostability of TOM core complex, another trial to improve crystallization was 
performed by incubation of the protein at 45°C for 20 min and subsequent crystallization, but 
no amelioration of the crystal order could be achieved by this experiment. 
 
 
2.3.5.2.2 Manipulation of the crystals  
 
The direct manipulation of already grown crystals represents an alternative option to the 
optimization of the crystallization conditions. It is known, that glutaraldehyde, a frequently 
used amine-reactive homobifunctional crosslinker reagent, can link protein molecules in a 
crystal and thereby improve the order of a crystal (Prof. Cramer, LMU Munich, personal 
communication). Such a protein crystal, in which the molecules are sufficiently crosslinked, 
will not dissolve in water anymore. Crosslinking of the protein molecules in the TOM core 
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complex crystal with this reagent was possible, but this treatment appeared to disturb the 
crystal order as the diffraction became even worse. 
As typical for membrane proteins, it is expected that TOM core complex crystals possess a 
high solvent content, since crystals turned out to be very soft. An alternative to improve 
crystal order might be the stepwise transfer of TOM core complex crystals to increasing 
PEG400 concentration, thereby reducing the solvent content and possibly transforming the 
crystals to higher order. However, the crystals could not be transformed using this method. 
 
 
2.3.5.2.3 Heavy metal atom soaks and cocrystallization 
 
Owing to the high solvent content of protein crystals, it is possible to soak chemicals and in 
some cases even small proteins into crystals which bind at defined positions of the protein. 
Heavy metal atoms or heavy metal atom clusters are able to bind specifically to sites of a 
protein and are therefore essential for determining the crystallographic phases to solve the 
three-dimensional structure. Soaking of crystals with heavy metal atoms can not only deliver 
initial phases, but sometimes also improve the diffraction properties of the crystals by 
occupation of specific symmetry plies or alteration of crystal contacts. For this experiments, 
the Heavy Atom Screen kits (Hampton Research) and the collection of heavy metal atom 
clusters like W6Br12, W18, K2Ta6Br12, Mo6Cl14 and K6Mo7O22(O2)2 (kindly provided by Prof. 
Patrick Cramer, Gene Center, Munich and Prof. Huber, Max-Planck-Institute of 
Biochemistry, Munich) served as the platform to try various different heavy metal 
compounds. Additionally, heavy metal atoms were used for co-crystallization trials with 
TOM core complex. In case of Ta6Br122-, which shows a green colour in solution, the soaked 
crystals adopted the colour, indicating the presence of the cluster in the crystals (Figure 2.13). 
However, the diffraction quality of the crystals suffered for each employed heavy metal and 
consequently, determination of initial phases was not possible. 
 
 
Figure 2.13: TOM core complex crystals, soaked with the 
TaBr heavy metal atom cluster. 
 
 
 
 
2.3.5.3 Crystallization of the TOM core:P1C10 antibody complex  
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As reported in Section 2.3.4.2, the complex of TOM core protein with the Fv fragment P1C10 
was copurified and subjected to crystallization. Therefore, the initial crystallization conditions 
as well as conditions for robot screening (200 nl + 200 nl drops) were tested to grow crystals.  
 
 
Figure 2.14: Crystals of TOM core:P1C10 complex. (a) Initial crystals from the robot 
screening sitting drop plate (200 nl + 200 nl drops). (b) Optimized crystals using the hanging 
drop technique. 
 
Crystals occurred in the original TOM core complex condition and in a similar condition from 
the Nextal Classics Screen 0.2 M CaCl2, 0.1 M HEPES pH 7.5 and 28% PEG 400 
(Figure 2.14). After optimization in both cases, crystals were large enough for measuring 
using synchrotron radiation. Although crystal morphology was different, space group, cell 
dimensions and diffraction quality were the same as for crystals of the TOM core complex. 
SDS gel analysis of washed and dissolved crystals revealed that all components of the TOM 
core complex and both chains of the antibody were present in the crystals. 
 
 
2.3.5.4 Detergent exchange during purification 
 
Stability and the crystallization characteristics of membrane proteins are highly dependent of 
the choice of the detergent. Since the optimized solubilization and purification of TOM core 
complex yielded highly pure and sufficient amounts of protein, it would not be suitable to 
switch to another detergent during the first steps of the isolation. However, the detergent 
exchange upon gel filtration allowed monitoring of the complex stability as its disassembly 
would significantly alter the peak distribution. Detergents which did not negatively influence 
the crystallization in the detergents additive screen from Section 2.3.5.2.1 were used in 
concentrations above their CMC in the gel filtration experiment. TOM core complex was 
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purified according to the standard procedure, but in the final step was run on a Superose 6 
column with the new detergent in the mobile phase, respectively. As it is reported, that the use 
of n-Dodecyl-α-D-maltoside instead of n-Dodecyl-β-D-maltoside can improve the diffraction 
quality markedly239, this was also tried. 
 
Detergent CMC (%) Concentration (%) 
n-Dodecyl-α-D-maltoside 0.009 0.03 
n-Undecyl-β-D-maltoside 0.029 0.10 
n-Decyl-β-D-maltoside 0.087 0.26 
n-Nonyl-β-D-maltoside 0.280 0.84 
FOS-choline 12 0.047 0.14 
Table 2.3: Detergents of the exchange experiment with CMC and applied concentration. 
 
Crystallisation trials were performed by hanging drop vapour diffusion using the original 
TOM core complex crystallization condition in DDM and by sitting drop screening using the 
Nextal system as well as a crystallization-robot to perform drops on nanolitre scale. Fractions 
of the size exclusion were analyzed by urea SDS-PAGE using silver staining. For all 
detergents of the maltoside class the TOM core complex was fully assembled and showed 
standard running behaviour on the Superose 6 column.  
 
 
Figure 2.15: Detergent exchange with FOS choline 12 (a) Peak distribution upon gel 
filtration shows two peaks. (b) Silver-stained urea SDS-PAGE of the fractions. TOM core 
complex of the first peaks lacked the subunit Tom5 (named Tom core ∆Tom5). M = marker. 
 
In case of the detergent FOS choline 12, the size exclusion chromatography exhibited a 
distribution of two peaks, which corresponds to TOM core complex with and without the 
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subunit Tom5 (Figure 2.15). In all these crystallization trials TOM core complex crystallized 
only in the detergent n-Undecyl-β-D-maltoside so far. However, these crystals diffracted 
comparable to the crystals obtained in DDM despite their smaller size.  
 
 
2.3.5.5 Crystallographic data of TOM core complex 
 
The purified TOM core complex was subjected to crystallization and after optimization large 
crystals of different morphologies were obtained (Section 2.3.5.1). The change of the 
purification strategy and the use of additives improved the diffraction quality and allowed for 
the first time determination of crystallographic data such as the space group and the unit cell 
parameters (Figure 2.16b). The measurement of the crystals took place at the synchrotron 
radiation sources BW6 at Deutschen Elektronen Synchrotron (DESY) in Hamburg, Germany 
and at the X06SA Swiss Light Source (SLS) at Paul Scherrer Institut in Villingen, 
Switzerland. The crystals of the TOM core complex were exposed to X-rays both at RT in 
capillary and flash-cooled at 100 K in a nitrogen-gas stream (for fast-freezing crystals were 
taken directly out of the mother liquor which served as a cryoprotectant). Crystals of the 
Tom:antibody complex were only measured frozen. The frozen crystals were stable in the 
beam, which allowed collection of the first isomorphic complete dataset at 8 Å resolution 
(Figure 2.16).  
Indexing, processing and reduction of the data were possible, but low resolution did not allow 
determination of phases. Data were processed with DENZO and data reduction was 
performed with SCALEPACK240. The space group was determined to be C2 with unit cell 
dimensions of a=181 Å, b=113 Å, c=129 Å, β=113° and these parameters remained constant 
for all measured crystals (Figure 2.16). 
Only one out of 20 crystals showed diffraction in the range of 6-8 Å and morphology of 
crystals did not correlate with diffraction quality, but resolution appeared to be dependent on 
the protein batch. No radiation damage was observed. With the estimative molecular mass 
(gel filtration) of about 400 kDa, the relatively high solvent content of 85% was calculated, 
which is consistent with the resolution limit and the softness of the crystals. Based on the 
analyzed structure factors, the autocorrelation of the squared structure factors (Patterson 
selfrotation function) at different kappa angles of 180°, 120°, 90°, 72° and 60° resulted in 
noncrystallographic (ncs) two- and three-fold molecule symmetry of the TOM core complex 
(Figure 2.16).  
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Figure 2.16: Crystallographic data on TOM core complex (a) Diffraction image. The plate 
frame reflects 6 Å resolution. (b) Result table of the processed data at 8 Å. (c) Selfrotation 
with κ = 180° (twofold axis) and (d) κ = 120° (threefold axis). Owing to the crystallographic 
axis, an additional twofold axis, which was orthogonal to the twofold ncs axis, was generated  
 
 
The three-fold ncs symmetry axis was not along the two-fold ncs and crystallographic axis. 
The four-, five- and six-fold molecule symmetry could be excluded. The analysis of the 
Patterson showed no pseudo origin peak and therefore two-fold ncs symmetry along the 
crystallographic axis also could be excluded. 
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2.3.6  Investigation of the pore-forming component Tom40 
 
The main component of the TOM complex is Tom40, which constitutes the pore of the 
translocase. The stoichiometry of the complex and how many Tom40 molecules are present in 
one TOM core complex molecule are not known so far. Tom40 was predicted to adopt β-
barrel topology like many translocases of the bacterial outer membrane (outer membrane 
proteins = OMPs) such as porins. Due to the size of the complex, more than one Tom40 
molecule would be necessary to build the protein conducting channel. The recombinant 
expression and refolding of Tom40 should lead to crystallization-grade protein and its 
structure determination would provide essential information about the topology and the 
working mechanism of the TOM complex.  
 
 
2.3.6.1 Secondary structure prediction of Tom40 
 
An important step in investigating the architecture and topology of Tom40 is primary 
sequence analysis. For sequence analysis and the prediction of protein structure and function 
PredictProtein was used (Figure 2.17), which returns multiple sequence alignments, 
PROSITE sequence motifs, low-complexity regions (SEG), prediction of secondary structure, 
transmembrane helices, coiled-coil regions, disulfide-bonds (DISULFIND), sub-cellular 
localization, and functional annotations.  
 
 
  ....,....10...,....20...,....30...,....40...,....50...,....60 
AA  MASFSTESPLAMLRDNAIYSSLSDAFNAFQERRKQFGLSNPGTIETIAREVQRDTLLTNY 
PROF_sec                              HHHHHHHHHHHH          HHHHHHHHH  
Rel_sec   966676564212245765220011231000100026776767466785462024410232 
SUB_sec     LLLLLLLL......LLLL.................LLLLLLL.HHHHH.H.......... 
 
  ....,....70...,....80...,....90...,....100..,....110..,....120 
AA  MFSGLRADVTKAFSLAPLFQVSHQFAMGERLNPYAFAALYGTNQIFAQGNLDNEGALSTR 
PROF_sec            EEEEEE        EEEEEEEEEE      EEEEEEE   EEEEEEEE     EEEE 
Rel_sec   001023431034444541345444553354564035566415405786454366403336 
SUB_sec     ...............L....E...EE..L.LL...EEEE..L..EEEE.E..LL.....E 
 
  ....,....130..,....140..,....150..,....160..,....170..,....180  
AA  FNYRWGDRTITKTQFSIGGGQDMAQFEHEHLGDDFSASLKAINPSFLDGGLTGIFVGDYL 
PROF_sec         EEEEE    EEEEEEEE    EEEEEEEE     EEEEEEE          EEEEEHHHH       
Rel_sec   654303430446566741563356654210254022432411553223540112201132 
SUB_sec     EE.........EEEEE..LL..EEEE.....L..........LL....L........... 
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  ....,....190..,....200..,....210..,....220..,....230..,....240 
AA  QAVTPRLGLGLQAVWQRQGLTQGPDTAISYFARYKAGDWVASAQLQAQGALNTSFWKKLT 
PROF_sec         H     EEEEEEEEEE         EEEEEEEEE    EEEEEEE    EEEEEEEEEE       
Rel_sec   012433013014565045565565103443334125422677785244315666655305 
SUB_sec     ............EEE..LLLLLLL...........L...EEEEEE.....EEEEEEE..L 
  
  ....,....250..,....260..,....270..,....280..,....290..,....300 
AA  DRVQAGVDMTLSVAPSQSMMGGLTKEGITTFGAKYDFRMSTFRAQIDSKGKLSCLLEKRL 
PROF_sec           EEEEEEEEEE               EEEEEEEEE    EEEEEE     EEEEEEEE       
Rel_sec   520344566531135432223445430456522453132035767547550211111120 
SUB_sec     L.....EEEE....L........L....EEE...E......EEEEE.LLL.......... 
 
  ....,....310..,....320..,....330..,....340..,.... 
AA  GAAPVTLTFAADVDHVTQQAKLGMSVSIEASDVDLQEQQEGAQSLNIPF 
PROF_sec              EEEEEEEEE       EEEEEEE     HHHHHH 
Rel_sec   4676057887553033465300136775168600554301477777788 
SUB_sec     .LLL.EEEEEEE.....LL.....EEEE.LLL..HH.....LLLLLLLL 
  
Figure 2.17: Secondary structure prediction of Tom40 from Neurospora crassa. PROFsec: 
predicted secondary structure in three states: helix H, sheet E, rest L. RELsec: reliability 
index for secondary structure prediction (0=low to 9=high). SUBsec: subset of the prediction, 
for all residues with an expected average accuracy >82%. 
 
Based on its functional and structural similarity with other β-barrel proteins such as Tob55 
and porin, the secondary structure of Tom40 should mainly reveal β-strands. A beta barrel is a 
large beta-sheet that twists and coils to form a closed structure in which the first strand is 
hydrogen bonded to the last. Beta-strands in beta-barrels are typically arranged in an 
antiparallel fashion. Barrel structures are commonly found in porins and other proteins that 
span cell membranes. According to the program SUBsec, representing the subset of all 
residues, for which secondary structure elements are predicted with an average accuracy 
above 82%, Tom40 from Neurospora crassa (ncTom40) contains 14 β-strands flanked by one 
α-helix at the N- and C-terminus, respectively. None of the helices appeared to be a 
transmembrane helix as calculated by the program PHDsec. Presumably, the 14 β-strands of 
each pore-constituting Tom40 molecule form the β-barrel, which is located in the membrane, 
whereas the soluble flanking helices are exposed to the cytosol and the intermembrane space 
(IMS). For the first approximately 40 amino acid residues of ncTom40, no pronounced 
secondary structure could be observed, whereas in the human homologue same is true for the 
first 80 amino acid residues. Interestingly, the human Tom40 lacks the C-terminal α-helix. 
Tom40 from N. crassa contains only one cysteine and according to DISULFIND, a program 
calculating disulfide bonding state, this cysteine is not disulfide-bonded.  The human 
homologue for example possesses six cysteines, which were also predicted to be non-bonded. 
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The predicted secondary structure was composed of 9.17%, 43.84% and 46.99% of the types 
helix, strand and loop, respectively. 
 
 
2.3.6.2 Sequence conservation of Tom40 
 
The investigation of the sequence conservation among homologues together with the 
secondary structure prediction could provide important information about the domain 
architecture of a protein. Multiple sequence alignment of Tom40 family proteins revealed the 
high sequence conservation among higher eukaryotes with 27% sequence identity and 47% 
sequence similarity between the Tom40 homologues from Homo sapiens, Mus musculus, 
Drosophila melanogaster and Caenorhabditis elegans. The protein sequence of Tom40 is 
even well conserved between higher and lower eukaryotes with 44% similarity between 
human and yeast. The N-terminal region (27 to 76 amino acid residues in length, depending 
on the species), which lacks secondary structure elements (Section 2.3.7.1) is not conserved in 
length and charge among species. In contrast to higher eukaryotes fungi contain a C-terminal 
extension of 20-27 amino acid residues. As shown by the secondary structure prediction, this 
C-terminal flanking residues seem to form an α-helix in Neurospora crassa, whereas the 
human Tom40 for example lacks this extension and the α-helix at its C-terminus. 
 
 
2.3.6.3 Recombinant expression and refolding of Tom40 
 
For some membrane proteins of the β-barrel class, recombinant expression in E. coli and 
subsequent refolding in the presence of detergent was successful and crystal structures of 
these proteins were determined241. The expression, refolding and crystallization of the pore 
component Tom40 might represent an efficient alternative to the crystallization and structure 
determination of TOM core complex.  
The coding sequences of Tom40 from the species H. sapiens, C. elegans and N. crassa were 
cloned into the pRSET vectors PL0 and PL1 and proteins were expressed in E. coli. The 
vector PL0 does not contain any tag, whereas PL1 introduces an N-terminal His-tag to the 
expressed protein. Solely Tom40 from N. crassa was expressed in these vectors 
(Figure 2.18a) and also usage of the pET-DuetTM-1 system for hsTom40 and ceTom40 did not 
result in noticeable expression. All variants, ncTom40 (aa 38-329), hsTom40 (aa 77-361) and 
ceTom40 (aa 17-301) were truncated to obtain the conserved core domain of Tom40. 
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Figure 2.18: Expression and refolding of Tom40 from Neurospora crassa. (a) Coomassie 
stained SDS-gel of ncTom40 expression. –I=before induction; +I=after induction. (b) 
Coomassie stained SDS gel of the isolation of inclusion bodies with subsequent refolding. 
S=cell lysat; P1, P3-P5=inclusion bodies after different washing steps; W2-W5=different 
washing steps; S1 and S2=inclusion bodies dissolved in 8M urea before and after 
centrifugation; M=marker; Pellet and Sup represent the pellet and the supernatant after 
refolding and centrifugation. Most of Tom40 is in the supernatant. (c) Fluorescence 
spectroscopy of refolded Tom40. The maximum peak of the emission is at 332 nm for folded 
proteins.  
 
Tom40 from N. crassa was highly expressed in inclusion bodies (Figure 2.18a), which were 
isolated in different washing and centrifugation steps (Figure 2.18b). Purified inclusion bodies 
were treated with 8M urea to completely unfold the Tom40 molecules, centrifuged and 
refolded. For the refolding two methods were tried: stepwise dialysis of the unfolded protein 
against decreasing concentrations of urea as well as sudden dilution of Tom40 in urea-free 
buffer. The first option of dialysis failed as the protein precipitated during the process, 
whereas the dilution assay succeeded in diluted, but folded Tom40. Most of Tom40 was 
soluble after refolding as depicted in Figure 1.18b.  
The folding state of the protein was analyzed by fluorescence spectroscopy. The protein was 
excited at 280 nm and the maximum of fluorescence emission is located at around 332 nm, 
which indicates folding of Tom40. Unfolded proteins show maximas at 350 nm. 
Concentration and further purification of Tom40 should result in crystallization-grade protein 
and will be subjected to crystallization.  
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2.4  Discussion 
 
2.4.1  Membrane protein crystallization 
 
2.4.1.1 Detergents in crystallization of TOM core complex 
 
Twenty to thirty-five percent of the proteins encoded by an organism`s genome are integral 
membrane proteins. Membrane proteins such as channels, transporters, and receptors are 
critical components of many fundamental biological processes242. Most of the successful 
experimental methods for obtaining membrane proteins crystals suitable for structure 
determination by X-ray crystallography are identical to those used for soluble proteins. The 
major difference is the necessity for inclusion of detergents above the critical micelle 
concentration (CMC) in the membrane protein solution. The most typical use of a detergent is 
to maintain a target membrane protein in a functional, folded state in the absence of a 
membrane. Eukaryotic multisubunit membrane proteins such as the TOM core complex 
cannot be overexpressed in E. coli and have to be isolated directly from its native 
environment, for example the outer mitochondrial membrane. When the membrane is 
removed during the solubilization of the protein, it must be replaced with a detergent as 
solvent. Despite the large number of detergents that are commercially available, no single 
“universal detergent” is ideally suited to all biochemical applications. As a result, the choice 
of detergent is one of the most fundamental decisions in isolation and crystallization 
procedures of membrane proteins. With essentially no exception, membrane proteins purified 
for structural studies are isolated in alkyl-chain detergents with generally 7-12 carbon in 
length and with headgroups that are typically uncharged or zwitterionic, but conceivably 
could also be charged. However, most membrane proteins have been crystallized from 
maltosides, glucosides, dimethyl N-amine oxides (e.g. LDAO) and CnEm polyoxyethylene 
detergents242.  
The detergent n-dodecyl-β-D-maltoside (DDM, the alkyl-chain is 12 carbons in length) is 
used for the isolation of TOM core complex from mitochondria which results in highly pure 
and stable protein. The TOM core complex in DDM is functional: it has the characteristics of 
the general insertion pore, contains high-conductance channels and binds preprotein in a 
targeting sequence-dependent manner. In contrast to the holo complex, it forms a 
homogeneous double ring structure in electron microscopy231. DDM is one of the gentler 
detergents, and has very favourable properties for maintaining the functionality of more 
aggregation-prone membrane proteins in solution. Its main drawback is the formation of large 
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micelles making crystallization difficult. This may be responsible for the limited diffraction 
quality of TOM core complex crystals. The crystal lattice of a membrane protein crystal has 
to accommodate three components: protein, detergent and aqueous solution. Protein-protein 
contacts from the principal scaffolding of the lattice, and proteins with large extra-
membranous domains are often favoured in crystallization trials. Small-micelle detergents 
such as octyl glycoside (OG) and lauryldimethylamine oxide (LDAO) form smaller belts 
around the transmembrane region of a protein. Potentially, this allows more contacts between 
exposed polar surface of the protein, and hence stronger lattices and better diffracting 
crystals243. Unfortunately, these detergents are often destabilizing and their application results 
in partial dissociation of TOM complex233. The use of different detergents can yield different 
crystal forms, as in the case of the bacterial photosynthetic reaction centre from Rhodobacter 
sphaeroides244 and often, the best-quality crystals may be obtained only in one or a small 
number of detergents. Due to the limited quality of TOM core complex crystals in DDM, 
detergent exchange was performed in this study by size exclusion chromatography to screen 
for more suitable detergents. The low CMC of DDM makes it considerably easier to remove 
DDM by dialysis or gel filtration. Membrane protein detergent exchange can be accomplished 
by a variety of methods. However, the size exclusion approach allows monitoring the stability 
of TOM core complex in various detergents by observation of the peak shape and the 
retention time. Thereby, aggregation and oligomerization are easily detectable. A very 
successful strategy for improving poorly-diffracting membrane protein crystals is to first 
optimize a lead condition by testing closely related detergents (for example, undecylmaltoside 
versus dodecylmaltoside). In general, the head group has a strong influence on the 
interactions of detergents with proteins, while the length of the alkyl chain affects the 
detergent CMC and aggregation number. Upon variation of alkyl chain-length the physical 
properties remain very similar, whereas the slight but significant differences in micelle size 
can result in improved packing within the crystal lattice243. For example, good-diffracting 
crystals of bovine mitochondrial cytochrome c oxidase were obtained with the detergent 
decylmaltoside and varying of the detegent`s chain-length degraded crystal quality245. In case 
of TOM core complex maltosides with longer alkyl chain length like tridecylmaltoside238 and 
shortened maltosides like undecyl- and decylmaltoside were exchanged but could not improve 
crystallization. The α-anomer of DDM (n-dodecyl-α-D-maltoside) is generally less soluble 
and not commonly used. Although it was essential for the crystallization of the NhaA Na+/H+ 
antiporter239, no crystals of TOM core complex were obtained in α-DDM. A next level of 
optimization might involve the use of detergent mixtures as in case of the crystallization of 
bacterial outer membrane protein TolC246. 
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In addition to the choice of a suitable detergent its concentration in the protein-detergent 
complex (PDC) may be critical. Too much detergent can denature the protein or impede 
crystallization. Too little and the protein can become insoluble. Detergents self-assemble into 
relatively small, well-defined micelles that typically contain several hundred molecules243. 
The number of molecules in the micellar particle is termed the aggregation number, a 
characteristic of each detergent. Every detergent possesses a critical micelle concentration 
(CMC). At concentrations above the CMC, there is equilibrium between monomers and an 
increasing concentration of micelles. 
After the final purification step, the protein is often concentrated many-fold by centrifugation 
which can increase the detergent concentration, with possible negative consequences. This is 
especially true in case of a final gel filtration polishing step, which dilutes the protein. Excess 
detergent can be denaturing and can lead to a large amount of unwanted phase separation in 
crystallization experiments. Existing methods to decrease detergent concentration include 
dialysis, the use of absorbing materials such as BioBeads247,248 or other detergent removing 
gels (e.g., Extracti-Gel D, Pierce). However, for low CMC detergents possessing large 
micelles (such as dodecylmaltoside) dialysis fails. The application of the largest possible 
molecular mass cut-off filter will reduce the amount of detergent that is concentrated along 
with the protein. Due to the large size of TOM core complex (~400 kDa), centrifugal devices 
with 100 kDa cut-off can be used for concentration and even the large DDM micelles (~60 
kDa) should pass the filter. 
Controlling the detergent concentration may be important for crystal reproducibility. A 
variety of methods exist for determination of detergent concentration. For example, for 
detergents that contain a sugar headgroup (such as maltosides or glucosides), phenol/sulphuric 
acid hydrolysis and reaction with molybdate is a valuable colorimetric assay. Furthermore 
attenuated total reflection Fourier transformation infrared spectroscopy (ATR-FTIR) and 
quantitative thin-layer chromatography (TLC) can be used to determine the amount of 
detergent. It might be important for crystallization of TOM core complex to monitor the 
detergent concentration during the purification and crystallization procedures by one of these 
methods. 
 
 
2.4.1.2 Lipid requirements of TOM core complex 
 
Membrane proteins are isolated as protein-lipid-detergent particles and in addition to the 
detergent influence the lipid composition is often a critical aspect for preparing samples 
suitable for structural analysis. Indeed, specific lipids are sometimes required to maintain the 
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structural stability of membrane proteins. The detergent choice correlates with the presence of 
a particular amount of lipids in the PDCs as detergents can directly remove tightly bound 
lipids that may be important for the native structure of the protein. Ordered lipids have been 
observed in several high-resolution membrane protein crystal structures249,250, and excessive 
detergent concentrations may lead to protein aggregation by stripping away these essential 
bound lipids. The presence of excess lipids in the PDC can also reduce the chances for 
crystallization since they reduce monodispersity251, but lipid/detergent mixtures may be 
favourable for maintaining protein function. For example, the first successful functional 
reconstitution of the lactose permease required a mixture of OG and lipids to preserve protein 
function during purification252. Without added phospholipids the protein did not survive OG 
solubilization. Twenty-five years later, the addition of a mixture of E. coli phospholipids was 
found to improve crystals of lac permease purified in DDM253. It can be very difficult to 
adjust the appropriate lipid levels in a protein-detergent complex. For instance, suitable 
crystals of the glycerol 3-phosphate transporter (Glp3T) were not obtained if too much lipid 
was removed during purification254, whereas optimal crystals of the bacterial cytochrome b6f 
complex were only obtained when lipids were added to the purified protein255.  
Characterization of PDCs in respect to their lipid content is critical for the optimization of 
downstream sample preparation and crystallization. FTIR and TLC can both determine the 
amounts and specific types of lipids present. From experiments where lipids were added to 
the crystallization trials of TOM core complex no crystals were obtained, but determination of 
the lipid composition in the isolated complex might give hints about its lipid requirements and 
for optimization of its crystallization.  
 
 
2.4.1.3 Additive approach in TOM core complex crystallization 
 
The use of additives has played a significant role in membrane protein crystallization. Due to 
the high solvent content of protein crystals, soaking of chemicals into the crystal is possible. 
Soaking or co-crystallization with additives can improve the diffraction quality of crystals. 
Therefore, crystals were subjected to crystallisation additives such as detergents, heavy metal 
compounds and lipids. For instance, the use of amphiphilic additives (such as heptane-triol) 
has been shown to assist in the formation of highly ordered crystals256. Small amphiphiles can 
act to effectively reduce the size of the detergent region with subsequent improvement of 
crystal quality257,258. Heavy metal additives can deliver initial phases, form and stabilize 
crystal contacts, and have led to some spectacular improvements in resolution259,260.  
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In case of TOM core complex mainly FOS-choline12 and CuCl2 showed an effect on the 
crystallization. Addition of the detergent FOS-choline12 shifted the crystallisation condition 
to higher PEG concentrations and slightly improved crystal quality, whereas addition of 
CuCl2, which was reported to block the TOM channel221, increased the crystal size. 
 
 
2.4.2 Antibody-fragment mediated crystallization of TOM 
core complex 
 
Protein-detergent complexes form three-dimensional crystals in which contacts between 
adjacent protein molecules are made by the polar surfaces of the protein protruding from the 
detergent micelle257. Although attractive interactions between the micelles might stabilize the 
crystal packing261,262, these interactions do not lead to rigid crystal contacts. A strategy to 
increase the probability of getting well-ordered crystals is to attach polar domains to the 
membrane protein and thereby enlarge the polar surface. 
Although the antibody-fragment mediated crystallization of membrane proteins represents a 
time-consuming and expensive approach, it is a valuable tool for their structural investigation. 
X-ray structures of several different membrane proteins in complex with antibody fragments 
have been published263-265. The binding of Fv or Fab fragments increases the hydrophilic part 
of integral membrane proteins and provides additional surface for crystal contacts. In 
addition, antigen-antibody complexes can be used to stabilize specific conformations of a 
protein to aid crystallization attempts. In all reported cases, antibody binding was either 
essential for the crystallization of the membrane protein or it substantially improved the 
diffraction quality of the crystals. Up to know all antibody fragments successfully used for co-
crystallization were derived from hybridoma cell lines and these antibodies recognize native, 
nonlinear epitopes of their respective antigen236,266. Two prominent examples are the 
cytochrome c oxidase263 and the cytochrome bc1 complex264 (depicted in Figure 2.19). 
The availability of suitable amounts of highly purified TOM core complex is the basis for 
three-dimensional crystallization, but only poor-diffracting crystals were obtained. Disorder 
in the crystals may be caused by the protein existing in different conformations, 
substoichiometry of its subunits or flexibility. In addition, TOM core complex may exhibit 
only small hydrophilic domains which are essential for stable crystal contacts. Thus, enlarging 
the hydrophilic surface and stabilizing defined conformations by binding antibody fragments 
is a promising approach to obtain well-ordered crystals. 
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Figure 2.19: Crystal structure of cytochrome bc1 complex. The two monomers of the central 
molecule of the crystal are coloured in blue and green, with bound antibody in red264. 
 
Native antibodies are not suitable for co-crystallization attempts. They possess flexible linker 
regions connecting the variable and constant domains267, and their bivalent binding mode is 
undesirable. Monovalent antibody fragments can be generated by proteolytic cleavage of the 
whole antibody, producing two Fab fragments per antibody molecule. These proteolytic 
fragments are easy to obtain, but care has to be taken to produce homogeneous fragment 
preparations suitable for crystallization. Residual parts of the flexible linker and, in some 
cases, glycosylation can hinder crystallization attempts. The crystallization and structure 
determination of the KcsA K+ channel provides the first example of an integral membrane 
protein co-crystallized with a proteolytically derived Fab fragment265. Recombinant antibody 
fragments are more versatile: they can be used in either Fab or Fv format. The different size 
might be critical for crystallization success, as the bound fragment should outreach the 
detergent micelle. Antibody-fragments suitable for co-crystallization attempts should bind the 
protein in its native conformation, have a high binding affinity and form a stable and rigid 
complex with their native antigen. The last implies the use of antibodies that bind to a 
discontinuous epitope and therefore, one critical aspect appears to be obtaining antibodies that 
are native-state specific, i.e., ELISA-positive and Western-negative. In addition, antibodies 
can help in trapping a flexible protein in a fixed conformation. A variety of structures have 
been solved in complex with Fv or Fab fragments264,265,268-270. Strikingly, in these cases most 
or all of the crystal contacts are between the antibodies.  
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In this study, TOM-directed monoclonal Fv fragments were manufactured by the hybridoma 
technique and their subsequent bicistronic expression in the periplasma of E. coli237. Although 
eight different IgG antibodies were obtained, which showed increased affinity in ELISA 
experiments, the Fv fragment P1C10 showed a much higher affinity upon characterization 
and was the only fragment which specifically bound to TOM complex. Addition of this 
antibody fragment to the purified TOM complex in the molar ratio of 5:1 has not been 
sufficient to saturate the complex, indicating the presence of more than one antibody binding 
sites. Typically, selection of specific antibodies starts from several thousands of hybridoma 
clones271. In case of TOM core complex, just a few hundred clones were found, which might 
be related to the fact that the fusions were frozen for several years before their cultivation 
took place. The high excess of antibodies from the IgM subclass may result from a biased 
immunization procedure. Although copurification and cocrystallization of the Fv fragment 
P1C10 with TOM core complex was successful, no alteration of the crystal quality was 
observed. Since only one suitable antibody fragment was found, this reduces the probability 
to achieve an antibody-fragment mediated improvement of the diffraction quality. There is no 
comprehensive overview of binding constants for all antibodies, which have been co-
crystallized with their cognate antigen. Therefore it is not possible to specify yet which 
affinity threshold is required to successfully obtain well-diffracting crystals of antibody 
complexes, nor can one rule out the possibility that lower affinities may result in reduced 
chances of crystallization. In case of the Na+/H+ antiporter NhaA all specific antibodies 
possess affinities in the nanomolar range, but extensive co-crystallization did not lead to the 
desired structure determination. This was achieved through the optimization of the 
purification strategy and other approaches272. 
A promising alternative to raising monoclonal antibodies in mice is the construction of large 
combinatorial antibody libraries and the adaption of phage display antibody technology for in 
vitro selection. Another possibility in crystallization of TOM core complex might be to shift 
to other adaptable binding scaffolds such as the ankyrin repeat using ribosome display for 
selection141,273,274. For both techniques the selection and production of high-affinity binders 
are less expensive and time-consuming than for the standard hybridoma technology.
The cytochrome c oxidase (COX) from Paracoccus denitrificans was the first successful 
example to demonstrate the feasibility of the antibody-fragment mediated crystallization 
approach263. In this case, the co-complex was purified by indirect immunoaffinity 
chromatography. This strategy could be also pursued for the purification of TOM core 
complex and might alter its crystallization state. 
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2.4.3  Expression of β-barrel protein Tom40 
 
Although the first membrane protein structure was solved in 1985275, the first structure of a 
recombinant membrane protein was not determined until 1998276. This fact speaks to the 
challenges of integral membrane protein overexpression. As a basic rule for any 
crystallization attempt, the protein of interest should be chemically and conformationally 
homogeneous and large amounts of the produced protein favour this homogeneity. 
Accordingly, in case of bacterial outer membrane proteins, the initial isolation procedures 
starting from the naturally expressed protein are often abandoned for methods that increased 
the yield by homologous overexpression into the outer membrane. For instance, sufficient 
pure material of bacterial TolC was obtained by functional expression in E. coli BL21 cells 
and the purified protein was crystallized in two and in three dimensions246,277. As an 
alternative, protein yields were also enhanced by non-functional overexpression. For bacterial 
outer membrane proteins, this expression into cytoplasmic inclusion bodies with subsequent 
solubilization in denaturing buffer and in vitro refolding was surprisingly successful. For 
example, the refolded outer membrane phospholipase A (OmpLA) yielded better crystals than 
the protein isolated from membranes278,279. In most cases of outer membrane protein 
expression into inclusion bodies, the T7-promoter system together with the strain E. coli 
BL21(DE3) was used241. In contrast to the quite detailed knowledge about the structural 
properties of bacterial outer membrane proteins280, no high-resolution structures of similar 
mitochondrial or plastid outer membrane proteins are known. The low-resolution projection 
of the human voltage-dependent anion-selective channel (VDAC) from two-dimensional 
crystals281,282 and X-ray analysis of the human liver monoamine oxidase B (MAO-B)283 are 
examples of rarely described structures of mitochondrial outer membrane proteins so far. 
However, MAO-B was classified as an anchored cytosolic rather than a membrane protein. 
Until now the only possibility to express eukaryotic organellar outer membrane protein in 
E. coli is using inclusion bodies. Recombinant expression and crystallization of the main 
component Tom40 of the TOM core complex may represent a convenient alternative to the 
crystallization of the whole complex. The yeast protein Tom40 was refolded by dilution and 
incorporated into liposomes220. As shown in this study, expression and refolding of the 
homologue from N. crassa was achieved. Since the first approx. 40 amino acid residues of 
ncTom40 exhibit no pronounced secondary structure and sequence conservation, a truncated 
version was used for this experiment to increase chance for crystallization. Further analytical 
measurement like CD spectroscopy should give more detailed information about the folding 
state of this construct and guide to initial crystallization attempts. The main problem with 
non-functional expression into inclusion bodies is the in vitro refolding of the inactive 
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polypeptide, an obstacle which is already surmounted. As Tom40 homologues are also 
present in thermophilic fungi as Chaetomium thermophilum, their recombinant expression, 
refolding and crystallization might increase the chances for structure determination.
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2.5  Materials and Methods 
 
2.5.1  Materials 
 
2.5.1.1 Oligonucleotides 
 
The following oligonucleotides were used as primers to amplify different constructs from the 
cDNA of the hybridoma cells and to clone the Fv fragments into the pASK68 vector. 
Additionally, primers were used to amplify the Tom40 genes from Neurospora crassa, Homo 
sapiens and Caenorhabditis elegans. For the ligation of the amplified genes into the vectors 
pASK68, pRSET-PL0 and pRSET-PL1, all primers carried specific restriction sites. These 
sites were BamHI (forward and reverse) in case of the pRSET vectors and BamHI/EcoRI in 
case of pET-DuetTM-1 vector. Primers used for cloning into bicistronic pASK68 vector 
carried the restriction sites PstI (NsiI)/BstEII for the Fv heavy chain (VH) and SacI/XhoI for 
the Fv light chain (VL). Forward primers for cloning into pET-DuetTM-1 vector carry 
additionally a PreScission Protease cleavage site. For the amplification of genes from the 
cDNA of hybridoma clones a set of 10 different forward primer for VH and 11 forward primer 
for VL were used, whereas for the backward primers one primer was enough. All these 
primers were kindly provided by Carola Hunte (MPI of Biophysics, Frankfurt). All other 
primers were designed to have an overhang to ensure high cleavage efficiency and were 
synthesized and purified from Metabion international AG. 
 
Name         Enzyme Organism 
 
VH-P1C10 
 
VH_P1C10_fo  5`-GAA GTT AAA ATG CAT CAG TCT GGA NsiI  Mus musculus 
 GCT GAG CTG-3` 
 
VH_P1C10_re  5`-GGA GAC GGT GAC CAG AGT CCC TTG BstEII  Mus musculus 
 GCC CCA G-3` 
 
VL-P1C10 
 
VL_P1C10_fo  5`-GAC ATC GAG CTC ACC CAG TCT   SacI  Mus musculus 
CCA TCC TCC-3` 
 
 
VL_P1C10_re  5`- CCG TTT GAT CTC GAG CTT GGT GCC XhoI  Mus musculus 
 TCC ACC GAA C-3` 
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VH-P9E9 
 
VH_P9E9_fo  5`- GAA GTT AAA ATG CAT CAG TCT GGG  NsiI  Mus musculus 
CCT GAG CTG -3` 
 
VH_P9E9_re  5`- GGA GAC GGT GAC CGT GGT GCC TTG BstEII  Mus musculus 
 GCC CCA G -3` 
 
VL-P9E9 
 
VL_P9E9_fo  5`- GAC ATC GAG CTC ACC CAG TCT CCA SacI  Mus musculus 
GCT TCT TTG -3` 
    
VL_P9E9_re  5`- CCG TTT GAT CTC GAG CTT GGT GCC XhoI  Mus musculus 
 TCC ACC GAA C -3` 
     
VH-P7C1 
 
VH_P7C1_fo  5`- GAA GTT AAA ATG CAT CAG TCT GGG NsiI  Mus musculus 
 ACT GTG CTG G-3` 
 
VH_P7C1_re  5`- GGA GAC GGT GAC CGT GGT GCC TTG BstEII  Mus musculus 
 GCC CCA ATA G-3` 
 
Tom40 
 
hsTom40_77_BamHI_fo 5`-AAA AAA GGA TCC CTG CCC AAC CCG BamHI  Homo sapiens 
 GGC AC-3` 
 
hsTom40_361_BamHI_re 5`-AAA AAA GGA TCC TTA GCC GAT GGT BamHI  Homo sapiens 
 GAG GCC AAA G-3` 
 
hsTom40_Duet_77_BamHI_fo 5`-AAA AAA GGA TCC GCT GGA AGT BamHI  Homo sapiens 
 TCT GTT CCA GCT GCC CAA CCC ` 
GGG CAC-3 
 
hsTom40_Duet_361_EcoRI_re 5`-AAA AAA GAA TTC TTA GCC GAT EcoRI  Homo sapiens 
 GGT GAG GCC AAA G-3` 
 
ceTom40_17_BamHI_fo  5`-AAA AAA GGA TCC AAT CCG GGT BamHI  C. elegans. 
 TCA TAC GAA GAA C-3` 
 
ceTom40_301_BamHI_re  5`-AAA AAA GGA TCC TTA ACC AAT BamHI  C. elegans. 
 GAT AAG TCC GAT TCC-3` 
 
ceTom40_Duet_17_BamHI_fo 5`-AAA AAA GGA TCC GCT GGA AGT BamHI  C. elegans. 
 TCT GTT CCA GAA TCC GGG 
 TTC ATA CGA AGA AC-3` 
 
ceTom40_Duet_301_EcoRI_re 5`-AAA AAA GAA TTC TTA ACC AAT EcoRI  C. elegans. 
 GAT AAG TCC GAT TCC 
 
 
ncTom40_38_BamHI_fo  5`-AAA AAA GGA TCC CTT TCC AAC BamHI  N. crassa 
 CCC GGC ACG-3` 
 
ncTom40_329_BamHI_re 5`-AAA AAA GGA TCC TTA CTC AAT BamHI  N. crassa 
 GGA GAC GGA CAT GC-3` 
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2.5.1.2 Vectors 
 
2.5.1.2.1 pRSET-PL0 and pRSET-PL1 
 
The expression vectors pRSET-PL0 and PL1 were derived from the pRSET vector 
(Invitrogen). pRSET-PL1 was constructed by cutting out the MCS with restriction enzymes 
NdeI and BamHI and insertion of the DNA encoding a PreScission Protease cleavage site and 
a His-tag. Tom40 constructs were ligated with BamHI restriction sites into the pRSET-PL0 
and PL1 vectors, which carry a T7 promoter, ampicillin resistance (Ampr) and a lac operator, 
allowing gene expression to be induced by IPTG (isopropyl-b-D-thiogalactopyranosid). A 
protein expressed with the pRSET-PL1 vector could be purified by affinity chromatography 
via his-tag, which can be cleaved off with PreScission Protease. 
 
 
2.5.1.2.2 pET-DuetTM-1 
 
The pET-DuetTM-1 vector (Novagen) was applied for expression of hsTom40 and ceTom40 
variants, which did not express in the pRSET system. The Duet vectors are based on T7 
promoter expression and each designed to coexpress two target proteins in E. coli, but can 
also be used for expression of only one gene, which is then inserted into the first open reading 
frame. The vector encodes two multiple cloning sites (MCS), each of which is preceded by a 
T7 promoter, lac operator and ribosome binding site (rbs). The vector also carries the 
pBR322-derived ColE1 replicon, lacI gene and ampicillin resistance gene as well as the N-
terminal fusions to his-tag. A PreScission Protease cleavage site was introduced by the 
forward primer. 
 
 
2.5.1.2.3 pCR2.1-TOPO and pDrive
 
The PCR products from the amplified genes of the Fv fragments, which sequences were 
unknown, were cloned directly from the PCR reaction into the pCR2.1-TOPO (Invitrogen) or 
the pDrive cloning (Qiagen) vector. Both vectors carried ampicillin resistance for selection. 
The cloning was performed according to the instructions of the protocols of the TOPO and the 
pDrive cloning kits as well as the Qiagen A-Addition kit. The insertions could then be 
sequenced and were used as templates for the PCR using specific primers with restriction 
sites, followed by cloning into the pASK68 vector (Section 2.5.1.2.4). 
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2.5.1.2.4 pASK68 
 
The pASK68 vector is designed for periplasmic production of Fv fragments and was kindly 
provided by Carola Hunte (MPI of Biophysics, Frankfurt). It represents a bicistronic system, 
where heavy (VH) and light chain (VL) of the Fv fragment are inserted into the open reading 
frames one and two. The vector provides VH with a C-terminal strep-tag I and the VL with a 
C-terminal myc-tag. Both chains are fused to the OmpA and PhoA signals, respectively, for 
periplasmic targeting, ensuring proper folding of the disulfide bonds of the antibody fragment. 
The VH and VL genes were inserted with the restriction enzymes PstI (NsiI)/BstEIII and 
SacI/XhoI. The vector carries ampicillin resistance (Ampr) for selection. 
 
 
2.5.1.3 Bacteria 
 
The following E. coli strains were used for molecular biological working and for the 
expression. The strains were ordered from Stratagene, Heidelberg or provided by Carola 
Hunte (in case of JM 83, from MPI of Biophysics, Frankfurt). 
 
Strain Genotype Application 
XL-1 blue strain a 
 
 
 
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac{F’ proAB 
laclqZM15Tn10(Tetr)} 
non inducible promoter 
Preparation of high-quality plasmid 
DNA. 
BL21-CodonPlus(DE3)-RIL 
 
 
B F-ompT hsdS(rB- mB-) dcm+ Tetr 
galλ (DE3) endA Hte {argU ileY leuW 
Camr), extra copies of argU, ileY and 
leuW tRNA genes on a ColE1-
compatible plasmid with canamycine 
resistance marker, protease deficiency, 
chromosomal T7-polymerase gene 
Induced high-yield protein expression 
with, especially with T7 promoter. 
 
 
 
 
 
JM83 rpsL ara ∆(lac-proAB) 
Φ80dlacZ∆M15, 
streptomycin resistance 
Periplasmic expression of Fv 
fragments  
Table 2.4: Different E. coli strains which were used in this study. 
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2.5.1.4 Enzymes 
 
Name Company 
Taq Polymerase New England Biolabs, Schwalbach 
Pfu Polymerase Promega 
Shrimp Alkaline Phosphatase Roche 
T4 DNA Ligase New England Biolabs, Schwalbach 
Restriction Enzymes (BamHI, EcoRI…..) New England Biolabs, Schwalbach 
Table 2.5: List of applied enzymes. 
 
 
2.5.1.5 Equipment and chemicals 
 
ÄKTA Explorer, ÄKTA Purifier and Amersham Biosciences, Freiburg 
ÄKTA Prime Chromatography Systems   
Amicon Ultra 10K, 30K device   Millipore, Bedford, MA, USA 
Autoklav Bioclav     Schütt 
Autoklav Varioklav     H+P Labortechnik GmbH 
Balance MC1 AC210P    Sartorius, Göttingen 
Balance CPG22     Sartorius, Göttingen 
Branson Sonifier 250     G. Heinemann 
Centrifuges: Avanti J-25, Avanti J-20 XP  Beckman Instruments   
Centrifuge 5810 R     Eppendorf 
22 mm x 0.96 mm thick Plain circle cover slides Hampton R., Laguna Niguel, CA,US  
22 mm Circular Cover Slides  (siliconized)  Jena Bioscience 
Cups (1.5 ml and 2.0 ml)    Sarstedt 
ThermoTubeTM PCR Tubes 0.2 ml   Peqlab Biotechnology GmbH 
Digital Camera     Sony 
Econo-Column Chromatography Column  Biorad 
Electrophoresis Power Supply   Consort 
Electrophoresis Power Supply EPS 601  Amersham Biosciences 
Freezer –20 °C     Liebherr 
Freezer –80 °C Forma Scientifie, Life Sciences 
International GmbH 
Fridge 4 °C      Liebherr 
Fraction collector Frac 100    Amersham Pharmacia, Freiburg 
GDS-7900 System Transilluminator   UVP
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(Agarose gel documentation) 
Gel chambers workshop, Institut für Physiologische 
Chemie, München 
Gel Drying Film     Promega Corp., Madison, WI, USA 
Glas ware      Schott, Duran 
Grease       Hampton R., Laguna Niguel, CA, USA 
Greiner 96well plates     Greiner und Söhne, Frickenhausen 
Incubators for molecular biology   Heraeus Christ 
Incubator for crystallisation    RUMED 
Microscope      Carl Zeiss AG, Oberkochen, Germany 
Mikro 22 R centrifuge    Hettich 
Mikrowave      Bosch 
Mono Q HR 10/10     Amersham Pharmacia, Freiburg 
Multichannel Pipette Research Pro 10 and 300 Eppendorf 
Multitron II shaker     Infors AG, Bottmingen 
Nanosep Centrifugal Devices (3 and 10K)  Pall Life Sciences (New York, USA)  
NMR spectrometer Varian 
Overhead shaker workshop, Institut für Physiologische 
Chemie, München 
Mastercycler gradient  (PCR)    Eppendorf 
Petriplates      Greiner und Söhne, Frickenhausen 
Peristaltik-Pumpe P-1    Amersham Biosciences 
pH-Meter CG 822     Schott 
Photometer Gene Quant pro    Amersham Biosciences 
Photometer Ultrospec 10    Amersham Biosciences 
Pipettes 2, 20, 100, 200, 1000 µl   Gisco 
Primus (PCR)      MWG Biotech 
PP-Test tubes, 15 and 50 ml (falcons)  Greiner 
Quarz precision cuvettes 105.201-QS  Hellma Müllheim 
Röntgen films NewRX    Fuji 
Sterile benches     BDK, Genkingen 
Superdex 200 HR 10/30    Amersham Pharmacia, Freiburg 
Table centrifuge 5415 D    Eppendorf-Netheler, Hamburg 
Thermomixer compact    Eppendorf 
VDX™ 24well plate (greased)   Hampton R., Laguna Niguel, CA, US 
Vortex Mixer      Bender&Hobein, Zürich 
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Unless stated otherwise all chemicals were from the following companies in p.A. 
quality. 
●Amersham Biosciences, Freiburg 
●Fluka, Neu-Ulm  
●Fermentas, St.Leon-Rot  
●Merck, Darmstadt  
●New England Biolabs, Schwalbach/Taunus  
●Qiagen, Hilden 
●Promega 
●Roth, Karlsruhe 
●Serva, Heidelberg 
●Sigma Aldrich, Deisenhofen 
 
 
2.5.1.6 Media and Buffers 
 
All solutions and medium were prepared using bidestillized water (ddH2O, Millipore) and 
were autoclaved or sterile filtered if required. All media and buffers are listed in Table 2.6 
except cell culture media which is shown below. 
 
NAME PRESCRIPTION 
E. coli Medium 
LB 
10 g Trypton, 5 g Yeast Extract, 10 g NaCl, ad 1 l ddH2O (for culture plates ad 1.5% 
w/v Agar) 
Competent Cells 
electrocompetent 10% (v/v) Glycerol 
chemical competent 0.1 M CaCl2  
Isolation of plasmid DNA 
Resuspension buffer 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNAse 
Lysis buffer 200 mM NaOH, 1.0% (w/v) SDS 
Neutralization buffer 3 M potassium acetate, pH adjusted to 5.5 with acetic acid 
Agarose gels 
5xSample Buffer 
50 mM EDTA, 0.05%  (w/v) Bromphenolblue, 0.05%  (w/v) Xylencyanol, 30%  (v/v) 
Glycerol 
1xTAE -
Electrophoresis-Buffer 
40 mM Tris/Acetat, 20 mM Natriumacetat, 1 mM EDTA, pH 7.5 
  
Antibiotics (1000xstocks) 
Ampicillin 100 mg/ml H2O 
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Chloramphenicol 30 mg/ml Ethanol 
Tetracyclin 12.5 mg/ml Ethanol 
Streptomycin 30 mg/ml H2O 
ELISA 
Coating buffer 
0.2 M Na2CO3, 1.243% (w/v) NaHCO3, 0.551% (w/v) Na2CO3 or 1.487% (w/v)  
Na2CO3 * 10 H2O, pH without titration ~ 9.55 
Wash buffer 
0.9 % (w/v) NaCl, 0.1%  (v/v) Tween-20 (NaCl can be prepared as 10x stock, Tween 
20 was added fresh to 1x) 
Blocking buffer 50 mM Tris-Cl pH 7.5, 150 mM NaCl (can be prepared as 10 X stock), 2 % BSA 
TOM buffer 50 mM KAc/MOPS pH 7.2, 0.05 % (w/v) DDM 
Antibody solution  50 mM KAc, 0.05% (v/v) Tween-20, 0.5 % (w/v) BSA 
Development solution  
10% (v/v) Diethanolamine pH 9.8, 0.5 mM MgCl2 (2.5 µl from 2 M stock for 10 ml) 
1 mg/ml p-NPP (p-nitrophenylphosphate, 10 mg/ml stock in aliquots at -20 °C) 
Protein A affinity purification 
Binding buffer 100 mM Tris-Cl pH 9.0 
Elution buffer 100 mM sodium citrate pH 3.0 
Gene expression 
Lysis buffer 20 mM Tris-Cl pH 8.0, 100 mM NaCl 
Periplasmic extraction 
Extraction buffer 100 mM Tris-Cl pH 8.0, 500 mM sucrose, 1 mM EDTA 
Isolation of inclusion bodies 
Washing buffer 1 20 mM Tris-Cl pH 8.0, 200 mM NaCl, 0.5% (w/v) LDAO 
Washing buffer 2 20 mM Tris-Cl pH 8.0, 200 mM NaCl 
Protein refolding 
Urea buffer 20 mM Tris-Cl pH 8.0, 100 mM NaCl, 8 M urea 
Dilution buffer 20 mM Tris-Cl pH 8.0, 100 mM NaCl, 0.03% (w/v) DDM, 0.2 M L-arginine 
Streptavidin affinity chromatography 
Loading buffer 100 mM Tris-Cl pH 8.0, 150 mM NaCl, 1 mM EDTA 
Elution buffer 100 mM Tris-Cl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin 
Purification of TOM core complex 
Solubilization buffer 
20 mM Tris-Cl pH 8.5, 300 mM NaCl, 20% (v/v) glycerol, 20 mM imidazole, 1% 
(w/v) n-dodecyl-ß-D-maltoside (β-DDM; Glycon Biochemicals), 1 mM PMSF 
(freshly added) 
Equilibration buffer 50 mM Tris-Cl pH 8.5, 20% (v/v) glycerol, 0.2% (w/v) β-DDM, 1mM PMSF 
TOM washing buffer 1 
20 mM Tris-Cl pH 8.5, 300 mM NaCl, 10% (v/v) glycerol, 20 mM imidazole, 0.1% 
(w/v) β-DDM, 1 mM PMSF 
TOM washing buffer 2 
50 mM KAc/MOPS pH 7.2, 10% (v/v) glycerol, 40 mM imidazole, 0.1% (w/v) β-
DDM, 1 mM PMSF 
TOM elution buffer 
50 mM KAc/MOPS pH 7.2, 10% (v/v) glycerol, 300 mM imidazole, 0.1% (w/v) β-
DDM, 1 mM PMSF 
ResQ low salt buffer 50 mM KAc/MOPS pH 7.2, 10% (v/v) glycerol, 0.03% (w/v) β-DDM 
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ResQ high salt buffer 
50 mM KAc/MOPS pH 7.2, 10% (v/v) glycerol, 7.457% (w/v) KCl, 0.03% (w/v) β-
DDM 
Gel filtration buffer 10 mM KAc/MOPS pH 7.2, 0.03% (w/v) β-DDM 
SDS-PAGE 
4xSample buffer 
40% (v/v) glycerol, 240 mM Tris-Cl pH 6.8, 0.02% (w/v) Bromphenolblue, 20% (w/v) 
β-mercaptoethanol, 8% (w/v) SDS  
10xSDS runningbuffer 248 mM Tris-Cl, 1.9 M glycine, 10% (w/v) SDS 
5xUrea-SDS running 
buffer 
3.26% (w/v) Tris-Cl, 7.214% (w/v) glycine, 0.5% (w/v) SDS 
Coomassie staining of Protein gels 
Coomassie stain 40% (v/v) ethanol., 10% (v/v) acetic acid, 0.2% (w/v) Coomassie Brilliant Blue R-250 
Coomassie destain 30% (v/v) methanol., 10% (v/v) acetic acid 
Silver staining of SDS gels 
TCA solution 30 g  trichloracetic acid (TCA), 125 ml methanol, ddH2O ad 250 ml 
Fixation solution 30% (v/v) ethanol, 10% (v/v) acetic acid 
Reducing solution 0.1 % (w/v) sodium thiosulfate, 2% (v/v) glutaraldehyde 
Silver solution 
1.89 ml NaOH (1 M), 1.4 ml NH3 (25%), ddH2O ad 96 ml, drop wise addition of 
AgNO3 (20% (w/v) solution) under stirring till saturation is reached. 
Development solution 36.5 µl citric acid (34% (w/v)), 150 µl formaldehyde, ddH2O ad 250 ml 
Western Blot 
Transfer buffer 20 mM Tris-Cl, 150 mM glycine, 20% (v/v) methanol, 0.08% (w/v) SDS 
Ponceau S solution 0.2% (w/v) Ponceau S in 3% (w/v) trichloracetic acid 
Immunodecoration 
TBS 
10 mM Tris-Cl pH 7.5, 135 mM NaCl, blocking with either 3% (w/v) BSA or 5% 
(w/v) milk powder 
ECL reagent 
0.1 M Tris-Cl  pH 8.5, 2.5 mM 3-aminophtalhydrazide, 0.4 mM p-cumaric acid,  
0.0113% (v/v) H2O2  
10xNET/gelatine 
500 mM Tris-Cl pH 7.5, 1.5 M NaCl, 0.05 M EDTA, 0.5% (v/v) Triton-X-100, 8.3% 
(w/v) gelatine (Serva, heated in buffer) 
TCA precipitation 
Precipitant 72% trichloracetic acid 
TCA wash buffer 
100 mM Tris-Cl pH 8.8, 70% (v/v) Ethanol, small amount (spatula tip) 
Bromphenolblue 
TOM core complex crystallisation 
TOM core 
crystallisation condition  
100 mM ammonium citrate, 50 mM Tris-Cl pH 7.2, 20-30% (v/v) PEG 400 
TOM:P1C10 
crystallisation condition  
0.2 M calcium chloride, 0.1M HEPES pH 7.5,  25-28% (v/v) PEG 400 
 
Table 2.6: Media and buffers except for cell culture. 
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Media of hybridoma cell culture: 
Order numbers if not otherwise noted are from SIGMA. 
RPMI 1640    500 ml (supplements added to 500 ml medium) R-0883 
FCS  10/20%   50 ml/100 ml  
Glutamin 2 mM   5 ml (200 mM)  G-7513 or G-2150/Hybrimax 
Hepes  10 mM   5 ml (1 M)  H-0887 
Na-Pyruvat 1 mM   5 ml (50 mM)  11360039 Boehringer 
2-ME  50 µM   0.5 ml (50mM)  M-7522 
IL-6  50 U/ml   625 µl (40000) U/ml) 1444581 
 
 
Optional supplements: 
OPI  1 X   5 ml 100 X  O-5003 
Haz  1 X   10 ml (1 X is 100 µM Hypoxanthin and 1 µg/ml Azaserin) A-9666 
Hypoxanthin 2 X   5 ml 100 X  11364-015 GIBCO 
 
 
Stock solutions: 
 
Glutamin    200 mM stock, store in 5 ml aliquots, -20°C 
Hepes     1 M, 4°C 
Na-Pyruvat    100 mM, 4°C 
OPI (Sigma O-5003)   1 vial + 10 ml cell culture water (100 X), store at -20°C 
Haz     1 vial + 10 ml cell culture water (50 X), store at -20°C 
2-ME (78.13 MW, d=1.114 g/ml, p.a.) 88 µl to 25 ml with cell culture water (50 mM), store 4°C 
IL-6 (Interleukin-6, mouse, Roche)  1 ml (200000 U/ml) + 4 ml PBS (cell culture grade), store in aliquots 
at -20°C 
6- Thioguanin is 2-Amino-6-Mercaptopurine (Sigma A-4660) 
     2.5 mg + 10 ml cell culture water (W-3500), 50 X, store -20°C 
 
Supplements for freezing 
DMSO (Sigma D-8418)  10 % in basis medium, precooled medium before addition to the cells 
 
Alternative medium: 
Pan401 Medium  Panserin401 (PanBiotech, P04-710401), supplemented Iscove`s 
medium 
  Glutamin 
  IL-6 
 
Can be used for fusion with 10 % FCS plus 10 % HES (Sigma H-8142, enhancing supplement). Cells can be 
quickly adapted to 2 FCS or even FCS free in this medium 
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Selection Medium A 
RPMI 1640    500 ml (supplements are added to 500 ml medium) 
FCS  20 %   100 ml   (Myoclone) 
Glutamin 2 mM   5 ml 
Hepes  10 mM   5 ml 
Na-Pyruvat 1 mM   5 ml (100 mM) 
2-ME  50 µM   0.5 ml (50 mM) 
IL-6  50 U/ml   625 µl (40000 U/ml) 
Hypoxanthin 100 µM   10 ml 50 X Haz 
Azaserin 1 µg/ml 
1 X OPI     5 ml 100 X OPI 
no feeder cells, use conditioned medium 
as before but 10 % FCS 10% Hybridoma enhancing (Sigma H-8142) 
maybe 2 X OPI 
 
Selection Medium B 
Panserin401    500 ml (supplements are added to 500 ml) 
FCS  10 %   50 ml 
Glutamin 2 mM   5 ml 
IL-6  50 U/ml   625 µl (40000 U/ml) 
Hypoxanthin 100 µM   10 ml 50 X Haz 
Azaserin 1 µg/ml 
1 X OPI     5 ml 100 X OPI 
10% hybridoma enhancing supplement (HES, Sigma H-8142) 
no feeder cells, use conditioned medium 
 
 
2.5.1.7 DNA/RNA Isolation and Preparation Kits 
 
Name       Application 
 
Pure YieldTM Plasmid MidiPrep System Isolation of plasmid DNA from E. coli.  
 
Wizard® SV Gel and PCR Clean Up System Purification of PCR-products and 
extraction of DNA from agarose gel 
Company: Promega Corp., Madison, WI, USA 
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RNeasy Kit Isolation of mRNA from tissue culture 
Company: QIAGEN GmbH, Hilden, Germany 
 
2.5.1.8 Columns 
 
NAME VOLUME 
V0 = void 
volume 
LOADING 
RANGE 
MMW-Range TECHNIQUE
HiTrap Protein 
A HP 
1 ml  ~20 mg  
Affinity 
chromatography
Resource Q 6 ml  ~25 mg  Anion exchange
Superose 6 
10/300 GL 
24 ml 7.77 ml  
5 kDa - 
5 MDa 
Size exclusion 
Superose 6 PC 
3.2/30 
2.4 ml 0.796 ml  
5 kDa - 
5 MDa 
Size exclusion 
Table 2.7: Columns. 
 
 
2.5.1.9 Bioinformatics 
 
DNA and protein sequences were obtained from the „National centre for Biotechnology 
Information” (http://www.ncbi.nlm.nih.gov) and SWISS-PROT (http://www.expasy.ch). 
Primary sequence predictions were obtained from PredictProtein. PredictProtein is an Internet 
service (accessible via SWISS-PROT portal) for sequence analysis and the prediction of 
protein structure and function. Users submit protein sequences and PredictProtein returns 
multiple sequence alignments, PROSITE sequence motifs, low-complexity regions (SEG), 
nuclear localisation signals, regions lacking regular structure (NORS) and predictions of 
secondary structure, solvent accessibility, globular regions, transmembrane helices, coiled-
coil regions, structural switch regions, disulfide-bonds (DISULFIND), sub-cellular 
localization, and functional annotations. The secondary structure prediction was made by 
PROFsec, an advanced method of PHDsec. 
The computation of various physical and chemical parameters for a given protein by entering 
its sequence was performed by the ProtParam tool (SWISS-PROT portal). The computed 
parameters include the molecular mass, theoretical pI, amino acid composition, atomic 
composition, extinction coefficient, estimated half-life, instability index, aliphatic index and 
grand average of hydropathicity (GRAVY). 
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2.5.2  Methods 
 
2.5.2.1 Primer design 
 
The length of the primers varied from 29 to 53 bases and the primers had at least one G or C 
at the 3`-end to obtain better binding and elongation. The annealing parts were designed to 
have a melting temperature of approximately 60°C to allow sufficiently high annealing 
temperatures.  
In case of the pRSET-PL0, -PL1, pET-DuetTM-1 and pASK68, no start codon had to be 
introduced because it is already included in the vector. The forward primers for cloning into 
the pET-DuetTM-1, additional bases were introduced to shift the BamHI restriction site into 
frame. For all constructs the reverse primers had to contain a stop codon (TGA) before the 
restriction site (see Section 2.5.1.1). 
 
 
2.5.2.2 Methods in molecular biology 
 
2.5.2.2.1 Polymerase chain reaction (PCR) 
 
Since the beginnings of the PCR new applications were constantly found for this method, 
which allows amplifying DNA sequences of any sequence. For the PCR two oligonucleotide 
primers complementary to sequences at the ends of the required DNA, a mixture of all four 
dNTP`s and a for high temperature stable polymerase with the suitable buffer and the right 
concentrations of salt are required. After the denaturizing of the dsDNA (denaturizing), the 
primers hybridize with the complementary DNA (annealing) and the polymerase elongates 
the ssDNA construct starting with the 3`-end of the primer (elongation). Thus, the number of 
dsDNA constructs increases exponentially with each cycle. Either the enzymes Taq or Pfu 
were used as polymerases. 
 
Reaction mixture: 
 Substance         Volume 
1) DNA template (approx. 0.5 µg/µl)      1 µl 
2) Forward primer (100 pmol/µl)      0.5 µl 
3) Reverse primer (100 pmol/µl)      0.5 µl 
4) dNTP`s (5 mM per nucleotide)      2 µl 
5) Taq or Pfu buffer (10x)       5 µl 
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6) H2O steril         40 µl 
7) Taq (5 U/µl) or Pfu polymerase (3 U/µl)     1 µl 
 
The reaction mixture was pipetted into 500 µl PCR tubes and PCR reaction was carried out in 
a thermocycler. 
 
PCR program: 
 Temperature        Time 
1) 95 °C         10 min 
2) a) 92 °C         1 min 
    b) 58 °C         1 -2 min 
    c) 72 °C (Taq)/ 75 °C (Pfu)      1 min 
Step 2 was repeated thirty times. 
3) 72 °C (Taq)/ 75 °C (Pfu)      10 min 
 
Annealing temperature (2b) and elongation time (2c) of the reaction can be varied and had to 
be adjusted to the respective reaction. PCR products were analyzed by agarose gel 
electrophoresis and purified using the Wizard® SV Gel and PCR Clean Up System. To check 
for positive clones by PCR on E. coli colonies, colonies were picked with a sterile tip and 
resuspended in 10 µl of sterile ddH2O. The reaction volume was then only half of the above 
mixture, Taq was used as polymerase and the resuspended colony as template. The forward 
primer of the insert and a reverse primer annealing in the vector served as primers. For all 
PCR reactions concerning Tom40 constructs, commercially available cDNAs of the 
organisms were used as templates, respectively, whereas for cloning of the Fv fragments, 
cDNA of the hybridoma clones served as template.    
 
 
2.5.2.2.2 RNA isolation from hybridoma cell culture and Reverse Transcription 
 
Isolated cells from positive hybridoma clones were harvested and mRNA was isolated using 
the RNeasy kit (Section 2.5.1.7). Reverse transcription of the mRNA was performed with the 
Omniscript RT Kit (Qiagen), following the instructions of the protocol. The resulting cDNA 
served as template for the cloning of the Fv fragments into TOPO or pDrive vectors (Section 
2.5.1.2.3). 
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2.5.2.2.3 Digestion of DNA with restriction endonucleases 
 
For analytical and preparative purposes plasmid DNA and PCR products were digested with 
particular restriction endonucleases, which digest the DNA at specific, mostly palindromal 
sequences. All used enzymes produced an overhang, thus only ligation of sticky ends 
occurred. The incubation time, temperature and the buffer used in different reactions were 
applied according to the manufacturer’s recommendations. The obtained fragments were 
analyzed by agarose gel electrophoresis. Before the final sequencing of the resulting plasmid 
DNA, an additional restriction digestion was carried out to see whether the clone contained 
the required insert. 
 
PCR product Vector Control Restriction 
5 µl PCR construct 
5 µl BSA (10x) 
0.5 µl Enzyme 1 
0.5 µl Enzyme 2 
5 µl 10xBuffer 
ad 50µl sterile ddH2O  
3 µg vector 
5 µl BSA (10x) 
0.5 µl Enzyme 1 
0.5 µl Enzyme 2 
5 µl 10xBuffer 
ad 50µl sterile ddH2O 
2 µl vector 
2 µl BSA (10x) 
0.5 µl Enzyme 1 
0.5 µl Enzyme 2 
2 µl 10xBuffer 
13 µl sterile ddH2O 
Table 2.8: Restriction digestion of PCR product or vector. 
 
All constructs for insertion into the pRSET-PL0 and -PL1 vectors were digested with BamHI, 
whereas all constructs for ligation into pET-DuetTM-1 vector were digested with 
BamHI/EcoRI. Constructs for ORF1 and ORF2 of the pASK68 vector have to be digested 
with PstI/BstEII and SacI/XhoI, respectively. Inserts that contained an internal PstI restriction 
site, where cloned with NsiI (both endonucleases produce the same overhang). Analysis of the 
desired DNA fragments and cleaved vectors was done by gel electrophoresis (Section 
2.5.2.2.5). Self ligation of the linearized plasmid was suppressed by dephosphorylating the 5`-
end using shrimp alkaline phosphatase (SAP). Therefore 1 µl of SAP (10 U/µl) and the 
appropriate amount of 10 fold SAP buffer were added to the purified, digested vector and 
incubated for one hour at 37°C. The reaction was stopped through gel electrophoresis or 
purification with Wizard® SV Gel and PCR Clean Up System. This reaction was not used in 
all cases because the dephosphorylation could reduce the number of positive clones after 
transformation. 
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2.5.2.2.4 Ligation 
 
If PCR product and vector are restricted with the same enzymes the desired DNA construct 
can be inserted into the open plasmid and ligated with T4 DNA ligase. Linearized DNA 
vector and an approximately 10 fold molar excess of DNA fragment to be inserted were 
incubated with T4 DNA ligase and buffer. The ligation mixture was prepared on ice and 
incubation was performed either at RT for 1 h or at 4°C over night. The self ligation of the 
vector served as negative control. 0.5 to 1 µl of this mixture were used for transformation into 
E. coli cells. 
 
Ligation Negative-Control 
1 µl 
10 x molar excess 
2 µl 
1 µl 
vector 
PCR-construct 
10xLigase-buffer 
T4-DNA-Ligase 
1 µl 
16 µl 
2 µl 
1 µl 
vector 
H2O sterile 
10xLigase-buffer 
T4-DNA-Ligase 
Table 2.9: Ligation mixture. 
 
 
2.5.2.2.5 DNA agarose gel electrophoresis 
 
The agarose gel electrophoresis was used to separate and analyze DNA fragments between 
0.1 and 8 kb. Voltages were in the range of 80 to 120 V and the concentration of agarose was 
1%. Detection was done by the DNA intercalating dye ethidium bromide which can be 
observed in the ultraviolet. For preparation of the gel, agarose was solved under heat in 
1xTAE-buffer and supplemented with 1:10000 fold dilution of ethidium bromide (Sigma). 
The rigid gel was placed in a gel chamber and covered with TAE-buffer. Samples were mixed 
with 5 x sample buffer and loaded onto the gel. For the marker a 1kb or a 100bp DNA ladder 
(New England Biolabs) was used. DNA constructs and linearized vectors that were utilized 
for ligation were excised from the gel under UV light (λ = 254 nm) and purified with the 
Wizard® SV Gel and PCR Clean Up System. 
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2.5.2.2.6 Competent E. coli cells 
 
2.5.2.2.6.1 Chemical competent E. coli cells 
 
500 ml LB medium supplemented with tetracycline (XL1blue), chloramphenicol (BL21-
(DE3)-RIL) or streptomycin (JM83) were inoculated with 5 ml of over-night culture of the 
desired E. coli strain. The cells were grown at 37°C to OD600 of 0.4. After incubation on ice 
for 15 minutes cells were centrifuged for 15 minutes at 2580 x g (4000 rpm, JA10 rotor) and 
4°C. All following steps were done at ≤4°C. The pellet was resuspended in 40 ml 0.1 M 
CaCl2, incubated on ice for 30 min and harvested by centrifugation at 2580 x g and 4°C for 
15 min. This pellet was resuspended in 20 ml 0.1 M CaCl2 supplemented with 4 ml of 
glycerol. After an additional incubation on ice for 2 h, the suspension was dispensed in 200 µl 
aliquots and after shock-freezing in liquid nitrogen stored at –80°C. 
 
 
2.5.2.2.6.2 Electro-competent E. coli cells 
 
500 ml LB medium supplemented with tetracycline (XL1blue), chloramphenicol 
(BL21-(DE3)-RIL) or streptomycin (JM83) were inoculated with 5 ml of over-night culture of 
the desired E. coli strain. The cells were grown at 37°C to OD600 of 0.5 and then harvested by 
centrifugation for 15 minutes at 2580 x g (4000 rpm, JA10 rotor) and 4°C. All following steps 
were done at ≤4°C. The pellet was washed three times with 500, 250 and 50 ml of 10% (v/v) 
glycerol. After the washing steps, cell pellet was resuspended in 500 µl of 10% (v/v) glycerol, 
dispensed in 40 µl aliquots and after shock-freezing in liquid nitrogen stored at –80°C. 
 
 
2.5.2.2.7 Transformation 
 
Transformation of plasmid DNA into chemical competent E. coli cells was mostly done with 
the heat shock method. Therefore 100 µl of the competent cells were thawed on ice, mixed 
with 4-10 µl of the ligation suspension (or 1 µl of purified plasmid) and incubated on ice for 
10–30 min. Afterwards cells were heated at 42°C for 1 min. After a short recovery on ice for 
2 min, 500 µl of fresh LB medium were added and the mixture was shaken at 37°C for 
45 min. Finally, the bacteria were harvested by centrifugation, resuspended in 200 µl of fresh 
LB medium and plated on a selective medium (LB/Ampr for all used vectors). The plates 
were incubated at 37°C over night. 
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For the transformation of plasmid DNA into electrocompetent cells 0.5-1 µl of ligation 
suspension (or purified plasmid) were added to 40 µl of thawed competent cells. The 
suspension was transferred to a precooled cuvette and the cuvette was introduced in an 
electroporation apparatus (settings: 2.0 kV, 400 Ω, 25 µF, time constant 8-9 ms). After a brief 
application of a high electric voltage, the suspension was diluted with 800 µl LB-medium, and 
shaken for 30-60 min at 37°C. The experiment proceeded according to the transformation into 
chemical competent cells (see above). XL-1 blue cells were used for preparation of plasmid 
DNA, whereas BL21-(DE3)-RIL and JM83 cells served for gene expression. 
 
 
2.5.2.2.8 Isolation of plasmid DNA from E. coli 
 
To analyse whether the PCR constructs have been properly inserted into the vector, the 
plasmid DNA was isolated from XL1blue cells and digested with restriction enzymes. 
Alternatively, E. coli colonies were tested for the right insert by PCR as described in Section 
2.5.2.2.1. To isolate plasmid DNA, colonies were picked with pipet tips from the selective 
medium plate, transferred into 2 ml LB medium containing the suitable antibiotic (at a 
dilution of 1:1000) and placed into a 37°C shaker over night. 
The cultures were transferred to a 2 ml reaction tube, harvested by centrifugation for 1 min at 
16,000 g. Plasmid DNA was isolated according to the following procedure: 
 
10) Resuspension of cell pellet in 300 µl resuspension buffer. 
11) Addition of 300 µl of lysis buffer and incubation at RT for 5 min. 
12) Neutralization with 300 µl of neutralization buffer 
13) Centrifugation at 21900 x g for 10 min. 
14) Precipitation of DNA by mixing supernatant of centrifugation with 600 µl 
isopropanol. 
15) Centrifugation at 21900 x g for 10 min and 4°C. 
16) Washing with 500 µl of ice-cold 70% ethanol. 
17) Drying of DNA pellet at 50°C for at least 10 min. 
18) Dissolving of DNA in 30 µl of ddH2O. 
 
For large scale plasmid DNA isolation from 50 ml of culture medium the Pure YieldTM 
Plasmid MidiPrep System (Promega) was used according to the manufacturer`s instructions. 
After the restriction digestion and DNA sequencing the plasmid DNA was transformed into 
the expression strains BL21-(DE3)-RIL or JM83. 
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2.5.2.2.9 Mutagenesis 
 
For the cloning of the heavy and the light chains of the Fv fragment P9E9 as the first step the 
light chain VL was cloned into pASK68. Since this gene contained an internal PstI restriction 
site and PstI is needed to insert the heavy chain of P9E9, this restriction site in the VL gene 
was mutated (amino acid sequence was preserved). This experiment was performed by in 
vitro mutagenesis using the QuickChange Site-directed Mutagenesis Kit (Stratagene) and 
verified by restriction analysis and sequencing. 
 
 
2.5.2.2.10 DNA sequencing 
 
The concentration of isolated plasmid DNA was determined at 260 nm using a photometer 
and send to the company Eurofins Medigenomix GmbH for sequencing. 
 
 
2.5.2.3 Production of monoclonal antibodies 
 
For the production of monoclonal antibodies against TOM core complex from Neurospora 
crassa, fusion and single cell cloning were performed according to the standard procedure284. 
All experiments in cell culture to derive murine monoclonal antibodies and to analyze and test 
these antibodies were done in the lab of Carola Hunte in the MPI of Biophysics in Frankfurt.  
 
 
2.5.2.3.1 Immunization of mice and cell fusion 
 
The highly purified, detergent solubilized TOM core complex was utilized to produce murine 
monoclonal antibodies. The initial immunization of mice was followed by four injections with 
protein suspension in 4-week intervals and immunization was tested with ELISA (Section 
2.5.2.3.5). The myeloma cell line P3x63Ag4.653 was used for fusion with the spleen cells 
isolated from an immunized mouse. The fusions were dispensed to 1 ml aliquots, frozen and 
stored in liquid nitrogen. See the following timetable: 
 
1. Immunization 28.11.2000 
2. Immunization 09.01.2001 
 ELISA  24.01.2001 (mouse3 showed the best signal) 
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3. Immunization 16.02.2001 
4. Immunization 19.03.2001 
 ELISA  06.04.2001 
5. Immunization mouse2 23.04.2001 
   mouse3 24.04.2001  
 
 Fusion1 mouse2 26.04.2001 
 Fusion2 mouse3 27.04.2001 
 
Fusions were performed in Pan401 medium (5.1.6) and frozen. 
 
Fusion1: 1.26 * 108 spleen cells 
Freezing medium:   PANserin401  39 ml 
     DMSO  5 ml 
     Glutamin  500 µl 
     OPI (100x)  500 µl 
     FCS   5 ml 
 
        50 ml 
Fusion 2: 1.5 * 108 spleen cells 
Freezing medium:   RPMI   38 ml 
     FCS   5 ml 
     DMSO  5 ml 
     Glutamin  500 µl 
     Hepes   500 µl 
     Na-pyruvate  500 µl 
     β-mercaptoethanol 50 µl 
     OPI (100x)  500 µl 
        50 ml    
 
Immunization and fusion was not done in this study, but was carried out by Simone Schmitt.  
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2.5.2.3.2 Hybridoma cell culture 
 
While working with cell culture, it is necessary to check for contamination and for good 
growth rate every day by inspection under the microscope. The risk of mycoplasma 
contamination can be reduced by using medium without supplemented antibiotics. Handling, 
storing by freezing and thawing of cells was done according to standard procedures285.  
For cultivation and selection of hybridoma clones, 3 x 1 ml aliquots of the frozen cells 
(fusion1 or fusion2) were thawed carefully in a 37°C waterbath and transferred each into 5 ml 
(1:5 dilution), 10 ml (1:10) dilution and 20 ml (1:20 dilution) of precooled selection 
medium B (Section 2.5.1.6). Cell suspensions were distributed in 96well plates with 100 µl 
per well and plates incubated at 37°C. After 1 ½ weeks, grown hybridoma clones could be 
detected and 100 µl of fresh medium was added. If about one half of the well is covered by 
the clone and the medium start to turn yellow, the culture (200 µl) was transferred into 1 ml of 
fresh medium in 24well plates. In case of well grown cells from 24well plates, 1 ml of cell 
suspension was mixed with 2 ml of fresh selections medium B without azaserin and incubated 
in 6well plates. Cells were then grown logarithmic on the 6well plates with splitting every two 
days. Before the transfer steps cell culture supernatants were checked by ELISA (Section 
2.5.2.3.5). In case of analysis by Western Blot and subtyping, only supernatants from 6well 
plates were used due to the necessity of larger volumes of supernatant. 
OPI represents a mixture of oxalacetate, pyruvate and insulin which improves and sustains 
cell growth under conditions of stress. Haz is a mixture of hypoxanthine and azaserine, which 
is important for selective growth for the following reasons: 
-non-fused murine spleen cells die in vitro. 
-Ag4 myeloma cells are HGPRT- (namely hypoxanthine-guanine-phosphoribosyl transferase).  
Azaserine interferes with the cellular purine synthesis allowing growth of cells only when 
these are supplemented with hypoxanthine (alternative way of purine synthesis). The 
alternative pathway includes formation of inosin-monophosphate as an intermedium via the 
HGPRT enzyme. The mutant myeloma cell lacking this enzyme will die, if it is not fused to a 
spleen cell. 
-fused clones (hybridomas) survive since they are HGPRT+ and have been immortalized via 
conjugation with the myeloma cells. 
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2.5.2.3.3 Single cell cloning 
 
Hybridoma clones, which supernatants showed positive signals in ELISA test, were diluted in 
a single cell cloning step. This procedure has to be repeated a minimum of three times to 
ensure single cell cloning essential for the characterization of the antibody and the cloning of 
Fv fragments. Therefore, in each well of a 96well plate, 100 µl of cloning medium were 
pipetted and 100 µl of cell suspension of a nicely grown well were mixed with 900 µl of 
cloning medium (Pan401 Medium with 20% FCS and 1xOPI). 100 µl of this mixture were 
added to well A1 of the prefilled plate and carefully mixed. In the next step, 1:1 dilution were 
prepared by mixing 100 µl suspension of A1 with medium in A2, then 100 µl of this mix with 
well A3 and so forth. 1:1 dilutions for all lines were performed in a similar way using an 
8-channel multi-channel pipet by pipetting from row 1 to row 12. Clones should be grown 
after 8 days and growth of the cells was checked regularly under the microscope. 
Supernatants were tested as above.  
 
 
2.5.2.3.4 Freezing and cryo-storage of hybridoma cells 
 
If cells are nicely grown in 6well plates for 2-3 cycles, cells were centrifuged at 1200 rpm for 
10 min. Ice cold cryo medium (Section 2.5.1.6) was added drop wise (1 ml for one 6-well) 
and cells were resuspended. The suspension was filled into a precooled cryo-tube, slowly 
frozen in a closed Styrofoam box (2 h at -20°C, o/n at -80°C) and transferred to the liquid 
nitrogen storage device. 
 
 
2.5.2.3.5 Enzyme Linked ImmunoSorbent Assays (ELISA) 
 
After testing different ELISA techniques, the sandwich ELISA method was used for clone 
selection. His-tag ELISA worked with the same efficiency, but Ni2+-NTA pre-coated plates 
(Qiagen, Hilden, Germany) are much more expensive. 
The principle of a Sandwich ELISA (or two antibodies assay) is to coat an antibody to the 
plate and thereafter binding of the antigen to the coated antibody. The method prevents 
denaturation of the antigen, which is convenient to find antibodies, which are directed against 
discontinuous epitopes. The assay was done with 96well plates of Greiner, because of their 
better signal to noise ratio in comparison to Polysorb or Maxisorb plates: 
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1) Coating of rabbit anti-TOM40 (polyclonal serum, 1:1000 diluted) in coating buffer for 
1h at RT, 100 µl per well. Empty wells by draining over sink. 
2)   3 x washing (20 sec) with 400 µl of wash buffer per well. 
3)  Blocking of the free sites with blocking buffer, 200 µl per well, 15 min at RT.  
4)  2 x washing with washing buffer, 1 x with TOM buffer. 
5) Incubation of the TOM complex antigen (10 µg/ml) in TOM buffer for 1h at RT, 100 
µl per well.  
6)  3 x washing with TOM buffer. 
7)  Incubation with undiluted cell culture supernatant or polyclonal mouse serum (diluted 
1:10000) for 1h at RT, 100 µl per well. 
8)  washing step as 6). 
9)  Incubation with secondary antibody (anti-mouse IgG; Sigma) conjugated to alkaline 
phosphatase, diluted 1:1000 in antibody solution, for 1 h at RT. 
10)  washing step as 6). 
11)  Developing of the plates in freshly prepared development solution for 15 – 30 min, 
100 µl per well. 
12)  Measurement of the optical density at 405 nm (450 nm as reference) with an ELISA 
reader. 
 
Composition of the buffers is shown in Table 2.6 in Section 2.5.1.6. 
 
 
2.5.2.3.6 Determination of the antibody subtype 
 
Immunological subtyping of the monoclonal antibodies was done using the kit from 
Boehringer (1183117) according to the manufacturer`s instructions. This kit is also based on 
ELISA. 
 
 
2.5.2.3.7 Large-scale production of monoclonal antibodies 
 
For the purification of monoclonal antibodies the production in cell culture was scaled up and 
the cells were adapted to FCS-free medium. Cells were grown in 6well plates and adapted 
stepwise to cloning medium (Section 2.5.1.6) supplemented only with 5% FCS. Hybridoma 
cells from three fully grown 6well plates of each antibody were harvested by centrifugation 
(1200 rpm, 10 min) and resuspended in 30 ml of FCS-free cloning medium. The suspension 
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was transferred in a 260 ml cell culture flask, which was kept in the incubator in upright 
position. After ~4 days, further 30 ml of medium was added. Cells were grown for another 
three days, harvested by centrifugation, supplemented with 1/10 volume of 1 M Tris-Cl pH 
8.0 and stored at -20°C. This method will result in hybridoma supernatants with very low FCS 
content, which is important for subsequent purification of the antibodies. For each antibody, 
three flasks with the total volume of 180 ml were cultivated. 
 
 
2.5.2.3.8 Monoclonal antibody purification by protein A affinity chromatography 
 
Affinity purification is the most suitable method for monoclonal antibody purification. It is 
based on the binding of the antibody molecule to immobilized staphylococcal protein A or 
streptococcal protein G. These are bacterial Fc receptors that mainly bind to the Fc part of the 
antibody molecule. For protein A affinity purification of monoclonal antibodies from tissue 
culture supernatant, the 1 ml HiTrap Protein A HP column (Section 2.5.1.8) was used together 
with the Äkta Chromatography System (Amersham Bioscience). The ~200 ml of the cell 
culture supernatant was loaded on the equilibrated column (binding buffer, Section 2.5.1.6) 
using a sample pump (flow rate: 1 ml/min) and the column was washed with 10 ml of binding 
buffer. Bound antibodies were eluted at low pH with 10 ml of elution buffer. The pH was 
adjusted to higher pH directly after fractionation. Typical monoclonal antibody yields are 
2-20 µg/ml. The protein concentration was measured and the fractions containing protein 
were immediumtely concentrated using membrane filters with a 50 kDa molecular mass cut-
off (Millipore, Pall). Purified proteins were used for binding assays via analytical gelfiltration. 
 
 
2.5.2.3.9 Analytical gel filtration binding assay 
 
In this experiment, the purified antibodies were adjusted to TOM buffer (Section 2.5.1.6, 
ELISA) and the purified TOM core complex was mixed with the respective antibody in the 
molar ratio of 1:4 and the total volume of 50 µl (approx. 50 µg of TOM core and 70 µg of the 
antibody). After incubation of 1 h at RT, the mixture was sterile filtered and run on a 
Superose 6 PC 3.2/30 column (Section 2.5.1.8) using a SMART system. Fractions of 50 µl 
were collected and analyzed by SDS-PAGE. 
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2.5.2.3.10 Biochemical pull-down assay 
 
His-tagged TOM core complex antigen was bound to Ni-NTA Magnetic Agarose beads 
(Qiagen) to pull down monoclonal antibodies from cell culture supernatants. Therefore, 1 ml 
of cleared cell culture supernatant was adjusted to TOM buffer conditions (Section 2.5.1.6), 
mixed with 25 µl (50 µg) of TOM core complex and incubated for 1 h at 4°C on an end-over-
end shaker. After addition of 10 µl of Ni-NTA beads suspension the mixture was incubated 
for an additional hour. The supernatant was removed and the beads were washed three times 
with TOM buffer supplemented with 20 mM imidazole. The bound proteins were eluted with 
25 µl of elution buffer (TOM buffer + 300 mM imidazole) and analyzed by SDS-PAGE and 
Western Blot. 
 
 
2.5.2.4 Methods in protein biochemistry 
 
2.5.2.4.1 Gene expression 
 
After transformation of the Tom40 plasmid DNA in E. coli BL21-(DE3)-RIL cells, 100 ml of 
LB medium containing ampicillin (100 µg/ml) and chloramphenicol (30 µg/ml) were 
inoculated with the transformed cells (500 µl suspension, see Section 2.5.2.2.6) and incubated 
in a 37°C shaker over night. Three litres of LBAmp,Cam medium were inoculated with this 
preculture at a ratio of 1:40 and incubated at 37°C. After cell density reached OD600 0.6 to 
0.8, expression was induced with 0.5 mM IPTG (end concentration). The cells were incubated 
at 24°C over night and harvested by centrifugation at 4°C and 2580 x g (4000 rpm, JLA 
8.1000 rotor) for 10 min. Finally the supernatant was discarded and the resulting pellet was 
gently resuspended in cold lysis buffer (Section 2.5.1.6) at 1/100 of the culture volume. For 
storage, the suspension was frozen and stored at –20°C. For test expressions 100 ml of LB 
medium as well as different expression times and temperatures were applied (normally 3 h at 
37°C, O/N at 37°C and O/N at 24°C). 
The monoclonal antibody fragments were expressed bicistronically in the plasmid pASK68. 
The plasmid was transformed into E. coli strain JM83 for periplasmic protein expression. 
100 ml LB medium containing 100 µg/ml Ampicillin and 30 µg/ml streptomycin were 
inoculated using the transformed E. coli stock and cells grew over night at 37°C. 75 ml of the 
preculture were used to inoculate 3 l LBAmp medium in 3 l flasks (Fernbach flasks, Corning) 
preincubated at 22.5°C. After cells were grown at 22.5°C and 140 rpm to an OD of 0.5, 
expression was induced by adding IPTG to a final concentration of 1 mM, and incubation was 
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continued under the same condition for 3 hrs. Cells were harvested as described in Section 
2.5.2.4.3 
 
 
2.5.2.4.2 Cell lysis 
 
The thawed suspended cells were disrupted on ice using an appropriately equipped sonicator 
for the suspended volume (parameters: big tip, pulse maximum and duty cycle 60) for 10 min. 
After centrifugation at 24000 x g (20000 rpm in Beckman JA20 rotor) and 4°C for 20 min, the 
cell pellet including the Tom40 proteins was used for isolation of inclusion bodies.  
 
 
2.5.2.4.3 Periplasmic extraction 
 
For periplasmic extraction cells were harvested at 4000 x g at 4°C in precooled centrifugation 
buckets and gently resuspended in ice-cold extraction buffer (Section 2.5.1.6) at 1/100 of the 
culture volume. After 30 min incubation on ice, cells and cell debris were spun down at 
5000 x g for 45 min at 4°C. The periplasmic extract was poured off and stored at -20°C. 
 
 
2.5.2.4.4 Isolation of inclusion bodies 
 
Tom40 from Neurospora crassa was expressed in inclusion bodies which were isolated as 
follows: The cell pellet (see Section 2.5.2.4.2) from 1 l of culture was washed three times with 
washing buffer 1 and twice with washing buffer 2 (all centrifugations at 24000 x g for 15 
min). Sonifying could facilitate resuspension of the inclusion bodies. Between the washing 
steps, samples of the resuspended inclusion bodies and of the washing fractions were taken 
for SDS-PAGE analysis. 
 
 
2.5.2.4.5 Protein refolding 
 
The washed inclusion bodies (Section 2.5.2.4.4) were dissolved in urea buffer (Section 
2.5.1.6) and stirred for 1 h at 70°C. The mixture was cleared by centrifugation at 24000 x g 
for 15 min and contained the unfolded Tom40. The protein concentration was measured 
spectrometrical and diluted to the end concentration of 100-200 µg/ml.  Therefore, the protein 
solution was added drop wise (under stirring) to 500 ml of cold dilution buffer (Section 
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2.5.1.6) using a peristaltic pump and incubated over night at 4°C. The diluted solution was 
centrifuged resulting in refolded Tom40 in the supernatant. 
 
 
2.5.2.4.6 Streptavidin affinity purification 
 
Since the vector pASK68 provides a C-terminal fusion of strep-tag I to the heavy chain of the 
fragment, the Fv fragments P1C10 and P9E9 were purified by streptavidin affinity 
chromatography. The periplasmic extract (from 48 and 6 l of culture volumes for P1C10 and 
P9E9, respectively) was loaded onto a 1 ml Strep-Tactin Sepharose column (IBA, Göttingen) 
equilibrated with loading buffer (Section 2.5.1.6). The column was washed with 10 column 
volumes of loading buffer and specifically bound protein was eluted with elution buffer 
(Section 2.5.1.6). The eluted protein was collected and concentrated using spin filtration 
devices (10 kDa cut-off) to an appropriate concentration for binding experiments. The 
purification was monitored by SDS-PAGE analysis and Western blot was performed to detect 
the light chain which carries a C-terminal myc-tag. 
 
 
2.5.2.4.7 Purification of TOM core complex 
 
TOM core complex was isolated from a Neurospora crassa strain (GR-107) that carried a 
version of Tom22 with a hexahistidinyl tag at its C terminus. Growth of the cells and 
preparation of mitochondria were performed as described previously230,235,238. The TOM core 
complex was isolated according to Athing et al., 1999231, with some modifications in the 
protocol. Isolated mitochondria were solubilized in solubilization buffer (Section 2.5.1.6) at a 
protein concentration of 10 mg/ml for 30 min at 4°C. Insoluble material was removed by 
centrifugation, and the clarified extract was loaded onto the equilibrated (equilibration buffer, 
Section 2.5.1.6) nickel nitrilotriacetic acid agarose column (Ni-NTA; Qiagen) using 4 ml 
resin per g of total mitochondrial protein. The column was washed with 5 column volumes of 
TOM washing buffer 1 and with 10 vol of TOM washing buffer 2. The bound protein was 
eluted with 4 column volumes of TOM elution buffer (Section 2.5.1.6). The eluted fraction of 
the Ni-NTA column was loaded onto an equilibrated Resource Q anion exchange column. 
The complex was eluted with a linear potassium chloride gradient (buffers in Section 2.5.1.6).  
For further purification, the fractions containing TOM core complex were pooled, 
concentrated to 500 µl (spin filtration devices from Pall Corporation, 100 kDa cut-off) and 
loaded onto a Superose 6 size exclusion column. Proteins were eluted in gel filtration buffer. 
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Stock solutions of purified TOM core complex were stored at a protein concentration of 10-20 
mg/ml at 4°C. An average preparation of the protein started with ~1.5 kg of Neurospora cells 
(wet wt) which yielded about 5 g of mitochondrial proteins and 1-2 mg of purified Tom core 
complex. 
 
 
2.5.2.4.8 Co-complex formation of TOM core complex and Fv fragments 
 
To obtain the co-complex, purified TOM core complex was mixed with the Fv fragment at a 
molar ratio of 1:10 and incubated at RT for 30 min in gel filtration buffer (Section 2.5.1.6). 
Due to their much smaller size, the unbound Fv fragments were separated from the co-
complex by size exclusion chromatography using the Superose 6 column (Section 2.5.1.8). 
The co-complex containing fractions were pooled, analyzed by SDS-PAGE and concentrated. 
 
 
2.5.2.4.9 Detergent exchange 
 
For the detergent exchange, TOM core complex was purified in DDM according to the 
standard procedure (Section 2.5.2.4.7) except the gel filtration, which was performed in the 
new detergent. After anion exchange chromatography TOM core complex was concentrated 
to approx. 500 µl of volume and its buffer was adjusted to the concentration of the new 
detergent as shown in Table 2.3. After the clarifying spin, the protein was loaded onto the 
Superose 6 column (Section 2.5.1.8) and run in gel filtration buffer (Section 2.5.1.6) 
supplemented with the new detergent instead of β-DDM. This experiment was monitored by 
urea SDS-PAGE (Section 2.5.2.5.1). 
 
 
2.5.2.5 Detection and quantitative determination of the protein 
 
2.5.2.5.1 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Proteins can be separated according to their molecular mass by discontinuous 
sodiumdodecylsulfat polyacrylamide gelelectrophoresis (SDS-PAGE) as described286. 
Smaller proteins migrate faster through the gel towards the negative pole than larger ones. 
Although the electrophoretic mobility depends not only on molecular mass but also on the 
shape and the charge of the protein, the molecular mass could be estimated through 
 155 
Materials and Methods  Chapter 2 
comparison to a marker because the protein solution is denaturized under reducing conditions 
(β-mercaptoethanol) by adding SDS (it binds to the unfolded peptide and has a high negative 
charge).  
In general, the standard SDS gels (Table 2.10) served for separation of proteins, but in case of 
TOM core complex urea-SDS gels were used (Table 2.10), which show much higher 
resolution for proteins in the low molecular mass range (necessary to separate the small Tom 
components). The concentration of acrylamide and bis-acrylamide in the standard separating 
gel was chosen according to the molecular size of the proteins to be separated (mostly 16 or 
17.5%). Glass plates of 160x140 mm and spacers of 1 mm thickness were utilized. Before 
loading, the samples were dissolved in appropriate volumes of 4 x sample buffer and 
incubated at 95°C for 5 min. The electrophoresis for standard gels was performed at 30-
45 mA for 1-2 h in 1 x SDS running buffer and in case of urea gels at 35 mA for 3-4 h in urea 
gel running buffer. Protein molecular mass standards (#SM0431, Fermentas) were used in 
each gel.  
 
Standard SDS gel  
Separating gel 
Separating gel 16% (w/v) acrylamide, 0.16-
0.33% (w/v) bis-acrylamide, 380 mM Tris-
HCl (pH 8.8), 0.1% (w/v) SDS, 0.05% (w/v) 
APS, 0.035% (v/v) TEMED. 
Stacking gel 
Stacking gel 5% (w/v) acrylamide , 0.1% 
(w/v) bis-acrylamide, 60 mM Tris-HCl (pH 
6.8), 0.1% (w/v) SDS, 0.05% (w/v) APS, 
0.035% (v/v) TEMED 
Urea-SDS gel  
Separating gel 
Separating gel 20% (w/v) acrylamide, 0.25% 
(w/v) bis-acrylamide, 6 M urea, 750 mM 
Tris-HCl (pH 8.8), 0.1% (w/v) SDS, 0.07% 
(w/v) APS, 0.13% (v/v) TEMED. 
Stacking gel 
Stacking gel 5% (w/v) acrylamide , 0.07% 
(w/v) bis-acrylamide, 6 M urea, 125 mM 
Tris-HCl (pH 6.8), 0.1% (w/v) SDS, 0.05% 
(w/v) APS, 0.17% (v/v) TEMED 
Table 2.10: Composition of SDS and urea-SDS gels. 
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All SDS-PAGE experiments, which were done in the MPI of Biophysics in Frankfurt were 
based on commercial NuPAGE® Novex 4-12% Bis-Tris gels (Invitrogen). 
 
 
2.5.2.5.2 Staining SDS-PA gels with Coomassie brilliant blue 
 
To visualize the protein on the gel, Coomassie Brilliant Blue dye was used, which allows 
detection of protein amounts down to 0.1 µg. After SDS-PAGE and removal of the bottom 
and stacking gels, the separating gel was heated in Coomassie stain for 1 min using a 
microwave, incubated for 20-40 min at room temperature, subsequently washed with water 
and destained in Coomassie destain until distinct bands became visible against a clear 
background. The gel was scanned and then dried overnight between two gel-drying films. 
 
 
2.5.2.5.3 Silver staining of SDS-PA gels 
 
Silver staining of SDS gels represents a staining method that shows much higher sensitivity 
than staining with Coomassie brilliant blue and is particular convenient to detect small 
amounts of proteins or proteins of small size. To analyze small TOM components, silver 
staining is necessary and was performed by the following incubation steps (under shaking): 
 
- 30 min incubation in TCA solution 
- 30 min fixation in fixation solution 
- 20 min reduction in reducing solution 
- 5 x 5 min wash in ddH2O 
- 15 min incubation in silver solution 
- 5 x 5 min wash in ddH2O 
- development in development solution till bands become visible 
- stop the reaction by washing in ddH2O or 0.5 M EDTA 
 
All solutions were prepared freshly and are shown in Table 2.6 (Section 2.5.1.6). 
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2.5.2.5.4 Transfer of proteins to nitrocellulose membrane (Western-blot) 
 
Proteins separated via SDS-PAGE were transferred onto nitrocellulose membrane using the 
semi-dry blotting method149,150. The gel, the membrane, and six sheets of Whatman filter 
paper (3MM) were incubated in transfer buffer. Three sheets of filter paper were placed on 
the anode electrode followed by the membrane and on top of it the gel. This was covered with 
other three filter papers and with the cathode electrode. The transfer was performed at 200 
mA for 1.5 h. To verify transfer efficiency, the nitrocellulose membranes were reversibly 
stained with Ponceau S solution. Afterwards, the membrane was immunodecorated. 
 
 
2.5.2.5.5 Immunodecoration 
 
To visualize the immobilized proteins on nitrocellulose membrane, immunodecoration with 
specific antibodies was carried out. Membranes were first incubated for 1 h in 5% (w/v) milk 
powder/3% (w/v) BSA in TBS (Section 2.5.1.6) to block all non-specific binding sites. The 
immunodecoration was done for 1 h at RT or over night at 4°C, with specific antiserum 
(1:200 to 1:1000 dilutions in milk/BSA in TBS). The membrane was then washed 3 times 
(each wash lasts 5 min), with TBS, TBS/0.05% (w/v) Triton X-100 and again with TBS, and 
incubated for 1 h with horseradish peroxidase coupled to secondary goat anti-rabbit-IgG 
(Sigma, diluted 1:10.000 dilutions in milk/BSA in TBS). The membrane was again washed 
(as above) and treated with ECL reagents (H2O2 was added fresh). The luminescence 
reactions were detected with Röntgen films. In case of the decoration with mouse α-myc 
antibody, all steps were done in NET/gelatine buffer. The mouse α-myc antibody was used 
undiluted (kindly provided from the group of Kai Hell, LMU Munich) and the conjugated 
goat anti-mouse-IgG (Sigma) served as secondary antibody. 
 
 
2.5.2.5.6 Determination of the protein concentration by Bradford assay 
 
The Bradford assay is based on the fact that the absorption of Coomassie-Brilliant Blue dye 
shifts from 465 nm to 595 nm when it binds to protein. Its sensitivity allows to measure 
protein concentrations between 0.1 mg/ml and 30 mg/ml per ml Bradford solution. Protein 
concentrations were determined using the “Bio-Rad-Protein assay” reagent (Bio-Rad)152. The 
protein solution was mixed with 1 ml reagent (1:5 dilution) and incubated for at least 5 min at 
RT. To increase the accuracy of the assay six samples were examined (twice 2.5 µl, 5 µl and 
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7.5 µl of the protein solution). The absorbance was measured at 595 nm using a 10 mm path 
length microcuvette. Finally, the protein concentration was calculated according to a standard 
curve (bovine serum albumin standard from Biorad Laboratories was used as protein 
standard). 
 
 
2.5.2.5.7 Determination of the protein concentration by UV spectroscopy 
 
Protein concentration could be also determined by measuring the absorbance at 280 nm using 
a photometer. Therefore, the extinction of an appropriate dilution of 150-200 µl of the protein 
solution was measured in a quartz cuvette with the buffer solution as blank value. The 
theoretical extinction coefficient was calculated by the ProtParam tool (Section 2.5.1.9) and 
used for the determination of the protein concentration. 
 
 
2.5.2.5.8 Concentration of proteins 
 
For crystallization high protein concentrations were required. Protein was concentrated by 
centrifugation using Amicon Ultra 10K or 30K devices (Millipore) or Nanosep Centrifugal 3 
and 10K Devices (Pall Corporation) according to the manufacturer`s instructions.  
 
 
2.5.2.5.9 Protein precipitation 
 
Sometimes the concentration of a protein fraction was less than is required for SDS-PAGE. 
Therefore, the protein was precipitated with 1/5 volume of 72% trichloracetic acid (TCA), 
incubated on ice for 10 min and centrifuged at 14000 rpm for 1 min. The precipitate was 
washed with 0.5 ml of TCA wash buffer (Section 2.5.1.6), and dried at 56°C for 10 min. The 
precipitated protein was dissolved in 1 x sample buffer and analysed by gel electrophoresis. 
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2.5.2.6 Crystallization 
 
2.5.2.6.1 Crystallization of TOM core complex  
 
The TOM core complex alone and in complex with the Fv fragment were concentrated to 
10-14 mg/ml and subjected to crystallization trials. The TOM core complex was initially 
crystallized by the vapour diffusion method using a hanging drop setup. 1 µl of protein 
solution was mixed with 1 µl mother liquor to constitute the hanging drop in twenty-four well 
Linbro-plates. Initially Crystal Screens I, II and the MembFac Screen from Hampton 
Research were used. Small crystals appeared after two days in the solution containing 0.2 M 
magnesium chloride, 0.1 M HEPES, pH 7.5 and 30% (v/v) PEG 400. Large crystals were 
obtained after setting up fine screen (mixing 1.5 µl of protein solution with 1 µl of well 
solution) with solutions containing 100 mM ammonium citrate, 50 mM Tris-Cl pH 7.2, 20-
30% PEG 400. The SDS gel analysis of washed and dissolved crystals showed that all 
components of the TOM core complex were present in the crystals. This work was done by 
Simone Schmitt238. 
In case of the TOM core complex with bound antibody initial crystallisation screens were set 
up using a pipetting robot. 200 nl of the concentrated protein solution were mixed with 200 nl 
of reservoir solution in 96well plates. The initial screening was performed with Classics, 
pHClear I, pHClear II and the PACT suites (Qiagen). Small crystals appeared in sitting drop 
and were reproducible in hanging drop with the optimized solution containing 0.2 M calcium 
chloride, 0.1M HEPES, pH 7.5 and 25-28% (v/v) PEG 400. Large crystals of the complex 
also grew with the original reservoir solution.  
 
 
2.5.2.6.2 Crystallization in capillary 
 
The crystallization in capillary was carried out similar to the protocol of Simone Schmitt238. 
 
 
2.5.2.6.3 Crystallization with additives 
 
The detergent additive screens 1, 2 and 3 from Hampton Research were used according to the 
manufacturer`s instructions. After determination of the optimal PEG400 concentration in the 
crystallization trials for each TOM core protein batch, the hanging drop vapour diffusion 
method was performed as described above by mixing 1.5 µl of the protein and 1 µl of the 
 160 
Materials and Methods  Chapter 2 
reservoir solution. In the next step, 0.28 µl of the additive were added each to one drop (1:10 
dilution of the additive). If crystals occurred fine screens were applied to optimize crystal 
growth and crystals were measured at synchrotron (Section 2.5.2.7). In case of copper 
chloride as additive, TOM core complex and copper chloride (10 mM) were mixed in a 10:1 
ratio and subjected to crystallisation attempts. 
 
 
2.5.2.6.4 Treatment of crystals with glutaraldehyde 
 
Incubation of the crystals to glutaraldehyde (crystallization-grade, Patrick Cramer, Gene 
Centre, Munich) was performed in the 24well plates by hanging drop vapour diffusion. 5 µl of 
glutaraldehyde were pipetted into the deep reservoir well and the cover slide containing the 
hanging crystal drop with the crystals was positioned on the well. Different incubation times 
from 0.5 h to 5 h in 30 min steps (at 20°C) were applied and the crosslink efficiency was 
tested by transfer of the crystals in ddH2O. Manipulated crystals were measured at 
synchrotron. 
 
 
2.5.2.6.5 Crystallisation with heavy metal atoms 
 
All heavy metals except tantalbromid (Proteros biostructures) and all other heavy metal atom 
clusters (Patrick Cramer, Gene Center, Munich) were provided by the Heavy Metal Atom 
Screens from Hampton Research. Only a very small spatula tip of the heavy metal was solved 
in 100 µl of the reservoir solution to prepare stock solutions and 0.1 to 0.5 µl of the stock 
solution was added to the crystallization drop. Either crystals were transferred to the heavy 
metal atom containing drop or the heavy metal solution was added to the crystals. In case of 
co-crystallization the heavy metal and the crystallisation solution were mixed and crystals 
should grow within the next few days. 
 
 
2.5.2.7 Data collection and processing 
 
The measurement of the crystals took place at the synchrotron radiation sources BW6 at 
Deutsches Elektronen Synchtrotron (DESY) in Hamburg and at the X06SA Swiss Light 
Source (SLS) at Paul Scherrer Institut in Villingen. The crystals of the TOM core complex 
were exposed to X-rays both at RT in capillary and frozen, whereas crystals of the 
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Tom:antibody complex were only measured frozen. The crystals were flash-frozen in a stream 
of cold nitrogen gas at 100 K (Oxford Cryosystems) directly from the crystal solution, which 
represents a cryo-protectant. The wavelength was set to 1.05 Å. Data was recorded using a 
MarCCD detector and the stability of the crystals in the beam allowed collection of the first 
isomorphic complete dataset at 8 Å resolution. Data were processed with DENZO and data 
reduction was performed with SCALEPACK240. The space group was determined to be C2 
with unit cell dimensions of a=181 Å, b=113 Å, c=129 Å, β=113°. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 162 
Abbreviations   
3  Abbreviations 
 
3’-end three prime (hydroxyl) end GST Glutathione-S-Transferase 
 of the oligonucleotide h hours 
5’-end five prime (phosphate) end HADDOCK High Ambiguity Driven protein–protein  
 of the oligonucleotide  Docking 
Å Ångstrom hs/h Homo sapiens/human 
aa amino acid residue(s) His (H) Histidine 
AAA ATPases associated with various cellular  IPTG Isopropyl-β-D-Thiogalactopyranosid 
 activities K Kelvin 
Adrm1/Arm1 Adhesion regulating molecule 1 kDa kilodaltons 
Ampr Ampicillin resistance kV kilovolt 
APS Ammonium peroxo disulphate LB Luria-Bertani 
Asp Aspartate mm/m Mus musculus/murine 
at Arabidopsis thaliana MCS Multiple cloning site 
ATP Adenosintriphosphate MIU motif interacting with ubiquitin 
A20 ZnF A20 zinc finger mRNA messenger ribonucleic acid 
BSA Bovine Serum Albumin Nc/N.c. Neurospora crassa 
Camr Chloramphenicol resistance NMM New Minimal Medium 
ce Caenorhabditis elegans NMR Nuclear magnetic resonance 
CP core particle of proteasome NOE Nulear Overhauser Effect 
C-terminus Carboxy terminus N-terminus amino terminus 
CUE coupling of ubiquitin conjugation to  OD optical density 
 endoplasmatic reticulum degradation O/N over night 
CV Column volumes ORF Open reading frame 
Da Dalton PAGE polyacrylamid Gel Electrophoresis 
ddH2O Millipore filtrated, demineralised water PACE proteasome–Associated Control Element 
DNA Deoxyribonucleic Acid PAN proteasome–activating nucleotidase 
dm Drosophila melanogaster PBS Phosphate buffered saline 
dNTP Desoxynucleosidtriphosphate PCR Polymerase chain reaction 
DTT  Dithiothreitol PDB Protein Data Bank 
DUB Deubiquitinating enzyme PEG Polyethylenglycol 
DUIM double-sided UIM PH Pleckstrin Homology 
E. coli Escherichia coli PIP phosphatidylinositolphosphate 
EDTA Ethylendiamintetraacetate PP PreScission Protease 
ERAD Endoplasmic Reticulum Associated Protein ppm Parts per million 
 Degradation Pru Pleckstrin–like receptor for ubiquitin 
GAT Golgi-localized, gamma-ear-containing,  PVDF polyvinylidene difluoride 
 ADP-ribosylation-factor-binding protein RBS Ribosomal binding site 
 and target of myb RP regulatory particle of proteasome 
GFP Green Fluorescent Protein rpm Rounds per minute 
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GLUE GRAM-like ubiquitin binding in ELL- Rpn regulatory particle non–ATPase 
 associated protein 45 RT room temperature 
Rpt regulatory particle triple–A protein Ub Ubiquitin 
SAP Shrimp Alkaline Phosphatase UBA ubiquitin–associated 
sc Saccharomyces cerevisiae Ubc ubiquitin-interacting motif 
SDS Sodiumdodecylsulfate UBL ubiquitin–like 
Ser Serine UCH Ubiquitin C–terminal hydrolase 
sp Schizosaccharomyces pombe UEV Ubc E2 variant 
TBS Tris-buffered saline UIM ubiquitin–interacting motif 
TCA Tri-chloracetate ZnF UBP zinc finger ubiquitin-specific processing  
TEMED N,N,N’,N’-Tetramethylethylendiamine  protease 
TIM Translocase of the inner  mitochondrial    
 membrane   
TOM Translocase of the outer mitochondrial    
 membrane   
Tris Tris(hydroxymethyl)-aminomethan   
U Units   
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